Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Open in Screener

DGX

Quest Diagnostics, Inc.

Sep 06 • 04:00PM ET

152.93

Dollar change -1.30
Percentage change -0.84	%

Healthcare • Diagnostics & Research • USA • NYSE

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

Held by: VTI VOO VO SPY IVV VTV RSP XLV VOE VIG

Index	S&P 500	P/E	20.63	EPS (ttm)	7.41	Insider Own	0.49%	Shs Outstand	111.00M	Perf Week	-2.11%
Market Cap	17.02B	Forward P/E	15.89	EPS next Y	9.62	Insider Trans	-6.31%	Shs Float	110.77M	Perf Month	4.65%
Income	836.00M	PEG	3.15	EPS next Q	2.28	Inst Own	92.53%	Short Float	2.52%	Perf Quarter	7.21%
Sales	9.35B	P/S	1.82	EPS this Y	2.48%	Inst Trans	-1.34%	Short Ratio	3.35	Perf Half Y	20.05%
Book/sh	59.61	P/B	2.57	EPS next Y	7.79%	ROA	6.12%	Short Interest	2.79M	Perf Year	20.28%
Cash/sh	2.43	P/C	62.82	EPS next 5Y	6.55%	ROE	13.00%	52W Range	119.59 - 159.36	Perf YTD	10.92%
Dividend Est.	2.91 (1.90%)	P/FCF	19.46	EPS past 5Y	7.36%	ROI	7.64%	52W High	-4.03%	Beta	0.89
Dividend TTM	2.92 (1.91%)	Quick Ratio	0.91	Sales past 5Y	4.86%	Gross Margin	31.81%	52W Low	27.88%	ATR (14)	2.64
Dividend Ex-Date	Oct 04, 2024	Current Ratio	1.00	EPS Y/Y TTM	7.62%	Oper. Margin	14.49%	RSI (14)	54.51	Volatility	1.92% 1.56%
Employees	48000	Debt/Eq	0.77	Sales Y/Y TTM	-1.50%	Profit Margin	8.95%	Recom	2.35	Target Price	156.00
Option/Short	Yes / Yes	LT Debt/Eq	0.65	EPS Q/Q	-0.82%	Payout	37.76%	Rel Volume	0.99	Prev Close	154.23
Sales Surprise	0.29%	EPS Surprise	0.65%	Sales Q/Q	2.52%	Earnings	Jul 23 BMO	Avg Volume	833.59K	Price	152.93
SMA20	0.12%	SMA50	4.05%	SMA200	11.50%	Trades		Volume	827,453	Change	-0.84%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-28-24	Resumed	Evercore ISI	In-line	$165
Jul-10-24	Upgrade	Citigroup	Neutral → Buy	$145 → $165
Feb-26-24	Initiated	Leerink Partners	Market Perform	$135
Feb-07-24	Upgrade	Jefferies	Hold → Buy	$140 → $155
Jan-03-24	Initiated	Barclays	Equal Weight	$145
Dec-12-23	Upgrade	BofA Securities	Neutral → Buy	$140 → $160
Jun-29-23	Initiated	Piper Sandler	Neutral
May-02-23	Downgrade	BofA Securities	Buy → Neutral	$166 → $148
Apr-03-23	Upgrade	Citigroup	Sell → Neutral	$125 → $142
Jan-23-23	Initiated	Evercore ISI	In-line	$159
Nov-17-22	Downgrade	Citigroup	Neutral → Sell	$145 → $125
Aug-22-22	Resumed	Morgan Stanley	Equal-Weight	$142
Apr-04-22	Downgrade	Citigroup	Buy → Neutral	$175 → $140
Feb-23-22	Downgrade	UBS	Buy → Neutral	$160 → $139
Feb-02-22	Downgrade	Jefferies	Buy → Hold	$135
Jan-28-22	Downgrade	Deutsche Bank	Buy → Hold	$190 → $129
May-04-21	Upgrade	UBS	Neutral → Buy	$135 → $158
Mar-12-21	Downgrade	Robert W. Baird	Outperform → Neutral	$137
Oct-21-20	Upgrade	Argus	Hold → Buy
Jul-29-20	Upgrade	KeyBanc Capital Markets	Sector Weight → Overweight	$144

Show Previous Ratings

Sep-05-24 09:40AM	Why Quest Diagnostics (DGX) is a Top Value Stock for the Long-Term (Zacks)
Aug-30-24 09:40AM	Should Value Investors Buy Quest Diagnostics (DGX) Stock? (Zacks)
Aug-28-24 03:31PM	Quest Diagnostics to Speak at the Morgan Stanley 22nd Annual Global Healthcare Conference (PR Newswire)
Aug-27-24 08:23AM	Quest Diagnostics completes LifeLabs acquisition from OMERS (Medical Device Network)
Aug-26-24 08:50AM	Quest Diagnostics Completes Acquisition of LifeLabs, Enhancing Access to Diagnostic Innovation (PR Newswire)
08:31AM	Loading…
08:31AM	Quest Diagnostics' (DGX) New Deal Aids Diagnostic Access in Ohio (Zacks)
Aug-23-24 07:53AM	Quest inks deal for University Hospitals outreach lab services (MedTech Dive)
Aug-22-24 11:30AM	Quest Diagnostics (DGX) Up 6.3% Since Last Earnings Report: Can It Continue? (Zacks)
10:35AM	Quest Diagnostics to buy University Hospitals outreach lab assets (Hospital Management)
09:15AM	Quest Diagnostics Incorporated (DGX) Hits Fresh High: Is There Still Room to Run? (Zacks)
Aug-21-24 08:55AM	Quest Diagnostics to Acquire University Hospitals' Outreach Laboratory Services Business (PR Newswire)
Aug-19-24 08:07AM	Quest Diagnostics (DGX) Debuts Micronutrient Deficiency Panels (Zacks)
Aug-16-24 06:33AM	Universal DX secures funding to advance Signal-C blood test trial (Medical Device Network)
Aug-15-24 06:13PM	Quest Diagnostics Prices $1.85 Billion of Senior Notes (PR Newswire)
09:05AM	Quest Diagnostics' (DGX) New Study Exposes Alarming Data on STI (Zacks)
07:32AM	Loading…
07:32AM	questhealth.com Introduces 13 New Blood Tests to Identify Micronutrient Deficiencies (PR Newswire)
Aug-14-24 07:04PM	Quest Diagnostics Declares Quarterly Cash Dividend (PR Newswire)
09:40AM	Should Value Investors Buy Quest Diagnostics (DGX) Stock? (Zacks)
Aug-13-24 11:24AM	Quest Diagnostics (DGX) Gains From Innovation, Customer Wins (Zacks)
08:55AM	Should Quest Diagnostics (DGX) be in Your Portfolio Now? (Zacks)
Aug-12-24 08:51AM	Pregnant Women Undertested for STIs, Finds Quest Diagnostics Health Trends Study of Over 4 Million Pregnancies (PR Newswire)
Aug-11-24 07:37AM	The 'G' in ESG is gaining more shareholder love than the 'E' or 'S' (Yahoo Finance)
Aug-05-24 09:15AM	Quest Diagnostics Incorporated (DGX) Hit a 52 Week High, Can the Run Continue? (Zacks)
Aug-01-24 06:48AM	Quest Diagnostics Named a 'Best Place to Work for Disability Inclusion' for Seventh Straight Year (PR Newswire)
Jul-29-24 09:40AM	Are Investors Undervaluing Quest Diagnostics (DGX) Right Now? (Zacks)
08:03AM	Haystack Oncology and Universit de Montral's affiliated hospital research centre, the CRCHUM, to Deploy Haystack MRD Technology in Research Study for Metastatic Colorectal Cancer (PR Newswire)
Jul-26-24 01:04AM	Decoding Quest Diagnostics Inc (DGX): A Strategic SWOT Insight (GuruFocus.com)
Jul-25-24 06:45AM	BD, Quest Diagnostics Join Forces to Develop Companion Diagnostics for Cancer, Other Diseases (PR Newswire)
Jul-24-24 07:47AM	Quest Diagnostics' (DGX) Haystack Oncology Forges New MRD Deal (Zacks)
03:24AM	Analyst Report: Quest Diagnostics Incorporated (Morningstar Research)
12:21AM	Loading…
12:21AM	Q2 2024 Quest Diagnostics Inc Earnings Call (Thomson Reuters StreetEvents)
Jul-23-24 10:05AM	Quest Diagnostics (DGX) Tops Q2 Earnings, Raises 2024 Outlook (Zacks)
07:55AM	Quest Diagnostics (DGX) Q2 Earnings and Revenues Top Estimates (Zacks)
06:51AM	Quest Diagnostics: Q2 Earnings Snapshot (Associated Press Finance)
06:45AM	Quest Diagnostics Reports Second Quarter 2024 Financial Results; Raises Guidance for Full Year 2024 (PR Newswire)
Jul-18-24 09:00AM	3 High Yield Healthcare Giants With Consistent Dividend Growth: Johnson & Johnson, Merck, And Quest Diagnostics (Benzinga)
08:00AM	Haystack Oncology and Lisata Therapeutics Initiate Research Collaboration to Use the Haystack MRD Technology to Evaluate Efficacy of Pancreatic Cancer Therapy (GlobeNewswire)
07:30AM	EXCLUSIVE: Haystack Oncology Inks Research Collaboration With Lisata Therapeutics To Use Haystack MRD Technology To Evaluate Pancreatic Cancer Therapy Efficacy (Benzinga)
Jul-17-24 09:50AM	Here's Why Quest Diagnostics (DGX) is a Strong Value Stock (Zacks)
06:00AM	Quest closing Pennsylvania lab, laying off 121 people (MedTech Dive)
Jul-16-24 09:15AM	Quest Diagnostics Incorporated (DGX) Soars to 52-Week High, Time to Cash Out? (Zacks)
Jul-15-24 08:35AM	Quest Diagnostics (DGX) Set to Acquire OhioHealth's Lab Services (Zacks)
06:17AM	Is Quest Diagnostics Incorporated (DGX) an Undervalued High Growth Stock? (Insider Monkey)
Jul-14-24 12:58PM	The Best Affordable Place to Live in New Jersey (Insider Monkey)
12:57PM	20 Best Affordable Places to Live in New Jersey (Insider Monkey)
Jul-12-24 09:37AM	What Awaits Quest Diagnostics (DGX) in Q2 Earnings Release? (Zacks)
Jul-11-24 10:55AM	Quest Diagnostics to purchase outreach lab assets from health system OhioHealth (Hospital Management)
Jul-10-24 08:58AM	Quest Diagnostics to Acquire Outreach Laboratory Services of OhioHealth (PR Newswire)
Jul-08-24 06:06AM	Quest to buy Lifelabs for $985M (MedTech Dive)
Jul-04-24 11:15AM	Quest Diagnostics (DGX) to Expand in Canada With LifeLabs Buyout (Zacks)
04:12AM	Quest Diagnostics to acquire Canadas LifeLabs for $985m (Medical Device Network)
Jul-03-24 08:45AM	Quest Diagnostics to Acquire LifeLabs from OMERS, Enhancing Diagnostic Services for Canadians (PR Newswire)
Jun-27-24 09:43AM	Quest Diagnostics (DGX) Inks Deal to Acquire Allina Health (Zacks)
06:45AM	Quest Diagnostics Releases 2023 Corporate Responsibility Report (PR Newswire)
Jun-26-24 04:03PM	Quest Diagnostics to Acquire Select Lab Assets from Allina Health (PR Newswire)
08:35AM	Is It Apt to Hold Quest Diagnostics (DGX) Stock for Now? (Zacks)
Jun-21-24 11:06AM	Quest Diagnostics (DGX) Gains From New M&As Amid Competition (Zacks)
Jun-19-24 03:00PM	Quest Diagnostics to Release Second Quarter 2024 Financial Results on July 23, 2024 (PR Newswire)
Jun-18-24 08:58AM	Quest Diagnostics' (DGX) New Buyout Ramps Up Cancer Diagnosis (Zacks)
Jun-12-24 11:15AM	My Quest Story - Mark Hamilton (ACCESSWIRE)
Jun-11-24 07:57AM	Quest Diagnostics Completes Acquisition of Select PathAI Diagnostics' Lab Assets from PathAI, Accelerating Adoption of AI and Digital Pathology to Speed Cancer Diagnosis (PR Newswire)
Jun-10-24 12:30PM	Quest Diagnostics Elects Robert B. Carter, CIO of FedEx Corporation, to Board of Directors (ACCESSWIRE)
Jun-06-24 10:15AM	Lab Week 2024 - Lisa Szeto-Tay (ACCESSWIRE)
Jun-05-24 12:10PM	Quest Diagnostics Grows Interest in Sustainability With Healthy NewsWorks Students (ACCESSWIRE)
May-31-24 04:08PM	Blood-based MRD Test for Cancer Recurrence Can Generate Cost Savings in Colorectal Cancer Treatment, Finds Study in JAMA Health Forum (PR Newswire)
May-29-24 12:20PM	Lab Week 2024 - Mimi Perdue-Loan (ACCESSWIRE)
May-23-24 11:30AM	Why Is Quest Diagnostics (DGX) Up 3.1% Since Last Earnings Report? (Zacks)
May-21-24 03:15PM	Ruth Clements Speaks at National Action Network Event Addressing Health Inequities (ACCESSWIRE)
01:15PM	Lab Week 2024 - Deepika Kumar (ACCESSWIRE)
May-16-24 04:15PM	Quest Diagnostics Elects Robert B. Carter, CIO of FedEx Corporation, to Board of Directors (PR Newswire)
08:41AM	Argus Research Adjusts Quest Diagnostics Price Target to $215 From $163 (MT Newswires)
05:44AM	Baird Adjusts Price Target on Quest Diagnostics to $145 From $144, Keeps Neutral Rating (MT Newswires)
05:41AM	Argus Adjusts Price Target on Quest Diagnostics to $215 From $163, Keeps Buy Rating (MT Newswires)
May-15-24 05:54PM	More Workers Are Cheating on Drug Tests (The Wall Street Journal)
05:45PM	Quest Diagnostics Declares Quarterly Cash Dividend (PR Newswire)
10:46AM	Employees are cheating on workplace drug tests at record ratesand legalized cannabis could be to blame (Fortune)
10:37AM	Employers Struggle with Drug Test Policies Amid Varying State Laws, Cheating on Drug Tests Reaches 30-Year High (Benzinga)
08:43AM	Workforce Drug Test Cheating Surged in 2023, Finds Quest Diagnostics Drug Testing Index Analysis of Nearly 10 Million Drug Tests (PR Newswire)
May-14-24 09:00PM	Cheating on Workplace Drug Tests Hits a Record (The Wall Street Journal)
May-13-24 01:00PM	Lab Week 2024 - Javarus Smith (ACCESSWIRE)
07:09AM	PRESS DIGEST-Canada - May 13 (Reuters)
May-08-24 12:30PM	Helping To Change Perceptions of Bloodwork by Being 'Phenomenal' (ACCESSWIRE)
May-07-24 04:50PM	Quest Diagnostics to Speak at the 2024 Leerink Partners Healthcare Crossroads Conference (PR Newswire)
11:23AM	Quest Diagnostics (DGX) Grows in Digital Pathology With New Deal (Zacks)
May-06-24 02:00PM	Quest Diagnostics to Acquire PathAI Diagnostics to Accelerate AI and Digital Pathology Adoption in Cancer Diagnosis; Forms Licensing Agreements With PathAI (ACCESSWIRE)
09:40AM	Quest Diagnostics Names Murali Balakumar Senior Vice President and Chief Information and Digital Officer (PR Newswire)
May-02-24 10:42AM	Reasons to Retain Quest Diagnostics (DGX) Stock for Now (Zacks)
09:02AM	Quest Diagnostics (DGX) Inks Deal to Acquire PathAI Diagnostics (Zacks)
08:10AM	Quest Supports Expansion of Community Center and Provides No-Cost Wellness Testing to Newark Faith Community (ACCESSWIRE)
01:23AM	Quest to ramp up AI capabilities with purchase of PathAIs diagnostic lab (MedTech Dive)
May-01-24 10:44AM	Quest Diagnostics to Acquire PathAI Diagnostics Assets in Collaboration Deal (MT Newswires)
06:57AM	Quest Diagnostics to Acquire PathAI Diagnostics to Accelerate AI and Digital Pathology Adoption in Cancer Diagnosis; Forms Licensing Agreements with PathAI (PR Newswire)
Apr-30-24 08:37AM	Baird Adjusts Quest Diagnostics' Price Target to $144 From $138 (MT Newswires)
Apr-26-24 08:45AM	Quest Diagnostics Foundation and Green Bronx Machine Expand Collaboration to Bring Acclaimed Indoor Gardening Curriculum to More Communities and Raise Awareness for Impact of Nutrition Education on Health Equity (ACCESSWIRE)
01:05AM	Decoding Quest Diagnostics Inc (DGX): A Strategic SWOT Insight (GuruFocus.com)
Apr-25-24 11:13AM	Quest Diagnostics Incorporated (NYSE:DGX) Q1 2024 Earnings Call Transcript (Insider Monkey)
Apr-24-24 03:02AM	Quest Diagnostics Inc (DGX) Q1 2024 Earnings Call Transcript Highlights: Key Financial Outcomes ... (GuruFocus.com)
Apr-23-24 10:35PM	Q1 2024 Quest Diagnostics Inc Earnings Call (Thomson Reuters StreetEvents) +5.08%
09:58PM	Analyst Report: Quest Diagnostics Incorporated (Morningstar Research)
10:52AM	DGX Stock Earnings: Quest Diagnostics Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)

Quest Diagnostics, Inc. engages in the provision of diagnostic testing, information and services. It operates through the Diagnostic Information Services (DIS) and All Other segments. The DIS segment offers diagnostic information services to patients, clinicians, hospitals, health plans, and employers. The All Other segment consists of risk assessment services, healthcare information technology, diagnostic products, and clinical trials testing businesses. The company was founded in 1967 and is headquartered in Secaucus, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
PREVOZNIK MICHAEL E	SVP & General Counsel	Aug 29 '24	Option Exercise	95.80	32,551	3,118,223	71,029	Sep 03 04:30 PM
PREVOZNIK MICHAEL E	SVP & General Counsel	Aug 29 '24	Sale	154.97	32,551	5,044,516	38,478	Sep 03 04:30 PM
KUPPUSAMY KARTHIK	SVP, Clinical Solutions	Aug 28 '24	Sale	153.26	1,990	304,990	11,459	Aug 29 04:45 PM
PREVOZNIK MICHAEL E	Officer	Aug 29 '24	Proposed Sale	154.97	32,551	5,044,516		Aug 29 01:55 PM
KUPPUSAMY KARTHIK	Officer	Aug 28 '24	Proposed Sale	153.26	1,990	304,990		Aug 28 04:49 PM
DELANEY MARK E	SVP & Chief Commercial Officer	Jul 24 '24	Sale	143.08	420	60,094	5,019	Jul 26 06:33 PM
KUPPUSAMY KARTHIK	SVP, Clinical Solutions	Apr 29 '24	Sale	140.00	1,760	246,400	13,435	May 01 04:26 PM
Doherty Catherine T.	EVP, Regional Businesses	Feb 28 '24	Sale	126.57	5,557	703,349	69,599	Mar 01 04:51 PM
Doherty Catherine T.	EVP, Regional Businesses	Feb 29 '24	Sale	125.88	1,187	149,420	68,412	Mar 01 04:51 PM
PREVOZNIK MICHAEL E	SVP & General Counsel	Feb 29 '24	Sale	125.88	5,611	706,313	38,478	Mar 01 04:50 PM
PREVOZNIK MICHAEL E	SVP & General Counsel	Feb 22 '24	Sale	126.14	661	83,379	40,206	Feb 23 04:35 PM
Gregg Vicky B	Director	Feb 23 '24	Sale	126.64	2,500	316,596	16,329	Feb 23 04:34 PM
Doherty Catherine T.	EVP, Regional Businesses	Feb 22 '24	Sale	126.14	821	103,561	70,800	Feb 23 04:32 PM

Open in Screener

NTRA

Natera Inc

Sep 06 • 04:00PM ET

112.90

Dollar change -4.60
Percentage change -3.91	%

Healthcare • Diagnostics & Research • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

Held by: VTI VB XBI VXF VBK IBB IWP SCHA IWF ARKG

Index	-	P/E	-	EPS (ttm)	-2.47	Insider Own	6.08%	Shs Outstand	119.58M	Perf Week	-2.88%
Market Cap	13.96B	Forward P/E	-	EPS next Y	-1.16	Insider Trans	-7.92%	Shs Float	116.16M	Perf Month	12.50%
Income	-292.12M	PEG	-	EPS next Q	-0.57	Inst Own	95.48%	Short Float	6.56%	Perf Quarter	3.37%
Sales	1.36B	P/S	10.26	EPS this Y	47.95%	Inst Trans	1.73%	Short Ratio	5.48	Perf Half Y	23.17%
Book/sh	6.78	P/B	16.65	EPS next Y	41.08%	ROA	-21.13%	Short Interest	7.62M	Perf Year	94.66%
Cash/sh	7.17	P/C	15.74	EPS next 5Y	-	ROE	-40.78%	52W Range	36.90 - 124.83	Perf YTD	80.24%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-11.28%	ROI	-24.73%	52W High	-9.56%	Beta	1.52
Dividend TTM	-	Quick Ratio	4.01	Sales past 5Y	33.95%	Gross Margin	53.85%	52W Low	205.96%	ATR (14)	5.01
Dividend Ex-Date	-	Current Ratio	4.14	EPS Y/Y TTM	48.84%	Oper. Margin	-23.06%	RSI (14)	47.13	Volatility	4.95% 4.49%
Employees	3293	Debt/Eq	0.52	Sales Y/Y TTM	46.13%	Profit Margin	-21.47%	Recom	1.45	Target Price	130.26
Option/Short	Yes / Yes	LT Debt/Eq	0.41	EPS Q/Q	68.71%	Payout	-	Rel Volume	0.68	Prev Close	117.50
Sales Surprise	20.51%	EPS Surprise	56.44%	Sales Q/Q	58.13%	Earnings	Aug 08 AMC	Avg Volume	1.39M	Price	112.90
SMA20	-4.61%	SMA50	1.42%	SMA200	26.11%	Trades		Volume	946,321	Change	-3.91%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-03-24	Resumed	Jefferies	Buy	$142
Apr-08-24	Resumed	Craig Hallum	Buy	$117
Feb-20-24	Downgrade	Raymond James	Strong Buy → Outperform	$68 → $85
Dec-29-23	Reiterated	BTIG Research	Buy	$75 → $85
Dec-14-23	Initiated	Guggenheim	Buy	$70
Dec-13-23	Initiated	Wolfe Research	Outperform	$70
Nov-13-23	Upgrade	Raymond James	Outperform → Strong Buy	$68
Sep-28-23	Initiated	Bernstein	Mkt Perform	$48
Jul-05-23	Resumed	JP Morgan	Overweight	$85
May-05-23	Initiated	UBS	Buy	$76
Jan-18-23	Upgrade	Raymond James	Mkt Perform → Outperform	$58
Aug-25-22	Initiated	Credit Suisse	Outperform	$70
Apr-25-22	Initiated	Stephens	Overweight	$54
Mar-08-22	Initiated	Goldman	Buy	$90
Jan-06-22	Resumed	Piper Sandler	Overweight	$110
Oct-15-21	Resumed	Cowen	Outperform	$150
Jun-15-21	Initiated	Raymond James	Mkt Perform
May-25-21	Initiated	Wells Fargo	Overweight	$110
Jan-28-21	Initiated	Truist	Buy	$143
Oct-08-20	Initiated	BTIG Research	Buy	$90

Show Previous Ratings

Sep-06-24 10:24AM	What Makes Natera (NTRA) an Investment Bet? (Insider Monkey)
Sep-03-24 02:37AM	Natera (NTRA) Rose After Revenues And Profit Margins Beat Estimates (Insider Monkey)
Aug-31-24 11:48AM	Billionaire Stan Druckenmiller Is Betting On Natera, Inc. (NTRA) (Insider Monkey)
Aug-29-24 02:07PM	The Committee's Comeback Kids: Trade Desk, Sweetgreen, Natera, Samsara, PayPal and Leidos (CNBC TV)
Aug-28-24 09:00AM	Natera to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference (Business Wire)
03:19PM	Loading…
Aug-27-24 03:19PM	PepsiCo, Inc. (PEP): Among Morgan Stanleys Highest Conviction Stocks (Insider Monkey)
03:16PM	Natera, Inc. (NTRA): Among Morgan Stanley's Highest Conviction Stocks (Insider Monkey)
Aug-17-24 01:01AM	Insider Sale: CEO and President Steven Chapman Sells Shares of Natera Inc (NTRA) (GuruFocus.com)
Aug-10-24 01:01AM	Decoding Natera Inc (NTRA): A Strategic SWOT Insight (GuruFocus.com)
Aug-09-24 09:46AM	Q2 2024 Natera Inc Earnings Call (Thomson Reuters StreetEvents) +6.38%
Aug-08-24 07:00PM	Compared to Estimates, Natera (NTRA) Q2 Earnings: A Look at Key Metrics (Zacks) +7.31%
05:19PM	Natera: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Natera Reports Second Quarter 2024 Financial Results (Business Wire)
Aug-06-24 09:00AM	Natera to Participate in the Canaccord Genuity 44th Annual Growth Conference (Business Wire)
Jul-30-24 04:05PM	Natera to Report its Second Quarter 2024 Results on August 8, 2024 (Business Wire) -5.80%
10:53AM	Loading…
Jul-29-24 10:53AM	Natera touts positive results for Merkel cell carcinoma surveillance test (Medical Device Network)
Jul-27-24 01:00AM	Insider Sale: CFO Michael Brophy Sells Shares of Natera Inc (NTRA) (GuruFocus.com)
Jul-26-24 08:00AM	New MultiCenter Prospective Study Demonstrates Signatera's Clinical Utility in Merkel Cell Carcinoma (Business Wire)
Jul-25-24 10:02AM	Natera (NTRA) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Jul-18-24 01:00AM	Insider Sale: CEO and President Steven Chapman Sells Shares of Natera Inc (NTRA) (GuruFocus.com) -8.35%
Jul-08-24 09:00AM	The 3 Best Gene Editing Stocks to Buy in July 2024 (InvestorPlace)
Jul-03-24 08:53AM	Natera (NTRA) Soared After a 43% Increase In Revenue (Insider Monkey)
07:00AM	Natera to Present at the 28th International Conference on Prenatal Diagnosis and Therapy (Business Wire)
05:30AM	Insider Sale: CEO and President Steven Chapman Sells 37,500 Shares of Natera Inc (NTRA) (GuruFocus.com)
Jun-27-24 07:00AM	Natera Announces DECIPHER: A Phase II, Single-Arm Adjuvant Trial in Gastroesophageal Cancer (Business Wire)
Jun-19-24 03:10AM	Insider Selling: CEO and President Steven Chapman Sells Shares of Natera Inc (NTRA) (GuruFocus.com)
Jun-17-24 07:00AM	Natera Launches Differentiated New Feature for Prospera Heart Test, Enhancing Detection of Rejection for Transplant Patients (Business Wire)
Jun-10-24 02:25PM	Final Trades: Amazon, Natera and KKR (CNBC TV)
Jun-03-24 08:00AM	Natera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference (Business Wire)
02:42AM	Natera (NTRA) Raised Initial 2024 Guidance in Q1 (Insider Monkey)
03:24AM	Loading…
Jun-01-24 03:24AM	Director Gail Marcus Sells 2,000 Shares of Natera Inc (NTRA) (GuruFocus.com)
May-31-24 03:13AM	Director Rowan Chapman Sells Shares of Natera Inc (NTRA) (GuruFocus.com)
May-30-24 08:00AM	Natera Presents Latest in Transplant Innovation Data Across Multiple Organs at ATC 2024 (Business Wire)
May-23-24 04:05PM	Natera to Present at the 2024 Leerink Partners Healthcare Crossroads Conference (Business Wire)
07:30AM	Natera Announces New MRD Data in Multiple Tumor Types, to be Presented at ASCO Annual Meeting (Business Wire)
May-18-24 03:00AM	Insider Sale: CEO and President Steven Chapman Sells Shares of Natera Inc (NTRA) (GuruFocus.com)
May-16-24 05:23PM	Stanley Druckenmiller Bet On Biotech, Financial Services in Q1, Trimmed Nvidia Stake (Investopedia)
May-11-24 01:02AM	Decoding Natera Inc (NTRA): A Strategic SWOT Insight (GuruFocus.com)
May-10-24 04:01PM	Why Natera Is 'A Stock To Focus On' Following Its Mighty Beat-And-Raise (Investor's Business Daily) +10.19%
01:58PM	Stocks to Watch Friday: TSMC, Novavax, Nvidia, Goldman Sachs (The Wall Street Journal)
12:24PM	Natera Inc (NTRA) Surpasses Analyst Revenue Forecasts in Q1 2024 (GuruFocus.com)
12:17PM	Sweetgreen, Natera rise; Collegium Pharmaceutical, Akamai fall, 5/10/2024 (Associated Press Finance)
12:04PM	Natera, Inc. (NASDAQ:NTRA) Q1 2024 Earnings Call Transcript (Insider Monkey)
09:48AM	Natera Stock Charges Higher. Positive Cash Flow Arrived Early. (Barrons.com)
07:30AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace)
06:00AM	Genomics Game-Changers: 3 Stocks Unlocking the Secrets of Life (InvestorPlace)
May-09-24 06:30PM	Natera (NTRA) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
04:47PM	Natera: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Natera Reports First Quarter 2024 Financial Results (Business Wire)
May-03-24 08:00AM	New Natera Publication Bolsters Evidence for Extended Surveillance with Signatera in Breast Cancer (Business Wire)
May-02-24 02:14PM	NeoGenomics, Inc. (NASDAQ:NEO) Q1 2024 Earnings Call Transcript (Insider Monkey)
02:50AM	Insider Sale: CFO Michael Brophy Sells Shares of Natera Inc (NTRA) (GuruFocus.com)
02:49AM	Insider Sale: CEO and President Steven Chapman Sells Shares of Natera Inc (NTRA) (GuruFocus.com)
May-01-24 04:05PM	Natera to Report its First Quarter 2024 Results on May 9 (Business Wire)
07:00AM	Natera Launches Fetal RhD NIPT Supporting Ob/Gyn Physicians and Patients During RhIg Shortage (Business Wire)
Apr-27-24 02:42AM	Insider Sell: CFO Michael Brophy Sells Shares of Natera Inc (GuruFocus.com)
Apr-26-24 06:32PM	10 Cathie Wood Stocks Insiders are Selling (Insider Monkey)
Apr-24-24 08:36AM	Natera (NTRA) Rose on Momentum in the Oncology Market (Insider Monkey)
02:38AM	Insider Sell: CFO Michael Brophy Sells Shares of Natera Inc (NTRA) (GuruFocus.com)
02:38AM	CEO and President Steven Chapman Sells Shares of Natera Inc (NTRA) (GuruFocus.com)
Apr-22-24 08:00AM	Natera Announces Significant Milestone with 200+ Peer-Reviewed Publications (Business Wire)
Apr-18-24 02:05AM	Insider Sell: CEO and President Steven Chapman Sells Shares of Natera Inc (NTRA) (GuruFocus.com)
Apr-17-24 08:31AM	TipRanks Perfect 10 List: Analysts See Opportunity in These 2 Top-Scoring Stocks (TipRanks)
Apr-11-24 08:00AM	Natera Announces Publication of Largest Prospective dd-cfDNA Study in Kidney Transplantation (Business Wire)
Apr-09-24 07:37AM	11 Best Biotech ETFs To Buy (Insider Monkey)
Apr-08-24 08:00AM	Natera Announces New Data From Two Studies Extending the Clinical Validation of Its Prospera Heart dd-cfDNA Test for Heart Transplant Recipients (Business Wire)
Apr-05-24 07:00AM	Natera Announces Positive Surveillance Analysis from the Randomized Phase III IMvigor011 Trial in Muscle-Invasive Bladder Cancer (Business Wire)
05:15AM	Is Natera (NTRA) On The Cusp Of Being Cash Flow Positive? (Insider Monkey)
01:51AM	Insider Sell: CFO Michael Brophy Sells Shares of Natera Inc (NTRA) (GuruFocus.com)
Apr-01-24 08:00AM	Natera and Alliance for Clinical Trials in Oncology Announce Activation of Alliance A032103 (MODERN): A Randomized, Phase II/III Adjuvant Trial in Urothelial Cancer (Business Wire)
Mar-21-24 10:25AM	11 Best Healthcare ETFs To Buy Now (Insider Monkey)
Mar-20-24 05:46AM	Will Natera (NTRA) Continue to Deliver Solid Topline Growth? (Insider Monkey)
Mar-18-24 03:39PM	Genetic Testing Stock Nears Buy Point After Earnings Gap-Up And 45% Gain (Investor's Business Daily)
07:00AM	Natera Announces Phase III Randomized CIRCULATE Trial in France, Evaluating Signatera in Stage II Colorectal Cancer (Business Wire)
Mar-14-24 08:00AM	New KDIGO Guideline Supports Genetic Testing for the Majority of CKD Patients to Establish Cause of Disease (Business Wire)
Mar-12-24 08:00AM	Natera to Present New Data at the 2024 SGO Annual Meeting on Womens Cancer, Following Recent Medicare Coverage Decisions in Ovarian and Breast Cancers (Business Wire)
Mar-11-24 02:22PM	Final Trades: Natera, Disney, Chubb and ASML Holding (CNBC TV)
Mar-08-24 01:31AM	SEC and Chief Legal Officer Daniel Rabinowitz Sells Shares of Natera Inc (NTRA) (GuruFocus.com)
Mar-07-24 08:00AM	Natera Announces Commercial Coverage for Prospera Kidney and Prospera Heart from a Top BCBS Plan (Business Wire)
Mar-04-24 12:00PM	What Makes Natera (NTRA) a Strong Momentum Stock: Buy Now? (Zacks)
Mar-01-24 12:09AM	Decoding Natera Inc (NTRA): A Strategic SWOT Insight (GuruFocus.com)
Feb-29-24 11:06AM	Q4 2023 Natera Inc Earnings Call (Thomson Reuters StreetEvents) +12.98%
08:12AM	Natera, Inc. (NASDAQ:NTRA) Q4 2023 Earnings Call Transcript (Insider Monkey)
08:00AM	Natera to Participate in March Investor Conferences (Business Wire)
Feb-28-24 06:30PM	Compared to Estimates, Natera (NTRA) Q4 Earnings: A Look at Key Metrics (Zacks)
04:32PM	Natera Inc (NTRA) Reports Significant Revenue Growth and Improved Gross Margins in Full Year 2023 (GuruFocus.com)
04:05PM	Natera Reports Fourth Quarter and Full Year 2023 Financial Results (Business Wire)
Feb-27-24 08:12AM	Natera (NTRA) Management Increased Full Year Guidance (Insider Monkey)
08:00AM	Natera Announces Next Phase of CareDx Patent Infringement Litigation Seeking Royalty For All Ongoing And Future AlloSure Tests (Business Wire)
01:07AM	Natera secures Medicare coverage for cancer test in 2 new indications (MedTech Dive)
Feb-26-24 07:00AM	Medicare Extends Coverage of Nateras Signatera MRD Test to Ovarian Cancer and Neoadjuvant Breast Cancer (Business Wire) +5.29%
Feb-20-24 08:00AM	Natera Announces Fourth Quarter and Fiscal 2023 Earnings Conference Call (Business Wire)
Feb-17-24 12:07AM	Natera Inc Director Herm Rosenman Sells 93,901 Shares (GuruFocus.com)
Feb-06-24 04:00PM	3 Strong Buy Biotech Stocks to Add to Your February Must-Watch List (InvestorPlace)
Feb-05-24 08:00AM	New Study Validates Signatera in Endometrial Cancer (Business Wire)
Feb-02-24 11:02PM	Insider Sell: CFO Michael Brophy Sells 22,281 Shares of Natera Inc (GuruFocus.com)
Jan-31-24 05:02PM	Insider Sell: CFO Michael Brophy Sells 3,235 Shares of Natera Inc (GuruFocus.com)
Jan-30-24 09:15AM	Multiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030 (GlobeNewswire)
07:00AM	New Publication Demonstrates Signateras Ability to Risk Stratify and Detect Recurrence Early in Resected Stage I-II Lung Cancer (Business Wire)
Jan-29-24 07:00AM	Jury Rules in Favor of Natera in Patent Infringement Lawsuit Against CareDx; Awards $96.3 Million in Damages to Natera in Lost Profits and Past Royalties (Business Wire)

Natera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. It provides Panorama non-invasive prenatal test (NIPT), Vistara, horizon carrier screening (HCS), spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception (POC) and non-invasive paternity testing (PAT). The company was founded by Matthew Rabinowitz and Jonathan Sheena in November 2003 and is headquartered in Austin, TX.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Chapman Steven Leonard	CEO AND PRESIDENT	Aug 15 '24	Sale	118.91	5,583	663,895	200,710	Aug 16 09:40 PM
Sheena Jonathan	CO-FOUNDER	Aug 15 '24	Sale	121.01	12,000	1,452,125	287,441	Aug 16 09:40 PM
STEVEN L CHAPMAN	Officer	Aug 15 '24	Proposed Sale	118.91	5,583	663,895		Aug 15 04:32 PM
Sheena Jonathan	CO-FOUNDER	Aug 12 '24	Sale	113.82	2,700	307,314	299,441	Aug 14 09:05 PM
Fesko John	PRESIDENT, CHIEF BUS. OFFICER	Aug 13 '24	Sale	116.67	3,956	461,547	114,606	Aug 14 09:05 PM
Sheena Jonathan	Director	Aug 12 '24	Proposed Sale	117.68	22,800	2,683,200		Aug 12 10:40 AM
Rabinowitz Matthew	EXECUTIVE CHAIRMAN	Aug 08 '24	Option Exercise	5.40	190,000	1,025,107	1,480,648	Aug 09 09:40 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Jul 29 '24	Sale	102.77	1,057	108,623	206,400	Jul 31 09:05 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Jul 29 '24	Sale	102.77	1,196	122,908	112,441	Jul 31 09:05 PM
Fesko John	PRESIDENT, CHIEF BUS. OFFICER	Jul 31 '24	Option Exercise	5.40	100	540	108,562	Jul 31 09:05 PM
Fesko John	PRESIDENT, CHIEF BUS. OFFICER	Jul 29 '24	Sale	102.77	929	95,469	108,462	Jul 31 09:05 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Jul 29 '24	Sale	102.77	4,084	419,695	206,293	Jul 31 09:05 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Jul 31 '24	Sale	99.65	1,866	185,947	71,955	Jul 31 09:05 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Jul 29 '24	Sale	102.77	1,238	127,224	73,821	Jul 31 09:05 PM
MICHAEL BURKES BROPHY	Officer	Jul 31 '24	Proposed Sale	97.75	1,866	182,402		Jul 31 04:17 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Jul 24 '24	Sale	105.53	918	96,877	76,500	Jul 26 09:40 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Jul 26 '24	Sale	102.18	751	76,737	75,059	Jul 26 09:40 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Jul 25 '24	Sale	105.29	690	72,650	75,810	Jul 26 09:40 PM
MICHAEL BURKES BROPHY	Officer	Jul 26 '24	Proposed Sale	102.15	751	76,715		Jul 26 04:17 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Jul 22 '24	Sale	105.16	1,059	111,364	77,917	Jul 23 09:40 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Jul 23 '24	Sale	107.40	499	53,592	77,418	Jul 23 09:40 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Jul 22 '24	Sale	105.16	549	57,733	113,637	Jul 23 09:05 PM
Fesko John	PRESIDENT, CHIEF BUS. OFFICER	Jul 22 '24	Sale	105.16	549	57,732	109,391	Jul 23 09:05 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Jul 22 '24	Sale	105.16	2,638	277,410	210,377	Jul 23 09:05 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Jul 22 '24	Sale	105.16	815	85,704	207,457	Jul 23 09:05 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Jul 15 '24	Sale	111.66	5,496	613,672	207,855	Jul 17 09:05 PM
Sheena Jonathan	CO-FOUNDER	Jul 01 '24	Sale	108.87	2,700	293,945	301,808	Jul 02 09:05 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Jul 01 '24	Sale	108.37	2,723	295,080	206,772	Jul 02 09:05 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Jul 01 '24	Sale	108.10	37,500	4,053,805	213,351	Jul 02 09:05 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Jul 01 '24	Sale	108.37	4,983	539,987	75,059	Jul 02 09:05 PM
Sheena Jonathan	CO-FOUNDER	Jun 18 '24	Sale	109.66	2,700	296,080	304,508	Jun 21 09:05 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Jun 17 '24	Sale	111.61	6,105	681,372	213,351	Jun 18 09:35 PM
Marcus Gail Boxer	Director	May 30 '24	Sale	110.17	2,000	220,330	18,634	May 31 09:05 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	May 28 '24	Sale	109.96	1,647	181,103	114,186	May 30 09:05 PM
Fesko John	PRESIDENT, CHIEF BUS. OFFICER	May 28 '24	Sale	109.96	1,438	158,122	109,940	May 30 09:05 PM
Chapman Rowan E	Director	May 28 '24	Sale	109.09	4,856	529,728	5,005	May 30 09:05 PM
Sheena Jonathan	CO-FOUNDER	May 23 '24	Sale	108.30	1,000	108,301	68,582	May 24 09:05 PM
Chapman Steven Leonard	CEO AND PRESIDENT	May 15 '24	Sale	107.08	6,779	725,911	219,456	May 17 09:35 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	May 10 '24	Option Exercise	19.68	30,000	590,400	234,495	May 10 09:35 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	May 10 '24	Sale	104.59	30,000	3,137,567	204,495	May 10 09:35 PM
Sheena Jonathan	CO-FOUNDER	May 10 '24	Sale	105.11	2,700	283,794	319,061	May 10 09:35 PM
Rabinowitz Matthew	EXECUTIVE CHAIRMAN	May 08 '24	Option Exercise	5.40	215,000	1,159,990	1,290,648	May 10 09:35 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	May 01 '24	Sale	93.97	1,866	175,344	67,542	May 03 09:35 PM
Fesko John	PRESIDENT, CHIEF BUS. OFFICER	Apr 29 '24	Sale	93.14	929	86,526	110,748	May 01 09:05 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Apr 29 '24	Sale	93.14	1,196	111,394	115,833	May 01 09:05 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Apr 29 '24	Sale	93.14	1,057	98,448	204,495	May 01 09:05 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Apr 29 '24	Sale	93.14	4,084	380,378	226,235	May 01 09:05 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Apr 29 '24	Sale	93.14	1,238	115,306	69,408	May 01 09:05 PM
Sheena Jonathan	CO-FOUNDER	Apr 25 '24	Sale	89.55	1,000	89,550	69,082	Apr 26 09:35 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Apr 24 '24	Sale	93.00	937	87,140	72,102	Apr 26 09:35 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Apr 26 '24	Sale	92.00	751	69,092	70,646	Apr 26 09:35 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Apr 25 '24	Sale	89.55	705	63,133	71,397	Apr 26 09:35 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Apr 23 '24	Sale	91.38	787	71,915	205,552	Apr 23 09:35 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Apr 23 '24	Sale	91.38	531	48,522	117,029	Apr 23 09:35 PM
Fesko John	PRESIDENT, CHIEF BUS. OFFICER	Apr 23 '24	Sale	91.38	522	47,700	111,677	Apr 23 09:35 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Apr 23 '24	Sale	91.38	2,552	233,200	230,319	Apr 23 09:35 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Apr 23 '24	Sale	91.38	1,523	139,171	73,039	Apr 23 09:35 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Apr 16 '24	Sale	90.82	80,000	7,265,651	117,560	Apr 17 09:05 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Apr 15 '24	Sale	93.13	6,816	634,797	227,710	Apr 17 09:05 PM
Sheena Jonathan	CO-FOUNDER	Apr 03 '24	Sale	92.47	26,700	2,468,822	321,031	Apr 04 09:35 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Apr 02 '24	Sale	92.62	1,378	127,629	70,646	Apr 04 09:35 PM
Sheena Jonathan	CO-FOUNDER	Mar 28 '24	Sale	90.13	1,000	90,130	69,582	Mar 29 09:35 PM
Sheena Jonathan	CO-FOUNDER	Mar 28 '24	Sale	90.22	447	40,326	347,731	Mar 29 09:35 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Mar 28 '24	Sale	90.42	743	67,179	204,839	Mar 29 09:35 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Mar 28 '24	Sale	90.42	707	63,924	197,560	Mar 29 09:35 PM
Fesko John	PRESIDENT, CHIEF BUS. OFFICER	Mar 28 '24	Sale	90.42	464	41,953	112,199	Mar 29 09:35 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Mar 15 '24	Sale	89.02	50,910	4,532,065	0	Mar 29 09:35 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Mar 28 '24	Sale	90.42	2,662	240,687	234,526	Mar 29 09:35 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Mar 28 '24	Sale	90.42	914	82,640	72,024	Mar 29 09:35 PM
BOTHA ROELOF	Director	Mar 15 '24	Option Exercise	42.17	19,924	840,197	20,276	Mar 15 09:05 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Mar 15 '24	Option Exercise	19.37	68,270	1,322,406	315,227	Mar 15 09:05 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Mar 15 '24	Sale	88.96	83,223	7,403,534	232,004	Mar 15 09:05 PM
Sheena Jonathan	CO-FOUNDER	Mar 06 '24	Sale	88.70	5,000	443,492	458,585	Mar 07 09:40 PM
Sheena Jonathan	CO-FOUNDER	Mar 05 '24	Sale	88.36	1,028	90,839	463,585	Mar 07 09:40 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Mar 05 '24	Sale	88.36	2,160	190,868	204,218	Mar 07 09:40 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Mar 05 '24	Sale	88.36	9,326	824,092	246,957	Mar 07 09:40 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Mar 05 '24	Sale	88.36	2,826	249,719	70,646	Mar 07 09:40 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Mar 05 '24	Sale	88.36	2,245	198,361	198,267	Mar 07 09:40 PM
Fesko John	PRESIDENT, CHIEF BUS. OFFICER	Mar 05 '24	Sale	88.36	1,838	162,400	112,663	Mar 07 09:40 PM
Rabinowitz Matthew	EXECUTIVE CHAIRMAN	Mar 05 '24	Sale	87.40	190,000	16,605,069	860,036	Mar 07 09:40 PM
Rabinowitz Matthew	EXECUTIVE CHAIRMAN	Mar 05 '24	Sale	88.36	1,012	89,416	1,075,648	Mar 07 09:40 PM
Sheena Jonathan	CO-FOUNDER	Feb 29 '24	Sale	86.34	10,000	863,433	463,585	Mar 01 08:45 PM
Sheena Jonathan	CO-FOUNDER	Feb 29 '24	Sale	90.02	6,000	540,109	14,655	Mar 01 08:45 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Feb 27 '24	Option Exercise	10.16	35,307	358,802	239,525	Feb 29 09:15 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Feb 29 '24	Option Exercise	9.29	20,526	190,687	224,744	Feb 29 09:15 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Feb 27 '24	Sale	75.09	35,307	2,651,298	204,218	Feb 29 09:15 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Feb 29 '24	Sale	89.01	20,526	1,826,970	204,218	Feb 29 09:15 PM
Rabinowitz Matthew	EXECUTIVE CHAIRMAN	Feb 23 '24	Option Exercise	2.66	380,036	1,009,718	1,050,036	Feb 23 09:40 PM
ROSENMAN HERM	Director	Feb 16 '24	Option Exercise	2.66	93,901	249,486	155,586	Feb 16 09:45 PM
ROSENMAN HERM	Director	Feb 16 '24	Sale	69.37	93,901	6,514,371	61,685	Feb 16 09:45 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Feb 06 '24	Option Exercise	16.61	34,029	565,063	104,675	Feb 08 09:40 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Feb 06 '24	Sale	70.03	34,029	2,383,129	70,646	Feb 08 09:40 PM
Sheena Jonathan	CO-FOUNDER	Feb 06 '24	Sale	70.00	6,000	420,011	18,155	Feb 08 09:05 PM
Sheena Jonathan	CO-FOUNDER	Feb 07 '24	Sale	70.10	5,000	350,486	473,585	Feb 08 09:05 PM
Sheena Jonathan	CO-FOUNDER	Feb 07 '24	Sale	70.10	1,000	70,099	17,655	Feb 08 09:05 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Feb 01 '24	Sale	67.73	22,281	1,509,081	70,646	Feb 02 09:40 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Jan 29 '24	Sale	65.09	3,235	210,570	92,927	Jan 30 09:15 PM
Sheena Jonathan	CO-FOUNDER	Jan 29 '24	Sale	65.09	546	35,540	478,585	Jan 30 09:05 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Jan 29 '24	Sale	65.09	4,265	277,614	204,218	Jan 30 09:05 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Jan 29 '24	Sale	65.09	14,813	964,194	246,957	Jan 30 09:05 PM

Open in Screener

VCYT

Veracyte Inc

Sep 06 • 04:00PM ET

28.57

Dollar change -1.20
Percentage change -4.03	%

Healthcare • Diagnostics & Research • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

Held by: ARKK IWM VTI ARKG VB XBI VXF VBK IWN IBB

Index	RUT	P/E	-	EPS (ttm)	-0.74	Insider Own	1.51%	Shs Outstand	76.81M	Perf Week	-10.55%
Market Cap	2.19B	Forward P/E	70.74	EPS next Y	0.40	Insider Trans	-7.99%	Shs Float	75.63M	Perf Month	5.62%
Income	-54.04M	PEG	-	EPS next Q	0.04	Inst Own	103.39%	Short Float	4.11%	Perf Quarter	33.44%
Sales	399.58M	P/S	5.49	EPS this Y	120.76%	Inst Trans	0.34%	Short Ratio	3.30	Perf Half Y	25.58%
Book/sh	14.76	P/B	1.94	EPS next Y	90.71%	ROA	-4.51%	Short Interest	3.11M	Perf Year	9.84%
Cash/sh	3.07	P/C	9.30	EPS next 5Y	-	ROE	-4.88%	52W Range	18.61 - 33.33	Perf YTD	3.85%
Dividend Est.	-	P/FCF	54.68	EPS past 5Y	-10.52%	ROI	-4.72%	52W High	-14.28%	Beta	1.66
Dividend TTM	-	Quick Ratio	4.17	Sales past 5Y	34.42%	Gross Margin	63.87%	52W Low	53.52%	ATR (14)	1.31
Dividend Ex-Date	-	Current Ratio	4.44	EPS Y/Y TTM	-84.43%	Oper. Margin	1.86%	RSI (14)	46.43	Volatility	3.97% 4.11%
Employees	815	Debt/Eq	0.02	Sales Y/Y TTM	21.59%	Profit Margin	-13.52%	Recom	1.80	Target Price	34.57
Option/Short	Yes / Yes	LT Debt/Eq	0.01	EPS Q/Q	164.11%	Payout	-	Rel Volume	0.86	Prev Close	29.77
Sales Surprise	14.09%	EPS Surprise	526.83%	Sales Q/Q	26.69%	Earnings	Aug 06 AMC	Avg Volume	941.31K	Price	28.57
SMA20	-8.75%	SMA50	8.95%	SMA200	18.23%	Trades		Volume	810,969	Change	-4.03%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-23-24	Reiterated	Needham	Buy	$30 → $33
Jan-18-23	Downgrade	Raymond James	Outperform → Mkt Perform
Jan-05-23	Initiated	Scotiabank	Sector Outperform	$33
Jan-07-22	Initiated	Stephens	Overweight	$52
Nov-18-21	Resumed	Goldman	Buy	$60
Jun-15-21	Initiated	Raymond James	Outperform	$45
Feb-18-21	Resumed	Needham	Buy	$88
Jan-28-21	Initiated	Truist	Buy	$61
Nov-10-20	Initiated	KeyBanc Capital Markets	Sector Weight	$48
Sep-09-20	Initiated	Morgan Stanley	Underweight	$35
Jul-31-19	Initiated	Lake Street	Buy	$35
Jul-02-19	Initiated	Needham	Buy	$33
Nov-29-18	Downgrade	Janney	Buy → Neutral
Oct-31-18	Upgrade	Janney	Neutral → Buy
Nov-07-17	Downgrade	Piper Jaffray	Overweight → Neutral
Nov-07-17	Downgrade	Janney	Buy → Neutral
Aug-31-17	Resumed	BTIG Research	Buy	$13
Nov-14-16	Resumed	Leerink Partners	Outperform	$12
Dec-18-15	Initiated	Cantor Fitzgerald	Buy	$13
Jun-11-15	Reiterated	Leerink Partners	Outperform	$11 → $13

Show Previous Ratings

Sep-06-24 07:01PM	Insider Sale: Chief Commercial Officer-CLIA John Leite Sells Shares of Veracyte Inc (VCYT) (GuruFocus.com)
Sep-05-24 11:31AM	Veracyte (VCYT) Up 9.2% Since Last Earnings Report: Can It Continue? (Zacks)
Sep-04-24 04:05PM	Veracyte Appoints Brent Shafer and Tom Miller, Ph.D., to Its Board of Directors (Business Wire)
09:50AM	Here's Why Veracyte (VCYT) is a Strong Momentum Stock (Zacks)
Aug-26-24 05:30PM	Veracyte to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference (Business Wire)
09:00AM	Loading…
09:00AM	Veracyte Named a Greater Bay Area Top Workplace by the San Francisco Chronicle (Business Wire)
04:36AM	Here's Why Baron Discovery Fund Increased its Holdings in Veracyte (VCYT) (Insider Monkey)
Aug-19-24 09:55AM	Veracyte (VCYT) Just Flashed Golden Cross Signal: Do You Buy? (Zacks)
Aug-15-24 09:50AM	Why Veracyte (VCYT) is a Top Momentum Stock for the Long-Term (Zacks)
Aug-14-24 09:15AM	Veracyte, Inc. (VCYT) Hit a 52 Week High, Can the Run Continue? (Zacks)
Aug-09-24 07:22PM	Insider Sale: Director Jens Holstein Sells 5,000 Shares of Veracyte Inc (VCYT) (GuruFocus.com)
Aug-08-24 09:09AM	Veracyte (VCYT) Q2 Earnings Beat Estimates, '24 Sales View Up (Zacks) +10.79%
Aug-07-24 02:08PM	Diagnostic Tests Maker Veracyte's Q2 Is 'All-Around Very Good Quarter': Analysts Maintain Bullish View (Benzinga) +23.97%
Aug-06-24 06:25PM	Veracyte (VCYT) Q2 Earnings and Revenues Beat Estimates (Zacks)
05:24PM	Veracyte: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Loading…
04:05PM	Veracyte Announces Second Quarter 2024 Financial Results (Business Wire)
Jul-24-24 10:57AM	The 3 Best Personalized Nutrition Stocks to Buy Now (InvestorPlace)
Jul-19-24 12:01AM	Insider Sale: Director Jens Holstein Sells 5,000 Shares of Veracyte Inc (VCYT) (GuruFocus.com)
Jul-17-24 05:00PM	Veracyte to Release Second Quarter 2024 Financial Results on August 6, 2024 (Business Wire) -5.34%
04:48AM	Veracyte (VCYT) Stock Jumps 13.2%: Will It Continue to Soar? (Zacks)
Jun-21-24 09:55AM	Wall Street Analysts See a 37.09% Upside in Veracyte (VCYT): Can the Stock Really Move This High? (Zacks)
Jun-06-24 11:31AM	Veracyte (VCYT) Up 8.4% Since Last Earnings Report: Can It Continue? (Zacks)
Jun-03-24 04:05PM	Veracyte Announces that New Afirma GRID Data Suggest Prognostic Ability of Molecular Testing for Thyroid Tumors (Business Wire)
May-29-24 09:55AM	Wall Street Analysts Think Veracyte (VCYT) Could Surge 39.07%: Read This Before Placing a Bet (Zacks)
09:30AM	Veracyte (VCYT) Crossed Above the 50-Day Moving Average: What That Means for Investors (Zacks)
May-28-24 09:31AM	Here's Why MarketAxess Holdings (MKTX) Fell in Q1 (Insider Monkey)
08:47AM	Workiva (WK) Fell on Disappointing Forward Guidance (Insider Monkey)
08:32AM	Veracyte (VCYT) Fell Due to a Lack of Rising Profitability (Insider Monkey)
May-23-24 10:00AM	Veracyte's (VCYT) New Findings to Advance Thyroid Cancer Care (Zacks)
May-22-24 04:05PM	Veracyte Announces Multiple Afirma GRID Presentations at ENDO 2024, Previewing the Future of Molecular Testing in Thyroid Nodules and Cancer (Business Wire)
09:59AM	Loading…
May-21-24 09:59AM	Veracyte (VCYT) Up 6% Since Last Earnings: Will it Continue? (Zacks)
May-15-24 05:04PM	Veracyte to Participate in Upcoming Investor Conferences (Business Wire)
May-13-24 09:55AM	Wall Street Analysts Believe Veracyte (VCYT) Could Rally 39.59%: Here's is How to Trade (Zacks) +5.29%
May-08-24 03:13PM	Veracyte, Inc. (NASDAQ:VCYT) Q1 2024 Earnings Call Transcript (Insider Monkey)
08:55AM	Veracyte (VCYT) Reports Narrower Q1 Loss, Raises '24 Sales View (Zacks)
07:12AM	Q1 2024 Veracyte Inc Earnings Call (Thomson Reuters StreetEvents)
03:48AM	Veracyte Inc (VCYT) (Q1 2024) Earnings Call Transcript Highlights: Strong Start with Revenue ... (GuruFocus.com)
May-07-24 10:55PM	VCYT Stock Earnings: Veracyte Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
06:13PM	Veracyte: Q1 Earnings Snapshot (Associated Press Finance)
06:00PM	Veracyte Inc (VCYT) Q1 2024 Earnings: Surpasses Revenue Forecasts with Strong Test Performance (GuruFocus.com)
04:05PM	Veracyte Announces First Quarter 2024 Financial Results (Business Wire)
May-06-24 04:05PM	14 Studies Presented at AUA 2024 Show Decipher Tests Ability to Help Personalize Care for Prostate and Bladder Cancer Patients and Advance Disease Understanding (Business Wire)
Apr-22-24 05:00PM	Veracyte to Release First Quarter 2024 Financial Results on May 7, 2024 (Business Wire)
08:30AM	New Study Shows Veracytes Decipher Prostate Test is Prognostic for Prostate Cancer Progression Among Patients Undergoing Active Surveillance (Business Wire)
Apr-16-24 08:30AM	Veracyte Announces that Nine Studies Reinforcing the Value of Decipher Prostate and Decipher Bladder Testing Will Be Presented at AUA 2024 (Business Wire)
Apr-02-24 10:33AM	What Makes Veracyte (VCYT) a Lucrative Investment? (Insider Monkey) -5.22%
Feb-27-24 05:55PM	Veracytes Decipher Prostate Test Receives Highest Evidence-Level Rating Among Molecular Tests in Updated Prostate Cancer NCCN Guidelines (Business Wire)
Feb-26-24 03:20PM	7 Under-the-Radar Biotech Stocks Gearing Up for Liftoff (InvestorPlace) +6.22%
Feb-23-24 11:10AM	Veracyte, Inc. (NASDAQ:VCYT) Q4 2023 Earnings Call Transcript (Insider Monkey) -8.87%
07:43AM	Veracyte's (VCYT) Q4 Loss Widens, Gross Margin Expands (Zacks)
07:37AM	Q4 2023 Veracyte Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-22-24 06:05PM	Veracyte (VCYT) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
05:03PM	Veracyte: Q4 Earnings Snapshot (Associated Press Finance)
04:40PM	Veracyte Inc (VCYT) Reports 22% Revenue Growth in 2023, Maintains Positive Cash Flow Outlook (GuruFocus.com)
04:05PM	Veracyte Announces Fourth Quarter and Full-Year 2023 Financial Results (Business Wire)
Feb-21-24 05:00PM	Veracyte to Participate in the Raymond James 45th Annual Institutional Investors Conference (Business Wire)
Feb-08-24 08:00AM	Veracyte to Release Fourth Quarter and Full-Year 2023 Financial Results on February 22, 2024 (Business Wire)
Feb-06-24 08:15AM	Veracyte Completes Acquisition of C2i Genomics (Business Wire)
Jan-08-24 08:00AM	Veracyte Announces Preliminary Full-Year 2023 Results, Acquisition of C2i Genomics to Add Minimal Residual Disease Capabilities to Its Novel Diagnostics Platform (Business Wire) +13.10%
Dec-12-23 04:30PM	Veracyte to Participate in the 42nd Annual J.P. Morgan Healthcare Conference (Business Wire) +7.51%
Dec-01-23 04:05PM	Real-World Data Presented at SUO 2023 Show that Veracytes Decipher Genomic Classifier Identifies Patients Whose Prostate Cancer is Likely to Progress (Business Wire)
Nov-29-23 08:30AM	Clinical Validation Data Published in CHEST Demonstrate that Veracytes Percepta Nasal Swab Test Improves Lung Cancer Risk Assessment for Patients with Lung Nodules (Business Wire)
Nov-22-23 08:30AM	Veracyte Announces Seven Posters Highlighting Clinical Value of Decipher Prostate Genomic Testing To be Presented at SUO 2023 (Business Wire)
Nov-08-23 04:39PM	Veracyte, Inc. (NASDAQ:VCYT) Q3 2023 Earnings Call Transcript (Insider Monkey) -7.26%
Nov-07-23 04:57PM	Veracyte: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Veracyte Announces Third Quarter 2023 Financial Results (Business Wire)
04:00PM	Veracyte Announces In Vitro Diagnostic Agreement with Illumina to Broaden Availability of Its Tests for Patients Globally (Business Wire)
Nov-02-23 08:15AM	Veracyte to Participate in the Stephens Annual Investment Conference (Business Wire) +6.13%
Oct-27-23 08:30AM	Veracyte Announces SITC 2023 Presentations Offering New Insight into Immuno-oncology Drug Development (Business Wire)
Oct-26-23 02:50PM	7 Undervalued Stocks That Analysts Love Right Now (InvestorPlace)
Oct-17-23 08:15AM	Veracyte to Release Third Quarter 2023 Financial Results on November 7, 2023 (Business Wire)
Oct-16-23 10:43AM	16 Best Stocks to Buy and Hold for the Next 15 Years According to Cathie Woods Portfolio (Insider Monkey)
Oct-12-23 09:00AM	New Data Presented at CHEST 2023 Demonstrate the Clinical Utility of Veracytes Envisia Genomic Classifier for Patients with Interstitial Lung Disease (Business Wire) -5.82%
Oct-04-23 04:05PM	New Data from Phase 3 Trial Further Validate Prognostic Value of Veracytes Decipher Prostate Genomic Classifier (Business Wire)
Sep-28-23 04:05PM	New Data Presented at the 2023 ATA Annual Meeting Demonstrate that Veracytes Afirma-Based Testing Can Uncover Key Molecular Hallmarks of Thyroid Cancer (Business Wire)
08:15AM	Veracyte Announces Multiple Studies Reinforcing the Value of Decipher Prostate Testing Will Be Presented at ASTRO 2023 (Business Wire)
Sep-27-23 09:00AM	Veracyte Names Phillip G. Febbo, M.D., as Chief Scientific Officer and Chief Medical Officer (Business Wire)
Sep-21-23 04:05PM	Veracyte Announces Novel Afirma-Based Findings that Advance Molecular Understanding of Thyroid Cancer to Be Presented at the 2023 ATA Annual Meeting (Business Wire)
Sep-07-23 04:05PM	Veracyte Names Marie-Claire Taine, Ph.D., as General Manager of Its IVD Business Unit To Advance Global Expansion of the Companys Tests (Business Wire)
Sep-06-23 08:15AM	Veracyte and Gustave Roussy Announce Collaboration to Help Biopharmaceutical Companies Accelerate Development of Novel Cancer Therapies (Business Wire)
Sep-02-23 06:15AM	Is This Underfollowed Genetic Diagnostics Stock a Buy for Growth Investors? (Motley Fool)
Aug-29-23 08:15AM	Veracyte to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference (Business Wire)
Aug-22-23 08:15AM	Veracyte Announces that Findings Published in JCO Precision Oncology Suggest Potential of Decipher GRID-Derived Gene Signatures to Predict Treatment Response in Recurrent Prostate Cancer (Business Wire)
Aug-15-23 04:15PM	Veracyte Earns Top Workplace Awards in the San Francisco Bay Area and San Diego (Business Wire)
Aug-08-23 06:05PM	Veracyte (VCYT) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +7.04%
04:55PM	Veracyte: Q2 Earnings Snapshot (AP Finance)
04:05PM	Veracyte Announces Second Quarter 2023 Financial Results (Business Wire)
Aug-01-23 08:15AM	Study Published in JNCI Cancer Spectrum Demonstrates Real-World Utility of Veracytes Decipher Prostate Genomic Classifier in Prostate Cancer Treatment (Business Wire)
Jul-19-23 05:00PM	Veracyte to Release Second Quarter 2023 Financial Results on August 8, 2023 (Business Wire)
Jul-08-23 08:43PM	Looking for Biotech AI Stocks? 3 Names That Will Benefit From the AI Boom (InvestorPlace)
Jun-20-23 08:31AM	New Data Suggest Veracytes Afirma Molecular Testing Capabilities Can Help Advance Scientific Understanding of Thyroid Nodules and Cancer (Business Wire)
Jun-12-23 08:31AM	Veracyte Announces Afirma-Focused Abstracts to Be Presented at ENDO 2023 (Business Wire)
May-30-23 06:56AM	Veracyte, Inc.'s (NASDAQ:VCYT) Revenues Are Not Doing Enough For Some Investors (Simply Wall St.)
May-25-23 05:13PM	New Data To Be Shared at 2023 ASCO Demonstrate Power of Veracytes Decipher GRID To Help Advance Molecular Understanding of Prostate Cancer (Business Wire)
May-24-23 09:00AM	New Data Presented at ATS 2023 Reinforce Clinical Utility of Veracytes Genomic Tests in Interstitial Lung Disease and Lung Cancer (Business Wire)
May-23-23 05:00PM	Veracyte to Participate in Upcoming Investor Conferences (Business Wire)
May-22-23 07:30AM	Here's Why This Little-Known Growth Stock Is a Buy (Motley Fool) +7.79%
May-12-23 06:15AM	Veracyte Announces that New Data Show Use of the Prosigna Test Significantly Changed Treatment Decisions for Patients with Early-Stage Breast Cancer (Business Wire)
May-05-23 01:59PM	Veracyte, Inc. (NASDAQ:VCYT) Q1 2023 Earnings Call Transcript (Insider Monkey)
May-04-23 06:25PM	Veracyte (VCYT) Reports Q1 Loss, Tops Revenue Estimates (Zacks)

Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Leite John	Chief Commercial Officer-CLIA	Sep 04 '24	Sale	29.78	5,479	163,159	76,174	Sep 06 04:18 PM
JOHN LEITE	Officer	Sep 04 '24	Proposed Sale	30.29	5,479	165,959		Sep 04 04:17 PM
JONES EVAN/ FA	Director	Aug 13 '24	Option Exercise	10.41	8,486	88,339	54,800	Aug 14 05:09 PM
JONES EVAN/ FA	Director	Aug 13 '24	Sale	32.20	27,188	875,565	5,173	Aug 14 05:09 PM
JONES EVAN/ FA	Director	Aug 13 '24	Sale	32.20	20,457	658,801	34,343	Aug 14 05:09 PM
JONES EVAN/ FA	Director	Aug 12 '24	Sale	30.00	101	3,031	32,361	Aug 14 05:09 PM
JONES EVAN/ FA	Director	Aug 12 '24	Sale	30.01	99	2,971	46,314	Aug 14 05:09 PM
JONES EVAN/ FA	Director	Aug 09 '24	Option Exercise	10.41	300	3,123	47,445	Aug 13 04:38 PM
JONES EVAN/ FA	Director	Aug 09 '24	Sale	30.03	1,032	30,990	46,413	Aug 13 04:38 PM
JONES EVAN/ FA	Director	Aug 09 '24	Sale	30.03	746	22,402	32,462	Aug 13 04:38 PM
Holstein Jens	Director	Aug 07 '24	Sale	29.00	5,000	145,000	27,878	Aug 09 04:47 PM
JONES EVAN/ FA	Director	Aug 07 '24	Option Exercise	10.41	1,214	12,638	50,288	Aug 09 04:47 PM
JONES EVAN/ FA	Director	Aug 07 '24	Sale	30.32	5,108	154,883	45,180	Aug 09 04:47 PM
Evan Jones	Director	Aug 07 '24	Proposed Sale	27.05	59,904	1,620,403		Aug 07 07:52 PM
EASTHAM KARIN	Director	Jul 16 '24	Sale	25.00	7,500	187,500	33,228	Jul 18 06:25 PM
Leite John	Chief Commercial Officer-CLIA	Jul 16 '24	Sale	25.00	1,277	31,925	82,968	Jul 18 06:25 PM
Holstein Jens	Director	Jul 16 '24	Sale	24.50	5,000	122,500	32,878	Jul 18 06:25 PM
EASTHAM KARIN	Director	Jun 11 '24	Sale	20.59	3,870	79,683	29,255	Jun 13 04:24 PM
Bhanji Muna	Director	Jun 10 '24	Sale	20.32	3,870	78,634	23,105	Jun 11 04:22 PM
EASTHAM KARIN	Director	Jun 07 '24	Option Exercise	10.41	2,500	26,025	35,625	Jun 11 04:21 PM
EASTHAM KARIN	Director	Jun 07 '24	Sale	20.97	2,500	52,425	33,125	Jun 11 04:21 PM
Bhanji Muna	Director	May 28 '24	Sale	21.00	1,539	32,319	26,975	May 30 04:41 PM
EASTHAM KARIN	Director	Apr 01 '24	Option Exercise	13.19	10,000	131,900	43,125	Apr 02 04:17 PM
EASTHAM KARIN	Director	Apr 01 '24	Sale	21.65	10,000	216,528	33,125	Apr 02 04:17 PM
JONES EVAN/ FA	Director	Mar 01 '24	Option Exercise	13.19	10,000	131,900	47,601	Mar 05 05:28 PM
JONES EVAN/ FA	Director	Mar 01 '24	Sale	24.36	10,000	243,599	37,601	Mar 05 05:28 PM

Open in Screener

CSTL

Castle Biosciences Inc

Sep 06 • 04:00PM ET

29.32

Dollar change -0.16
Percentage change -0.54	%

Healthcare • Diagnostics & Research • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

CSTL Castle Biosciences Inc daily Stock Chart

Held by: IWM VTI VXF IBB IWN SCHA DFAT VTWO IWO VHT

Index	RUT	P/E	-	EPS (ttm)	-0.13	Insider Own	6.53%	Shs Outstand	27.41M	Perf Week	-1.58%
Market Cap	813.34M	Forward P/E	-	EPS next Y	-2.32	Insider Trans	-7.30%	Shs Float	25.93M	Perf Month	9.36%
Income	-3.10M	PEG	-	EPS next Q	-0.03	Inst Own	87.93%	Short Float	6.56%	Perf Quarter	27.31%
Sales	287.59M	P/S	2.83	EPS this Y	72.71%	Inst Trans	-2.01%	Short Ratio	4.17	Perf Half Y	41.30%
Book/sh	15.30	P/B	1.92	EPS next Y	-296.71%	ROA	-0.68%	Short Interest	1.70M	Perf Year	53.67%
Cash/sh	9.36	P/C	3.13	EPS next 5Y	-	ROE	-0.77%	52W Range	12.07 - 30.50	Perf YTD	35.87%
Dividend Est.	-	P/FCF	31.75	EPS past 5Y	-28.57%	ROI	-0.69%	52W High	-3.87%	Beta	1.03
Dividend TTM	-	Quick Ratio	7.92	Sales past 5Y	60.93%	Gross Margin	78.13%	52W Low	142.92%	ATR (14)	1.52
Dividend Ex-Date	-	Current Ratio	8.12	EPS Y/Y TTM	96.35%	Oper. Margin	-5.48%	RSI (14)	61.81	Volatility	4.50% 5.12%
Employees	610	Debt/Eq	0.06	Sales Y/Y TTM	71.67%	Profit Margin	-1.08%	Recom	1.11	Target Price	35.56
Option/Short	Yes / Yes	LT Debt/Eq	0.06	EPS Q/Q	144.19%	Payout	-	Rel Volume	0.74	Prev Close	29.48
Sales Surprise	24.90%	EPS Surprise	215.37%	Sales Q/Q	73.53%	Earnings	Aug 05 AMC	Avg Volume	408.43K	Price	29.32
SMA20	3.96%	SMA50	23.68%	SMA200	31.99%	Trades		Volume	302,921	Change	-0.54%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-14-23	Initiated	Guggenheim	Buy	$25
Jan-05-23	Initiated	Scotiabank	Sector Outperform	$54
Jan-07-22	Initiated	Stephens	Overweight	$59
Apr-30-21	Initiated	Lake Street	Buy	$94
Nov-10-20	Initiated	KeyBanc Capital Markets	Overweight	$70
Dec-27-19	Reiterated	Canaccord Genuity	Buy	$34 → $35
Aug-19-19	Initiated	SVB Leerink	Outperform	$28
Aug-19-19	Initiated	Robert W. Baird	Outperform	$27
Aug-19-19	Initiated	Canaccord Genuity	Buy	$26
Aug-19-19	Initiated	BTIG Research	Buy	$25

Sep-05-24 07:02PM	Insider Sale: COO Kristen Oelschlager Sells Shares of Castle Biosciences Inc (CSTL) (GuruFocus.com)
07:00AM	Study Confirms the Ability of Castle Biosciences' DecisionDx-SCC Test to Predict Likelihood of Benefit from Adjuvant Radiation Therapy in Patients with High-Risk Cutaneous Squamous Cell Carcinoma (Business Wire)
Aug-28-24 07:00AM	Castle Biosciences to Participate in Upcoming Investor Conferences (Business Wire)
Aug-05-24 05:45PM	Castle Biosciences, Inc. (CSTL) Q2 Earnings and Revenues Beat Estimates (Zacks) +13.96%
04:05PM	Castle Biosciences Reports Second Quarter 2024 Results (Business Wire)
07:00AM	Loading…
Jul-30-24 07:00AM	Castle Biosciences to Present at the Canaccord Genuity 44th Annual Growth Conference (Business Wire) +7.72%
Jul-29-24 10:00AM	Will Castle Biosciences, Inc. (CSTL) Report Negative Earnings Next Week? What You Should Know (Zacks)
Jul-22-24 07:00AM	Castle Biosciences and Skin Cancer Survivor Teddi Mellencamp Arroyave Launch Campaign to Increase Awareness of Melanoma (Business Wire)
Jul-15-24 07:00AM	Castle Biosciences to Release Second Quarter 2024 Financial Results and Host Conference Call on Monday, Aug. 5, 2024 (Business Wire)
Jul-12-24 12:00PM	All You Need to Know About Castle Biosciences (CSTL) Rating Upgrade to Strong Buy (Zacks)
Jul-11-24 07:00AM	Castle Biosciences Honored with Top Workplaces Awards (Business Wire) +5.78%
Jun-24-24 07:00AM	Recent AGA Clinical Practice Guideline Acknowledges That Individuals Who May Be at Increased Risk of Progression to Esophageal Cancer Might Be Identified Using Tissue-Based Biomarkers, Particularly Castle Biosciences TissueCypher Test (Business Wire)
Jun-20-24 07:00AM	Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-14-24 04:30PM	Castle Biosciences Founder, President and CEO Derek Maetzold Named an EY Entrepreneur Of The Year 2024 Gulf South Award Winner (Business Wire)
Jun-13-24 09:40AM	Is Castle Biosciences (CSTL) Outperforming Other Medical Stocks This Year? (Zacks)
04:30PM	Loading…
May-30-24 04:30PM	Castle Biosciences to Present New Data at 2024 ASCO Annual Meeting Highlighting Use of DecisionDx-Melanoma to Identify Early-Stage Melanoma Patients at High Risk of Metastasis to the Central Nervous System to Prompt Use of Imaging Surveillance (Business Wire)
May-29-24 04:30PM	New Publication Shows DecisionDx-SCC Identifies High-Risk Squamous Cell Carcinoma Patients Who Are Likely to Benefit from Adjuvant Radiation Therapy and Those Who Can Consider Deferring Treatment Based on Biological Risk of Metastasis (Business Wire)
May-23-24 09:55AM	Does Castle Biosciences (CSTL) Have the Potential to Rally 36.15% as Wall Street Analysts Expect? (Zacks)
08:50AM	What Makes Castle Biosciences (CSTL) a Good Fit for 'Trend Investing' (Zacks)
May-15-24 07:00AM	Castle Biosciences to Present at the Leerink Partners Healthcare Crossroads Conference (Business Wire)
May-14-24 07:00AM	Castle Biosciences Expands Evidence Supporting the Performance of its TissueCypher Barretts Esophagus Test in Predicting Future Development of Esophageal Cancer Through Multiple Data Presentations at DDW 2024 (Business Wire)
May-10-24 07:00AM	Castle Biosciences IDgenetix Test Receives 2024 MedTech Breakthrough Award for Best Overall Mental Health Solution (Business Wire)
May-08-24 05:22PM	Castle Biosciences Insider Sold Shares Worth $574,679, According to a Recent SEC Filing (MT Newswires)
04:30PM	Largest Prospective Study to Date Further Supports Performance of DecisionDx-UM for Metastatic Risk Stratification in Uveal Melanoma and Utility of PRAME Biomarker for Refining Risk When Considered with DecisionDx-UM Class Result (Business Wire)
May-07-24 09:55AM	Wall Street Analysts Predict a 36.09% Upside in Castle Biosciences (CSTL): Here's What You Should Know (Zacks)
May-06-24 08:50AM	Castle Biosciences (CSTL) is on the Move, Here's Why the Trend Could be Sustainable (Zacks)
May-05-24 08:32AM	Castle Biosciences, Inc. (NASDAQ:CSTL) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-03-24 07:00AM	DecisionDx-SCC Significantly Improves Prediction Accuracy of Metastatic Events after Mohs Surgery in New Study of Patients with High-Risk Cutaneous Squamous Cell Carcinoma Tumors of the Head and Neck (Business Wire) +6.52%
May-02-24 08:56PM	CSTL Stock Earnings: Castle Biosciences Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
05:59PM	Castle Biosciences Inc (CSTL) Q1 2024 Earnings: Surpasses Revenue Forecasts and Raises Annual ... (GuruFocus.com)
05:50PM	Loading…
05:50PM	Castle Biosciences, Inc. (CSTL) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Castle Biosciences Reports First Quarter 2024 Results (Business Wire)
Apr-30-24 04:30PM	Castle Biosciences Kicks off Skin Cancer Awareness Month with a Ribbon Cutting to Celebrate the City of Friendswoods Designation as a Sun Safe Leadership Model City by IMPACT Melanoma (Business Wire)
Apr-11-24 07:00AM	Castle Biosciences to Release First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 2, 2024 (Business Wire)
Apr-10-24 05:00PM	Castle Biosciences Celebrates Esophageal Cancer Awareness Month through Advocacy and Educational Collaborations (Business Wire) -5.15%
07:00AM	Castle Biosciences Chief Financial Officer Frank Stokes Recognized as a Top CFO of Houston for Second Consecutive Year (Business Wire)
Apr-05-24 04:43AM	What Makes Castle Bioscience (CSTL) a Prospective Investment? (Insider Monkey)
Apr-04-24 04:30PM	Presentations at EADO Highlight Potential Impact of Castle Biosciences DecisionDx-Melanoma and DecisionDx-SCC Tests on the Management of Patients with Skin Cancer (Business Wire)
Apr-02-24 07:00AM	Castle Biosciences to Present at the 23rd Annual Needham Virtual Healthcare Conference (Business Wire)
Mar-27-24 05:00PM	Castle Biosciences Announces Updates to its Board of Directors (Business Wire)
Mar-25-24 07:00AM	Castle Biosciences Earns a Top Workplaces USA Award for the Third Consecutive Year (Business Wire)
Mar-22-24 04:30PM	Long-term Outcomes Data Shared at SSO 2024 Show That Patients with a Low-Risk DecisionDx-Melanoma Test Result Were Recurrence Free at Three Years, Including Those Who Utilized the Test to Help Guide the Decision to Avoid an SLNB (Business Wire)
Mar-20-24 05:17AM	Does Castle Bioscience (CSTL) Have Robust Growth Prospects? (Insider Monkey) +5.11%
Mar-19-24 07:00AM	Leading Squamous Cell Carcinoma Practitioners Publish Consensus Guidelines Integrating DecisionDx-SCC into a Clinical Workflow to Improve Decision-Making Regarding the Use of Adjuvant Radiation Therapy (Business Wire)
Mar-15-24 04:30PM	New Study Shows that the Drug-Drug Interactions and Lifestyle Factors Provided by Castle Biosciences IDgenetix Test Significantly Improve Medication Recommendations Over Drug-Gene Interactions Alone for Patients 65 and Older (Business Wire)
Mar-12-24 07:00AM	Castle Biosciences to Present at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum (Business Wire)
Mar-08-24 04:30PM	Castle Biosciences to Present New Data Highlighting the Clinical Value of its Dermatologic Tests for Patients with Skin Cancer at the 2024 American Academy of Dermatology (AAD) Annual Meeting (Business Wire)
Mar-07-24 07:00AM	In Novel Cohort, New Data Confirms DecisionDx-SCC Provides Significant, Independent and Clinically Actionable Risk-Stratification of Patients, Including in Various High-Risk Subgroups (Business Wire)
Feb-29-24 10:37AM	Castle Biosciences, Inc. (NASDAQ:CSTL) Q4 2023 Earnings Call Transcript (Insider Monkey) -25.95%
08:43AM	Q4 2023 Castle Biosciences Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-28-24 06:30PM	Castle Biosciences, Inc. (CSTL) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
05:40PM	Castle Biosciences, Inc. (CSTL) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:42PM	Castle Biosciences Inc (CSTL) Reports Robust Revenue Growth and Improved Margins in 2023 (GuruFocus.com)
04:05PM	Castle Biosciences Reports Fourth Quarter and Full-Year 2023 Results (Business Wire)
Feb-26-24 09:16AM	Insights Into Castle Biosciences, Inc. (CSTL) Q4: Wall Street Projections for Key Metrics (Zacks)
07:00AM	Study Finds DecisionDx-Melanoma Significantly Improves the Risk Stratification of Patients with Stage I Melanoma Compared to American Joint Committee on Cancer 8th Edition Staging (Business Wire)
Feb-07-24 07:00AM	Castle Biosciences to Release Fourth Quarter and Full-Year 2023 Financial Results and Host Conference Call on Wednesday, Feb. 28, 2024 (Business Wire)
Jan-18-24 07:00AM	New Study Highlights Significant Potential Medicare Savings Through Use of Castle Biosciences DecisionDx-SCC Test to Guide Adjuvant Radiation Therapy Decisions in Patients with Cutaneous Squamous Cell Carcinoma (Business Wire)
Jan-14-24 04:30AM	Castle Biosciences Presents Data Supporting the Utility of Its Tests in the Clinical Care of Patients with Skin Cancers at the 2024 Winter Clinical Dermatology Conference - Hawaii (Business Wire)
Jan-09-24 07:00AM	Castle Biosciences Chief Operating Officer Kristen Oelschlager Selected Among the Top 25 Women Leaders in Biotechnology by The Healthcare Technology Report (Business Wire)
Jan-07-24 08:00PM	Castle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2023 Results (Business Wire)
Dec-20-23 07:00AM	Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Dec-12-23 09:55AM	How Much Upside is Left in Castle Biosciences, Inc. (CSTL)? Wall Street Analysts Think 67.01% (Zacks)
Dec-01-23 07:00AM	Study Finds Nurse Practitioners and Physician Assistants Would Alter Patient Care Decisions Based on DecisionDx-Melanoma Test Results (Business Wire)
Nov-14-23 07:00AM	Castle Biosciences Announces Multiple Data Presentations at the 2023 American Society for Dermatologic Surgery Annual Meeting (Business Wire) +8.01%
Nov-13-23 07:00AM	Castle Biosciences Ranked Among the Top Workplaces in Houston by the Houston Chronicle for the Third Consecutive Year (Business Wire)
Nov-08-23 04:30PM	Real-World Evidence Confirms IDgenetix-Guided Medication Management Significantly Improves Response and Remission Rates in Patients with Major Depressive Disorder (Business Wire)
01:00PM	Castle Biosciences to Present at Upcoming Investor Conferences (Business Wire)
Nov-04-23 09:18AM	Castle Biosciences, Inc. (NASDAQ:CSTL) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-03-23 08:11AM	Q3 2023 Castle Biosciences Inc Earnings Call (Thomson Reuters StreetEvents) +7.99%
07:00AM	Castle Announces Early Exploratory Study Data for Potential Development of a Complementary Test to Accompany DecisionDx-UM That Could Aid in the Early Detection of Uveal Melanomas (Business Wire)
Nov-02-23 07:30PM	Here's What Key Metrics Tell Us About Castle Biosciences, Inc. (CSTL) Q3 Earnings (Zacks) +6.05%
07:24PM	Castle Biosciences Inc (CSTL) Reports 66% Revenue Increase in Q3 2023 (GuruFocus.com)
04:06PM	Early Discovery Data Shows Ability of Castle Biosciences Pipeline Program to Distinguish Between Responders and Non-Responders to an Atopic Dermatitis Therapy (Business Wire)
04:05PM	Castle Biosciences Reports Third Quarter 2023 Results (Business Wire)
Oct-24-23 07:00AM	Castle Biosciences to Present New Data on its TissueCypher Barretts Esophagus Test at the 2023 American College of Gastroenterology Annual Scientific Meeting (Business Wire)
Oct-19-23 07:00AM	Castle Biosciences to Release Third Quarter 2023 Financial Results and Host Conference Call on Thursday, Nov. 2 (Business Wire)
Oct-18-23 04:30PM	New Data Highlights Clinical Utility and Performance of Castle Biosciences Dermatologic Test Portfolio at the 2023 Fall Clinical Dermatology Conference (Business Wire)
Oct-05-23 07:00AM	DecisionDx-Melanoma Outperforms Memorial Sloan Kettering Cancer Center (MSKCC) Nomogram in Predicting Sentinel Lymph Node Positivity in Patients with Cutaneous Melanoma (Business Wire)
Oct-03-23 07:00AM	Castle Biosciences Presents New Data at ASTRO 2023 Highlighting Risk-Stratification Performance of DecisionDx-SCC in Patients with Cutaneous Squamous Cell Carcinoma Eligible for Adjuvant Radiation Therapy (Business Wire)
Oct-02-23 07:00AM	Castle Biosciences Shares New Data Demonstrating Ability of TissueCypher Test Results to Inform Clinical Decision-Making in Patients with Non-Dysplastic Barretts Esophagus (Business Wire)
Sep-25-23 07:00AM	Castle Biosciences, Leading Skin Cancer Expert, Darrell Rigel, M.D., M.S., and IMPACT Melanoma Board Member to Ring Nasdaq Closing Bell on Sept. 27, 2023, to Raise Awareness of Melanoma (Business Wire)
Sep-19-23 07:00AM	Castle Biosciences Ranked Third Among 2023 Top Workplaces in the Healthcare Industry (Business Wire)
Sep-14-23 07:00AM	TissueCypher® Barretts Esophagus Test Outperformed Standard of Care in Risk-Stratifying Patients with Barretts Esophagus (Business Wire)
Sep-12-23 07:00AM	Castle Biosciences Announces Receipt of New York Laboratory Permit for Pittsburgh Laboratory (Business Wire)
Sep-09-23 08:00PM	Integrating Drug-Drug Interactions and Lifestyle Factors with Drug-Gene Interactions Provided by Castle Biosciences IDgenetix® Test Significantly Impacted the Number of Drug Recommendations for Patients with Moderate to Severe Depression (Business Wire)
Sep-08-23 04:30PM	TissueCypher® Provides Clinically-Impactful Risk Stratification in Patients with Barretts Esophagus (Business Wire)
Sep-06-23 07:00AM	Castle Biosciences to Highlight Clinical Value of IDgenetix® Test at Psych Congress 2023 (Business Wire)
Sep-05-23 07:00AM	Castle Biosciences to Participate in Upcoming Investor Conferences (Business Wire)
Aug-07-23 07:00AM	New Publication Highlights the Ability of the TissueCypher® Barretts Esophagus Test to Improve and Standardize the Clinical Management of Low-Grade Dysplasia in Patients with Barretts Esophagus (Business Wire)
Aug-03-23 11:17AM	Why Castle Biosciences Stock Is Jumping Today (Motley Fool) +11.79%
08:31AM	Castle Biosciences, Inc. (NASDAQ:CSTL) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-02-23 07:30PM	Here's What Key Metrics Tell Us About Castle Biosciences, Inc. (CSTL) Q2 Earnings (Zacks)
06:15PM	Castle Biosciences, Inc. (CSTL) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Castle Biosciences Reports Second Quarter 2023 Results (Business Wire)
Aug-01-23 07:00AM	Castle Biosciences to Present at the Canaccord Genuity 43rd Annual Growth Conference (Business Wire)
Jul-26-23 10:02AM	Earnings Preview: Castle Biosciences, Inc. (CSTL) Q2 Earnings Expected to Decline (Zacks)
Jul-19-23 07:00AM	Castle Biosciences to Release Second Quarter 2023 Financial Results and Host Conference Call on Wednesday, Aug. 2 (Business Wire)
Jul-18-23 07:00AM	Castle Biosciences to Host Second Annual Castle Cares Charity Walk (Business Wire)
Jul-17-23 07:00AM	Castle Biosciences Honored as an Arizona Top Workplace for the Second Consecutive Year (Business Wire)

Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The firm offers DecisionDx-Melanoma, a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis and recurrence for patients diagnosed with invasive cutaneous melanoma. It also markets DecisionDx-UM, Decision Dx DiffDx-Melanoma, DecisonDx-CMSeq, DecisionDx-SCC, DecsionDx-UMSeq, and DecisonDX-PRAME. The company was founded by Derek J. Maetzold in September 2007 and is headquartered in Friendswood, TX.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Sep 03 '24	Sale	30.05	699	21,004	8,005	Sep 05 04:07 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Sep 04 '24	Sale	30.02	500	15,012	7,956	Sep 05 04:07 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Sep 03 '24	Sale	30.05	417	12,530	99,870	Sep 05 04:07 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Sep 04 '24	Sale	30.02	298	8,947	99,572	Sep 05 04:07 PM
Oelschlager Kristen M	Chief Operating Officer	Sep 03 '24	Sale	29.21	5,832	170,330	134,841	Sep 05 04:06 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Aug 29 '24	Sale	30.07	2,246	67,548	8,126	Sep 03 04:08 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Aug 29 '24	Sale	30.07	1,334	40,120	100,609	Sep 03 04:08 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Aug 30 '24	Sale	30.10	539	16,223	8,073	Sep 03 04:08 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Aug 30 '24	Sale	30.10	322	9,692	100,287	Sep 03 04:08 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Aug 23 '24	Sale	30.09	1,746	52,535	8,356	Aug 27 04:11 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Aug 23 '24	Sale	30.09	1,037	31,202	102,019	Aug 27 04:11 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Aug 26 '24	Sale	30.05	128	3,846	8,342	Aug 27 04:11 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Aug 26 '24	Sale	30.05	76	2,284	101,943	Aug 27 04:11 PM
Derek Maetzold	Officer	Aug 23 '24	Proposed Sale	29.57	44,380	1,312,317		Aug 23 05:17 PM
BRADBURY DANIEL	Director	Aug 12 '24	Sale	26.65	7,883	210,058	8,550	Aug 14 04:53 PM
Stokes Frank	Chief Financial Officer	Aug 07 '24	Sale	25.70	10,000	256,997	30,823	Aug 13 06:13 PM
Daniel Bradbury	Officer	Aug 12 '24	Proposed Sale	26.75	15,750	421,312		Aug 12 04:37 PM
Oelschlager Kristen M	Chief Operating Officer	Aug 01 '24	Sale	23.06	12,989	299,503	132,836	Aug 05 04:16 PM
Stokes Frank	Officer	Aug 07 '24	Proposed Sale	20.92	10,000	209,200		Aug 02 03:13 PM
Oelschlager Kristen M	Chief Operating Officer	Jul 29 '24	Sale	22.06	2,793	61,622	145,825	Jul 31 04:50 PM
Oelschlager Kristen M	Chief Operating Officer	Jul 01 '24	Sale	21.22	2,793	59,279	148,618	Jul 03 04:15 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Jun 03 '24	Sale	23.40	3,968	92,857	8,525	Jun 05 05:23 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Jun 03 '24	Sale	23.40	2,368	55,416	57,893	Jun 05 05:23 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	May 14 '24	Sale	24.27	3,968	96,290	8,911	May 16 04:20 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	May 14 '24	Sale	24.27	2,368	57,463	60,261	May 16 04:20 PM
BRADBURY DANIEL	Director	May 06 '24	Sale	24.64	23,323	574,679	9,981	May 08 04:51 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	May 06 '24	Sale	24.72	3,968	98,089	9,297	May 08 04:47 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	May 06 '24	Sale	24.72	2,368	58,537	62,629	May 08 04:47 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Apr 23 '24	Sale	20.11	705	14,177	9,683	Apr 25 04:54 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Apr 23 '24	Sale	20.11	421	8,466	64,997	Apr 25 04:54 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Apr 12 '24	Sale	20.35	3,263	66,402	9,752	Apr 16 04:46 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Apr 12 '24	Sale	20.35	1,947	39,621	65,418	Apr 16 04:46 PM
BRADBURY DANIEL	Director	Apr 08 '24	Sale	20.45	2,400	49,087	17,944	Apr 10 04:35 PM
BRADBURY DANIEL	Director	Apr 05 '24	Sale	20.86	11,771	245,543	18,763	Apr 08 04:31 PM
BRADBURY DANIEL	Director	Apr 04 '24	Sale	21.45	9,152	196,310	22,782	Apr 08 04:31 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Apr 03 '24	Sale	21.70	3,968	86,106	10,069	Apr 05 04:37 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Apr 03 '24	Sale	21.70	2,368	51,386	67,365	Apr 05 04:37 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Mar 20 '24	Sale	20.27	3,847	77,979	10,467	Mar 22 05:16 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Mar 20 '24	Sale	20.27	2,295	46,520	69,806	Mar 22 05:16 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Mar 21 '24	Sale	20.70	121	2,505	10,455	Mar 22 05:16 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Mar 21 '24	Sale	20.70	73	1,511	69,733	Mar 22 05:16 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Mar 07 '24	Sale	20.77	3,996	82,997	10,841	Mar 11 05:18 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Mar 07 '24	Sale	20.77	2,372	49,266	72,101	Mar 11 05:18 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Mar 05 '24	Option Exercise	3.72	10,686	39,752	78,604	Mar 06 05:58 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Mar 05 '24	Sale	21.41	4,131	88,461	74,473	Mar 06 05:58 PM
BRADBURY DANIEL	Director	Mar 04 '24	Sale	20.68	23,323	482,285	25,907	Mar 06 05:52 PM
BRADBURY DANIEL	Director	Feb 07 '24	Sale	23.20	2,074	48,117	33,870	Feb 09 04:49 PM
BRADBURY DANIEL	Director	Feb 05 '24	Sale	22.90	11,402	261,134	37,940	Feb 07 04:19 PM
BRADBURY DANIEL	Director	Feb 06 '24	Sale	23.63	9,847	232,685	34,578	Feb 07 04:19 PM
BRADBURY DANIEL	Director	Jan 04 '24	Sale	20.40	18,223	371,749	43,574	Jan 08 04:19 PM
BRADBURY DANIEL	Director	Jan 05 '24	Sale	20.36	5,100	103,836	41,833	Jan 08 04:19 PM
Juvenal Tobin W	Chief Commercial Officer	Jan 02 '24	Option Exercise	2.89	6,701	19,381	46,857	Jan 04 05:16 PM
Oelschlager Kristen M	Chief Operating Officer	Dec 29 '23	Option Exercise	3.01	12,615	38,034	150,302	Jan 03 04:11 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Dec 27 '23	Sale	21.90	8,076	176,864	68,038	Dec 29 04:05 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Dec 28 '23	Sale	22.17	3,954	87,660	64,084	Dec 29 04:05 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Dec 27 '23	Sale	21.90	1,137	24,900	11,688	Dec 29 04:05 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Dec 28 '23	Sale	22.17	557	12,349	11,629	Dec 29 04:05 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Dec 22 '23	Sale	21.96	5,224	114,719	81,294	Dec 27 04:18 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Dec 26 '23	Sale	21.93	5,180	113,597	76,114	Dec 27 04:18 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Dec 22 '23	Sale	21.96	736	16,163	11,884	Dec 27 04:18 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Dec 26 '23	Sale	21.93	729	15,987	11,807	Dec 27 04:18 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Dec 21 '23	Sale	21.40	10,999	235,412	86,518	Dec 22 04:06 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Dec 20 '23	Sale	21.05	5,201	109,455	97,517	Dec 22 04:06 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Dec 21 '23	Sale	21.40	1,549	33,153	11,962	Dec 22 04:06 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Dec 20 '23	Sale	21.05	733	15,426	12,125	Dec 22 04:06 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Dec 19 '23	Sale	20.84	5,719	119,161	102,718	Dec 20 04:46 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Dec 18 '23	Sale	20.27	5,720	115,962	108,437	Dec 20 04:46 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Dec 19 '23	Sale	20.84	3,314	69,051	12,202	Dec 20 04:46 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Dec 18 '23	Sale	20.27	1,498	30,369	12,552	Dec 20 04:46 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Dec 14 '23	Sale	20.89	9,976	208,363	12,827	Dec 18 04:06 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Dec 14 '23	Sale	20.89	9,152	191,151	117,866	Dec 18 04:06 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Dec 15 '23	Sale	20.21	3,709	74,959	114,157	Dec 18 04:06 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Dec 15 '23	Sale	20.21	1,113	22,494	12,710	Dec 18 04:06 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Dec 13 '23	Sale	20.21	3,980	80,436	13,879	Dec 14 05:39 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Dec 13 '23	Sale	20.21	3,652	73,807	127,018	Dec 14 05:39 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Dec 12 '23	Sale	20.01	546	10,925	130,670	Dec 14 05:39 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Dec 12 '23	Sale	20.01	254	5,083	14,298	Dec 14 05:39 PM
BRADBURY DANIEL	Director	Dec 12 '23	Sale	20.01	1,200	24,012	50,195	Dec 14 05:32 PM
BRADBURY DANIEL	Director	Dec 13 '23	Sale	20.04	1,168	23,407	49,796	Dec 14 05:32 PM
Oelschlager Kristen M	Chief Operating Officer	Dec 10 '23	Option Exercise	0.00	7,920	0	138,149	Dec 12 07:39 PM
Oelschlager Kristen M	Chief Operating Officer	Dec 09 '23	Option Exercise	0.00	15,961	0	136,061	Dec 12 07:39 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Dec 10 '23	Option Exercise	0.00	20,787	0	133,327	Dec 12 07:23 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Dec 09 '23	Option Exercise	0.00	33,496	0	128,391	Dec 12 07:23 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Dec 08 '23	Sale	20.10	2,530	50,853	14,325	Dec 12 07:23 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Dec 08 '23	Sale	20.10	2,322	46,672	94,895	Dec 12 07:23 PM
BRADBURY DANIEL	Director	Dec 08 '23	Sale	20.09	6,875	138,119	50,605	Dec 12 07:19 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Dec 06 '23	Sale	20.02	52	1,041	14,592	Dec 08 04:38 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Dec 06 '23	Sale	20.02	48	961	97,217	Dec 08 04:38 PM
BRADBURY DANIEL	Director	Dec 06 '23	Sale	20.02	200	4,004	52,952	Dec 08 04:35 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Dec 01 '23	Sale	20.06	3,526	70,732	14,756	Dec 05 05:49 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Dec 01 '23	Sale	20.06	3,235	64,894	98,644	Dec 05 05:49 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Dec 04 '23	Sale	20.08	1,504	30,200	14,597	Dec 05 05:49 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Dec 04 '23	Sale	20.08	1,379	27,690	97,265	Dec 05 05:49 PM
BRADBURY DANIEL	Director	Dec 01 '23	Sale	20.05	9,545	191,425	54,502	Dec 05 05:46 PM
BRADBURY DANIEL	Director	Dec 04 '23	Sale	20.08	4,340	87,165	53,020	Dec 05 05:46 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Nov 29 '23	Sale	20.13	6,261	126,034	15,645	Dec 01 04:34 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Nov 29 '23	Sale	20.13	5,743	115,607	106,389	Dec 01 04:34 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Nov 30 '23	Sale	20.07	4,915	98,644	15,127	Dec 01 04:34 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Nov 30 '23	Sale	20.07	4,510	90,516	101,879	Dec 01 04:34 PM
BRADBURY DANIEL	Director	Nov 29 '23	Sale	20.12	17,342	349,008	60,197	Dec 01 04:30 PM

Open in Screener

CELC

Celcuity Inc

Sep 06 • 04:00PM ET

15.06

Dollar change -0.63
Percentage change -4.02	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

Held by: VTI IWM VXF IWO VTWO IWC ITOT SBIO VTWG IWN

Index	RUT	P/E	-	EPS (ttm)	-2.74	Insider Own	18.78%	Shs Outstand	37.03M	Perf Week	-6.52%
Market Cap	557.67M	Forward P/E	-	EPS next Y	-3.21	Insider Trans	-0.02%	Shs Float	30.08M	Perf Month	-6.17%
Income	-82.59M	PEG	-	EPS next Q	-0.65	Inst Own	74.01%	Short Float	8.29%	Perf Quarter	4.95%
Sales	0.00M	P/S	-	EPS this Y	4.09%	Inst Trans	4.81%	Short Ratio	6.65	Perf Half Y	-16.05%
Book/sh	4.77	P/B	3.16	EPS next Y	-24.27%	ROA	-37.03%	Short Interest	2.49M	Perf Year	67.15%
Cash/sh	7.64	P/C	1.97	EPS next 5Y	29.00%	ROE	-57.59%	52W Range	8.39 - 22.19	Perf YTD	3.36%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-29.52%	ROI	-30.25%	52W High	-32.13%	Beta	0.76
Dividend TTM	-	Quick Ratio	14.95	Sales past 5Y	0.00%	Gross Margin	-	52W Low	79.52%	ATR (14)	0.89
Dividend Ex-Date	-	Current Ratio	14.95	EPS Y/Y TTM	-4.32%	Oper. Margin	0.00%	RSI (14)	36.26	Volatility	4.35% 6.08%
Employees	55	Debt/Eq	0.55	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	28.57
Option/Short	Yes / Yes	LT Debt/Eq	0.55	EPS Q/Q	7.13%	Payout	-	Rel Volume	0.40	Prev Close	15.69
Sales Surprise	-	EPS Surprise	8.64%	Sales Q/Q	-	Earnings	Aug 14 AMC	Avg Volume	375.32K	Price	15.06
SMA20	-8.34%	SMA50	-11.51%	SMA200	-7.28%	Trades		Volume	149,180	Change	-4.02%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-22-24	Initiated	Leerink Partners	Outperform	$29
Feb-22-24	Initiated	Stifel	Buy	$40
Dec-08-23	Initiated	H.C. Wainwright	Buy	$27
Oct-08-21	Initiated	Canaccord Genuity	Buy	$50
Sep-07-21	Initiated	Jefferies	Buy	$48
Jul-29-21	Initiated	Cowen	Outperform
Jul-27-21	Initiated	Needham	Buy	$50
Jan-28-21	Reiterated	H.C. Wainwright	Buy	$14 → $18
Dec-24-20	Reiterated	H.C. Wainwright	Buy	$11 → $14
May-11-20	Resumed	Craig Hallum	Buy
Nov-20-18	Initiated	H.C. Wainwright	Buy	$36

Show Previous Ratings

Aug-20-24 12:00PM	Celcuity (CELC) Upgraded to Buy: Here's Why (Zacks)
Aug-14-24 04:01PM	Celcuity Inc. Reports Second Quarter Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-07-24 07:05AM	Celcuity Inc. Schedules Release of Second Quarter 2024 Financial Results and Webcast/Conference Call (GlobeNewswire)
Jun-03-24 04:01PM	Celcuity To Participate in Jefferies Global Healthcare Conference (GlobeNewswire) -5.25%
May-30-24 07:36AM	Celcuity Announces Pricing of Underwritten Common Stock Offering (GlobeNewswire)
07:00AM	Loading…
07:00AM	Celcuity Inc. Announces Plan to Initiate a Phase 3 Clinical Trial for Gedatolisib as First-Line Treatment for HR+/HER2- Advanced Breast Cancer and Secures Approximately $62 Million Debt Financing (GlobeNewswire)
May-16-24 11:54AM	Craig-Hallum Adjusts Price Target on Celcuity to $27 From $25, Assumes Buy Rating (MT Newswires)
03:08AM	Celcuity Inc (CELC) (Q1 2024) Earnings Call Transcript Highlights: Navigating Challenges and ... (GuruFocus.com)
May-15-24 08:55PM	CELC Stock Earnings: Celcuity Beats EPS for Q1 2024 (InvestorPlace)
06:04PM	Celcuity Q1 Net Loss Widens; Shares Rise After Hours (MT Newswires)
04:01PM	Celcuity Inc. Reports First Quarter Financial Results and Provides Corporate Update (GlobeNewswire)
May-08-24 07:05AM	Celcuity Inc. Schedules Release of First Quarter 2024 Financial Results and Webcast/Conference Call (GlobeNewswire)
May-03-24 12:15PM	Top Five Cancer Types Dominate New US Cases as Biotech Sector Eyes $314B Market by 2032 (PR Newswire)
Apr-04-24 07:05AM	Celcuity To Present at Upcoming Needham and Stifel Investor Conferences (GlobeNewswire)
Apr-01-24 01:38PM	Celcuity Inc. (NASDAQ:CELC) Q4 2023 Earnings Call Transcript (Insider Monkey)
06:51AM	Loading…
Mar-28-24 06:51AM	Q4 2023 Celcuity Inc Earnings Call (Thomson Reuters StreetEvents) +18.94%
Mar-27-24 08:53PM	CELC Stock Earnings: Celcuity Beats EPS for Q4 2023 (InvestorPlace)
05:51PM	Celcuity Inc (CELC) Reports Full Year 2023 Financial Results and Highlights Key Developments (GuruFocus.com)
04:01PM	Celcuity Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-21-24 11:17AM	Why Celcuity (CELC) Might Surprise This Earnings Season (Zacks)
Mar-20-24 07:05AM	Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2023 Financial Results and Webcast/Conference Call (GlobeNewswire)
Mar-06-24 07:05AM	Celcuity to Participate in Leerink Partners Global Biopharma Conference 2024 (GlobeNewswire)
Feb-28-24 07:05AM	Celcuity to Participate in Cowen's 44th Annual Health Care Conference (GlobeNewswire)
Feb-22-24 04:05PM	Celcuity Announces First Patient Dosed in Phase 1b/2 CELC-G-201 Clinical Trial of Gedatolisib for the Treatment of Metastatic Castration Resistant Prostate Cancer (GlobeNewswire)
Feb-20-24 07:05AM	Celcuity Appoints Eldon Mayer as Chief Commercial Officer (GlobeNewswire) -5.51%
Dec-06-23 08:30AM	Celcuity Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Breast Cancer Models at the 2023 San Antonio Breast Cancer Symposium (GlobeNewswire)
Dec-01-23 11:02AM	Celcuity to Present Preclinical Data for Gedatolisib at the 2023 San Antonio Breast Cancer Symposium (GlobeNewswire)
Nov-22-23 08:05AM	Celcuity to Participate in the 6th Annual Evercore ISI HealthCONx Conference (GlobeNewswire)
Nov-14-23 10:50AM	Celcuity Inc. (NASDAQ:CELC) Q3 2023 Earnings Call Transcript (Insider Monkey) +10.10%
Nov-13-23 09:41PM	Q3 2023 Celcuity Inc Earnings Call (Thomson Reuters StreetEvents)
10:54AM	Loading…
10:54AM	Celcuity Inc (CELC) Reports Q3 2023 Financial Results and Strategic Developments (GuruFocus.com)
07:05AM	Celcuity Inc. Reports Third Quarter 2023 Financial Results and Provides Corporate Updates (GlobeNewswire)
Nov-06-23 07:30AM	Celcuity Inc. Schedules Release of Third Quarter 2023 Financial Results and Webcast/Conference Call (GlobeNewswire)
Nov-01-23 07:05AM	Celcuity To Present at Upcoming Stifel and Jefferies Investor Conferences (GlobeNewswire) -5.35%
Oct-18-23 09:15AM	Celcuity Inc. Announces $50 Million Private Placement (ACCESSWIRE) +11.38%
Sep-21-23 04:43PM	The 7 Best Short-Squeeze Stocks to Buy Now: September 2023 (InvestorPlace)
Sep-07-23 04:05PM	Celcuity to Host Virtual Science Day for Investors (GlobeNewswire)
Sep-06-23 07:10PM	7 Short-Squeeze Stocks That Actually Might Make Sense (InvestorPlace)
Aug-22-23 04:05PM	Celcuity Enters into a Clinical Trial Collaboration and Supply Agreement with Bayer to Provide Nubeqa® (darolutamide) for Planned Phase 1b/2 Clinical Trial (GlobeNewswire)
04:01PM	Celcuity Announces Plan to Conduct Phase 1b/2 Clinical Trial in Metastatic Castration Resistant Prostate Cancer (GlobeNewswire)
Aug-11-23 05:58AM	Q2 2023 Celcuity Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-10-23 04:04PM	Celcuity Inc. Reports Second Quarter 2023 Financial Results and Provides Corporate Updates (GlobeNewswire)
Aug-03-23 07:30AM	Celcuity Inc. Schedules Release of Second Quarter 2023 Financial Results and Webcast/Conference Call (GlobeNewswire)
Jul-31-23 08:00AM	Celcuity to Participate in the BTIG Virtual Biotechnology Conference 2023 (GlobeNewswire)
Jul-27-23 06:51AM	Celcuity Inc. (NASDAQ:CELC) stock most popular amongst individual investors who own 23%, while private equity firms hold 22% (Simply Wall St.)
Jun-20-23 09:02AM	Celcuity Set to Join Russell 2000 and 3000 Indexes (ACCESSWIRE)
May-24-23 08:00AM	Celcuity to Participate in Upcoming Craig-Hallum and Jefferies Investor Conferences (ACCESSWIRE)
07:59AM	Insiders of Celcuity Getting Good Value On Their US$1.6m Investment \ (Simply Wall St.)
May-16-23 06:26AM	Q1 2023 Celcuity Inc Earnings Call (Thomson Reuters StreetEvents)
May-15-23 04:00PM	Celcuity Inc. Reports First Quarter 2023 Financial Results and Provides Corporate Updates (ACCESSWIRE)
May-12-23 06:15AM	Celcuity Presents Updated Results from Phase 1b Study of Gedatolisib in Treatment-Naïve Patients at the 2023 ESMO Breast Cancer Annual Congress (ACCESSWIRE)
May-08-23 05:30PM	Celcuity Inc. Schedules Release of First Quarter 2023 Financial Results and Webcast/Conference Call (ACCESSWIRE)
08:00AM	Celcuity to Present Updated Results for Treatment-Naïve Patients from Phase 1b Study of Gedatolisib at the 2023 ESMO Breast Cancer Annual Congress (ACCESSWIRE)
Apr-18-23 01:30PM	Celcuity Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Gynecological Cancer Models at AACR Annual Meeting 2023 (ACCESSWIRE)
Apr-12-23 08:00AM	Celcuity to Participate in 22nd Annual Needham Virtual Healthcare Conference (ACCESSWIRE)
Mar-27-23 02:43AM	Celcuity Inc. (NASDAQ:CELC) Q4 2022 Earnings Call Transcript (Insider Monkey) +13.56%
Mar-24-23 07:07AM	Q4 2022 Celcuity Inc Earnings Call (Thomson Reuters StreetEvents) -5.47%
Mar-23-23 04:00PM	Celcuity Inc. Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update (ACCESSWIRE)
Mar-16-23 08:00AM	Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2022 Financial Results and Webcast/Conference Call (ACCESSWIRE)
Mar-15-23 07:35PM	Celcuity to Present Preclinical Data on Therapeutic Effects of Gedatolisib in Gynecological Cancer Models at AACR Annual Meeting 2023 (ACCESSWIRE)
Mar-01-23 08:00AM	Celcuity to Participate in Cowen's 43rd Annual Health Care Conference (ACCESSWIRE)
Feb-17-23 05:07AM	While institutions own 25% of Celcuity Inc. (NASDAQ:CELC), individual investors are its largest shareholders with 58% ownership (Simply Wall St.)
Feb-16-23 08:00AM	Celcuity Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Prostate Cancer at ASCO GU Cancers Symposium (ACCESSWIRE)
Dec-18-22 04:38AM	Insiders pour millions into these 3 stocks this is what makes them attractive buys (TipRanks)
Dec-15-22 05:59AM	Bullish insiders bet US$1.6m on Celcuity Inc. (NASDAQ:CELC) (Simply Wall St.)
Dec-12-22 07:30AM	Celcuity Closes $100 Million Private Placement (ACCESSWIRE) +11.62%
Dec-09-22 08:40AM	Celcuity Presents Updated Results of Phase 1b Study of Gedatolisib in Patients with Advanced Breast Cancer at the 2022 San Antonio Breast Cancer Symposium (ACCESSWIRE)
Dec-07-22 04:00PM	Celcuity Announces First Patient Dosed in Phase 3 VIKTORIA-1 Clinical Trial of Gedatolisib for the Treatment of HR+/HER2- Advanced Breast Cancer (ACCESSWIRE) -6.21% +26.36%
Nov-22-22 07:30AM	Celcuity to Present Additional Data for Gedatolisib at the 2022 San Antonio Breast Cancer Symposium (ACCESSWIRE) -5.36%
Nov-10-22 04:30PM	Celcuity to Participate in the 13th Annual Craig-Hallum Alpha Select Conference (ACCESSWIRE)
04:00PM	Celcuity Inc. Reports Third Quarter 2022 Financial Results and Provides Corporate Update (ACCESSWIRE)
Nov-03-22 08:50AM	Celcuity Inc. Schedules Release of Third Quarter 2022 Financial Results and Webcast/Conference Call (ACCESSWIRE)
Sep-14-22 09:00AM	Celcuity Appoints Polly Murphy, D.V.M., Ph.D., to Board of Directors (ACCESSWIRE)
Aug-15-22 09:39AM	What Is The Ownership Structure Like For Celcuity Inc. (NASDAQ:CELC)? (Simply Wall St.)
Aug-11-22 04:00PM	Celcuity Inc. Reports Second Quarter 2022 Financial Results and Provides Corporate Update (ACCESSWIRE)
Aug-04-22 08:15AM	Celcuity Inc. Schedules Release of Second Quarter 2022 Financial Results and Webcast/Conference Call (ACCESSWIRE) +5.66%
Aug-03-22 10:15AM	Celcuity to Participate in the Canaccord Genuity 42nd Annual Growth Conference (ACCESSWIRE) +10.74%
Jul-18-22 06:31PM	Celcuity stock soars after hours on breakthrough therapy designation for cancer drug (MarketWatch)
05:10PM	Celcuity Announces FDA Breakthrough Therapy Designation for Gedatolisib for Treatment of HR+/HER2- Metastatic Breast Cancer (ACCESSWIRE)
Jun-15-22 09:55AM	Wall Street Analysts Think Celcuity, Inc. (CELC) Could Surge 359%: Read This Before Placing a Bet (Zacks) +5.38%
May-30-22 09:55AM	Can Celcuity, Inc. (CELC) Climb 462% to Reach the Level Wall Street Analysts Expect? (Zacks)
May-26-22 07:30AM	Celcuity to Participate in Upcoming Craig-Hallum and Jefferies Investor Conferences (ACCESSWIRE)
May-16-22 04:00PM	Celcuity Inc. Reports First Quarter 2022 Financial Results and Business Updates (ACCESSWIRE) +5.79%
07:00AM	Celcuity Inc. Announces $100 Million Private Placement (ACCESSWIRE)
May-11-22 09:28AM	Celcuity (NASDAQ:CELC) Has Debt But No Earnings; Should You Worry? (Simply Wall St.) -17.53%
May-09-22 07:30AM	Celcuity Inc. Schedules Release of First Quarter 2022 Financial Results and Webcast/Conference Call (ACCESSWIRE)
Apr-05-22 07:30AM	Celcuity to Participate in Upcoming Needham and Canaccord Genuity Investor Conferences (ACCESSWIRE) -7.22%
Mar-23-22 04:00PM	Celcuity Inc. Reports Fourth Quarter and Full Year 2021 Financial Results, Pivotal Phase 3 Trial Design for Gedatolisib in the Treatment of Advanced Breast Cancer, and Business Updates (ACCESSWIRE)
Mar-16-22 07:30AM	Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2021 Financial Results and Webcast/Conference Call (ACCESSWIRE)
Mar-02-22 07:30AM	Celcuity to Participate in the Cowen 42nd Annual Health Care Conference (ACCESSWIRE)
Mar-01-22 07:02AM	What Percentage Of Celcuity Inc. (NASDAQ:CELC) Shares Do Insiders Own? (Simply Wall St.)
Jan-18-22 12:39PM	FDA Grants Fast Track Tags To Drug Candidates For Antares Pharma, Celcuity, Celularity (Benzinga)
07:30AM	Celcuity Receives FDA Fast Track Designation for Gedatolisib in HR+ / HER2- Metastatic Breast Cancer and Provides Corporate Update (ACCESSWIRE)
Dec-10-21 09:30AM	Celcuity Presents Updated Results of Phase 1b Study of Gedatolisib in Combination with Palbociclib and Endocrine Therapy for ER+ Advanced Breast Cancer (ABC) at the 2021 San Antonio Breast Cancer Symposium (ACCESSWIRE)
Dec-02-21 08:30AM	Celcuity to Present at the 2021 San Antonio Breast Cancer Symposium (ACCESSWIRE)
Nov-29-21 05:00PM	Celcuity Appoints Michael Snitkovsky as VP of Program Management and David Bridge as VP of Quality Assurance and Process Development (ACCESSWIRE)
Nov-15-21 08:00AM	Celcuity Announces Clinical Trial Collaboration and Supply Agreement with Pfizer to Provide Ibrance(R) (palbociclib) for Planned Phase 3 Clinical Trial (ACCESSWIRE)
Nov-09-21 05:30PM	Celcuity to Participate in Upcoming Jefferies and Craig-Hallum Investor Conferences (ACCESSWIRE) -5.41%
Nov-08-21 04:00PM	Celcuity Inc. Reports Third Quarter 2021 Financial Results and Provides Corporate Update (ACCESSWIRE)
Oct-29-21 09:00AM	Celcuity Inc. Schedules Release of Third Quarter 2021 Financial Results and Webcast/Conference Call (ACCESSWIRE)

Celcuity, Inc. is cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. Its proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Buller Richard E	Director	Aug 23 '24	Sale	16.95	350	5,932	7,031	Aug 27 04:13 PM
Buller Richard E	Director	Aug 23 '24	Proposed Sale	16.95	700	11,865		Aug 23 10:27 AM
Buller Richard E	Director	Jun 21 '24	Sale	15.68	350	5,488	7,381	Jun 25 04:19 PM
Buller Richard E	Director	Apr 24 '24	Sale	17.06	350	5,971	7,731	Apr 26 04:55 PM
Buller Richard E	Director	Feb 21 '24	Sale	14.15	350	4,952	8,081	Feb 23 04:43 PM
Buller Richard E	Director	Dec 20 '23	Sale	14.37	350	5,030	8,431	Dec 22 04:09 PM
Dalvey David	Director	Dec 14 '23	Sale	14.75	5,000	73,752	227,940	Dec 18 04:43 PM
Dalvey David	Director	Dec 15 '23	Sale	14.57	2,940	42,847	225,000	Dec 18 04:43 PM
Dalvey David	Director	Dec 13 '23	Sale	14.50	5,000	72,500	232,940	Dec 14 06:05 PM
Dalvey David	Director	Dec 12 '23	Sale	14.61	2,060	30,089	237,940	Dec 14 06:05 PM
Dalvey David	Director	Dec 08 '23	Sale	15.00	5,000	75,000	240,000	Dec 11 04:19 PM
Dalvey David	Director	Dec 07 '23	Sale	14.85	5,000	74,250	245,000	Dec 11 04:19 PM
Furcht Leo	Director	Nov 28 '23	Option Exercise	1.60	250	400	10,500	Nov 30 04:12 PM
Buller Richard E	Director	Oct 25 '23	Sale	10.23	350	3,580	8,781	Oct 27 04:30 PM

Open in Screener

RDNT

Radnet Inc

Sep 06 • 04:00PM ET

62.41

Dollar change -0.78
Percentage change -1.23	%

Healthcare • Diagnostics & Research • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

Held by: IJR VTI IWM VXF VB IJT IWO SPSM VBK SLYG

Index	RUT	P/E	425.14	EPS (ttm)	0.15	Insider Own	13.83%	Shs Outstand	67.96M	Perf Week	-3.52%
Market Cap	4.62B	Forward P/E	93.15	EPS next Y	0.67	Insider Trans	-2.84%	Shs Float	63.73M	Perf Month	9.70%
Income	9.92M	PEG	28.34	EPS next Q	0.16	Inst Own	82.93%	Short Float	4.77%	Perf Quarter	2.11%
Sales	1.71B	P/S	2.69	EPS this Y	506.67%	Inst Trans	0.51%	Short Ratio	5.10	Perf Half Y	28.57%
Book/sh	11.91	P/B	5.24	EPS next Y	120.88%	ROA	0.33%	Short Interest	3.04M	Perf Year	101.71%
Cash/sh	10.03	P/C	6.22	EPS next 5Y	15.00%	ROE	1.35%	52W Range	25.11 - 66.57	Perf YTD	79.49%
Dividend Est.	-	P/FCF	67.93	EPS past 5Y	-41.06%	ROI	0.39%	52W High	-6.25%	Beta	1.75
Dividend TTM	-	Quick Ratio	2.12	Sales past 5Y	11.14%	Gross Margin	6.21%	52W Low	148.55%	ATR (14)	2.85
Dividend Ex-Date	-	Current Ratio	2.12	EPS Y/Y TTM	165.79%	Oper. Margin	6.21%	RSI (14)	48.85	Volatility	6.14% 4.51%
Employees	7872	Debt/Eq	1.95	Sales Y/Y TTM	12.14%	Profit Margin	0.58%	Recom	1.33	Target Price	71.83
Option/Short	Yes / Yes	LT Debt/Eq	1.86	EPS Q/Q	-129.55%	Payout	0.00%	Rel Volume	1.40	Prev Close	63.19
Sales Surprise	4.83%	EPS Surprise	-123.63%	Sales Q/Q	13.87%	Earnings	Aug 08 BMO	Avg Volume	596.37K	Price	62.41
SMA20	-1.89%	SMA50	1.59%	SMA200	27.60%	Trades		Volume	833,710	Change	-1.23%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-06-24	Upgrade	Barclays	Equal Weight → Overweight	$57 → $79
Mar-06-24	Initiated	Barclays	Equal Weight	$48
Aug-31-23	Initiated	Truist	Buy	$40
Mar-31-23	Initiated	CJS Securities	Market Outperform	$30
Mar-03-23	Upgrade	Raymond James	Mkt Perform → Outperform	$30
Aug-12-21	Initiated	Barclays	Overweight	$39
Mar-15-19	Downgrade	Raymond James	Strong Buy → Outperform	$16 → $17.50
Mar-14-18	Initiated	Raymond James	Strong Buy
Aug-22-17	Upgrade	Jefferies	Hold → Buy
Jun-02-16	Initiated	Sterne Agee CRT	Neutral
Apr-15-16	Initiated	Sidoti	Buy	$9
Mar-17-09	Reiterated	Jefferies & Co	Buy	$12 → $4
Oct-15-08	Initiated	RBC Capital Mkts	Sector Perform	$4
Jul-14-08	Upgrade	Stanford Research	Hold → Buy	$9
Apr-02-08	Upgrade	Morgan Keegan	Mkt Perform → Outperform
Mar-14-08	Downgrade	Morgan Keegan	Outperform → Mkt Perform
Dec-19-07	Initiated	Leerink Swann	Outperform
Dec-07-07	Initiated	Stanford Research	Hold	$10.40
Nov-07-07	Initiated	Morgan Keegan	Outperform
Oct-19-07	Initiated	Deutsche Securities	Buy	$11.50

Show Previous Ratings

Sep-05-24 06:00AM	RadNet's DeepHealth and HOPPR Forge Partnership to Advance AI in Healthcare (GlobeNewswire)
Sep-03-24 06:00AM	RadNet, Inc. to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference on Thursday, September 5th, 2024 (GlobeNewswire) -6.26%
Aug-22-24 11:42PM	Insider Sale: EVP of Mergers and Acquisitions Michael Murdock Sells 15,000 Shares of RadNet Inc ... (GuruFocus.com)
Aug-12-24 08:46AM	Jim Cramer on RadNet, Inc. (RDNT): Quite a Good Story (Insider Monkey)
Aug-07-24 10:30PM	RadNet (RDNT) Reports Q2 Earnings: What Key Metrics Have to Say (Zacks) +8.40%
08:05PM	Loading…
08:05PM	RadNet (RDNT) Q2 Earnings Match Estimates (Zacks)
07:03PM	RadNet: Q2 Earnings Snapshot (Associated Press Finance)
04:10PM	RadNet Reports Second Quarter Financial Results with Record Quarterly Revenue and Adjusted EBITDA(1) and Revises Upwards 2024 Financial Guidance Ranges (GlobeNewswire)
Aug-01-24 10:01AM	Analysts Estimate RadNet (RDNT) to Report a Decline in Earnings: What to Look Out for (Zacks)
Jul-29-24 08:25AM	Can RadNet's (RDNT) Service Fee Revenues Help Lift Q2 Earnings? (Zacks)
Jul-20-24 09:51AM	RadNet, Inc. (RDNT): Is This Profitable Stock a Strong Buy Now? (Insider Monkey)
Jul-16-24 06:00AM	RadNet, Inc. Announces Date of its Second Quarter 2024 Financial Results Conference Call (GlobeNewswire)
Jun-20-24 07:00PM	Insider Sale: EVP, Chief Administrative Officer Mital Patel Sells 40,000 Shares of RadNet Inc (RDNT) (GuruFocus.com)
06:00AM	Maryland Passes Legislation Supported by RadNet to Expand Access to Breast and Lung Screening (GlobeNewswire)
Jun-19-24 02:39AM	Director Gregory Spurlock Sells 14,334 Shares of RadNet Inc (RDNT) (GuruFocus.com)
03:14AM	Loading…
Jun-15-24 03:14AM	Director Lawrence Levitt Sells 4,000 Shares of RadNet Inc (RDNT) (GuruFocus.com)
Jun-14-24 03:05AM	Insider Sale: Stephen Forthuber Sells 40,000 Shares of RadNet Inc (RDNT) (GuruFocus.com)
Jun-13-24 02:45AM	Insider Sale: Director Lawrence Levitt Sells 16,000 Shares of RadNet Inc (RDNT) (GuruFocus.com)
02:45AM	Insider Sale: EVP, CFO Mark Stolper Sells 25,000 Shares of RadNet Inc (RDNT) (GuruFocus.com)
Jun-11-24 07:01PM	Insider Sale: EVP and Chief Legal Officer David Katz Sells 16,400 Shares of RadNet Inc (RDNT) (GuruFocus.com)
07:01PM	Insider Sale: Director Christine Gordon Sells 4,500 Shares of RadNet Inc (RDNT) (GuruFocus.com)
10:50AM	Sidoti Events, LLC's Virtual June Small-Cap Conference (ACCESSWIRE)
06:00AM	RadNet, Inc. to Present at the Sidoti & Company 2024 Small Cap Conference on Wednesday, June 12th (GlobeNewswire)
Jun-07-24 06:00AM	RadNet, Inc. to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024 (GlobeNewswire)
Jun-06-24 09:15AM	RadNet, Inc. (RDNT) Hits Fresh High: Is There Still Room to Run? (Zacks)
Jun-05-24 12:45PM	3 Reasons Why Growth Investors Shouldn't Overlook RadNet (RDNT) (Zacks)
Jun-04-24 12:00PM	All You Need to Know About RadNet (RDNT) Rating Upgrade to Strong Buy (Zacks)
Jun-03-24 06:00AM	RadNet, Inc. to Present at the Jefferies 2024 Global Healthcare Conference on June 5, 2024 (GlobeNewswire)
May-15-24 06:14AM	Truist Securities Adjusts Price Target on RadNet to $63 From $55, Maintains Buy Rating (MT Newswires)
May-13-24 06:00AM	RadNet, Inc. to Present at the Bank of America Securities 2024 Health Care Conference on May 14th, 2024 (GlobeNewswire)
06:29PM	Loading…
May-10-24 06:29PM	RadNet, Inc. (NASDAQ:RDNT) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-09-24 04:02AM	RadNet Swings to Q1 Adjusted Earnings, Revenue Rises (MT Newswires) +5.81%
May-08-24 09:57PM	RDNT Stock Earnings: RadNet Beats Revenue for Q1 2024 (InvestorPlace)
06:30PM	RadNet (RDNT) Q1 Earnings and Revenues Surpass Estimates (Zacks)
05:38PM	RadNet: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	RadNet Reports First Quarter Financial Results with Record First Quarter Revenue, Adjusted EBITDA(1) and Adjusted Earnings(3) and Revises Upwards 2024 Financial Guidance Ranges (GlobeNewswire)
May-07-24 07:50AM	RadNet's Lenox Hill Radiology to Host Mother's Day Mammogram Screening Parties in New York City (GlobeNewswire)
May-01-24 10:01AM	RadNet (RDNT) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Apr-30-24 12:10PM	Will RadNet (RDNT) Beat Estimates Again in Its Next Earnings Report? (Zacks)
Apr-29-24 08:00AM	Loop Media Selected by RadNet to Provide Ad Sales Services, Branded Channels, and Customized Signage Across RadNetTV (Business Wire)
Apr-22-24 06:00AM	RadNet, Inc. Announces Date of its First Quarter 2024 Financial Results Conference Call (GlobeNewswire)
Apr-18-24 04:05PM	RadNet Announces Closing of its Previously Announced Term Loan and Revolving Credit Facility Refinancing Transaction (GlobeNewswire)
09:18AM	RadNet's Delaware Imaging Network Announces Ribbon-Cutting Ceremony for Mammography Service at Milford Walmart (GlobeNewswire)
Apr-12-24 06:00AM	RadNet Teams Up with Basketball Icon Sheryl Swoopes to Promote Healthcare Equity and Access (GlobeNewswire)
Apr-11-24 06:00AM	RadNet Announces Pricing and Upsizing of its Previously Announced Term Loan and Revolving Credit Facility Refinancing Transaction (GlobeNewswire)
Apr-10-24 11:41AM	Does RadNet (RDNT) Have a Long Runway for Growth? (Insider Monkey)
06:00AM	RadNet to Make its Second Acquisition in Houston, Texas (GlobeNewswire)
Apr-03-24 06:00AM	RadNet Announces a Proposed Refinancing of its Term Loan and Revolving Credit Facility (GlobeNewswire)
Apr-02-24 06:00AM	RadNet Announces Outpatient Radiology Partnership with Providence Health System to Include Seven Centers in Burbank, Santa Clarita and the Northern San Fernando Valley of Los Angeles (GlobeNewswire)
Mar-12-24 04:05PM	RadNet Announces Closing of Public Offering of Common Stock (GlobeNewswire)
Mar-07-24 09:54PM	RadNet Announces Pricing of Public Offering of Common Stock (GlobeNewswire)
04:05PM	RadNet Announces Proposed $200 Million Underwritten Public Offering of Common Stock (GlobeNewswire)
Mar-05-24 10:22AM	RadNet, Inc. (NASDAQ:RDNT) Q4 2023 Earnings Call Transcript (Insider Monkey)
06:00AM	RadNet, Inc. to Present at the 44th Annual Cowen & Company Healthcare Conference on Wednesday, March 6th (GlobeNewswire)
Mar-04-24 12:00PM	RadNet (RDNT) Upgraded to Buy: What Does It Mean for the Stock? (Zacks) +5.61%
12:00PM	RadNet (RDNT) Is Up 14.75% in One Week: What You Should Know (Zacks)
06:00AM	RadNet, Inc. to Present at the Raymond James 45th Annual Institutional Investors Conference Today, March 4th, 2024 (GlobeNewswire)
Mar-02-24 01:49AM	Q4 2023 RadNet Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-01-24 08:37PM	Radnet CEO Howard Berger goes one-on-one with Jim Cramer (CNBC TV) +17.14% +5.61%
08:37PM	Partnership with Walmart will help enhance breast cancer detection, says Radnet CEO Howard Berger (CNBC TV)
Feb-29-24 05:17PM	RadNet: Q4 Earnings Snapshot (Associated Press Finance)
04:10PM	RadNet Reports Fourth Quarter 2023 Results, Including Record Revenue and Adjusted EBITDA(1), Releases 2024 Financial Guidance and Forms a New Digital Health Reporting Segment (GlobeNewswire)
Feb-27-24 04:05PM	RadNet to Enter the Houston, Texas Market through Platform Acquisition of Houston Medical Imaging (GlobeNewswire)
Feb-15-24 06:00AM	RadNet and JVS SoCal Create ImagingWorks , an Innovative Partnership to Launch Career Training Programs for Medical Imaging (GlobeNewswire)
Feb-13-24 06:00AM	RadNet, Inc. Announces Date of its Fourth Quarter 2023 Financial Results Conference Call (GlobeNewswire)
Jan-24-24 06:00AM	RadNet's Arizona Diagnostic Radiology Group Joint Venture Acquires Seven Outpatient Imaging Centers in Phoenix, Arizona (GlobeNewswire)
Jan-08-24 06:00AM	RadNet, Inc. to Present at the 42nd Annual J.P. Morgan Healthcare Conference January 10th, 2024 (GlobeNewswire)
Dec-08-23 11:27AM	Walmart makes a big move into a crucial area customers will love (TheStreet.com)
11:05AM	Insider Sell Alert: EVP & Chief Development Officer Michael Murdock Sells 10,115 Shares of ... (GuruFocus.com)
Dec-05-23 08:59PM	Lightning Round: I'm sticking behind RadNet, says Jim Cramer (CNBC TV)
06:00AM	RadNet Launches a Pilot Inside Walmart of its New MammogramNow Offering (GlobeNewswire)
Nov-27-23 06:05AM	RadNet Unveils DeepHealth, a Pioneering AI-Powered Health Informatics Portfolio (GlobeNewswire)
06:00AM	RadNet, Inc. to Present at the BofA Securities 2023 Leveraged Finance Conference on November 28, 2023 (GlobeNewswire)
Nov-15-23 06:00AM	RadNet, Inc. to Present at the Sidoti & Company Fall 2023 Virtual Conference on Thursday, November 16th (GlobeNewswire)
Nov-14-23 08:55AM	Sidoti Events, LLCs Virtual November Micro-Cap Conference (ACCESSWIRE) +9.72%
Nov-10-23 02:43PM	RadNet, Inc. (NASDAQ:RDNT) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-08-23 08:15PM	RadNet (RDNT) Q3 Earnings and Revenues Beat Estimates (Zacks)
07:09PM	RadNet: Q3 Earnings Snapshot (Associated Press Finance)
04:30PM	RadNet Reports Third Quarter Financial Results and Revises Upwards 2023 Financial Guidance Range for Adjusted EBITDA (GlobeNewswire)
Oct-27-23 09:40AM	Should Value Investors Buy RadNet (RDNT) Stock? (Zacks)
Oct-17-23 06:00AM	RadNet, Inc. Announces Date of its Third Quarter 2023 Financial Results Conference Call (GlobeNewswire)
Sep-28-23 07:43AM	3 Value Medical Stocks to Buy for Safety Amid Market Volatility (Zacks)
Sep-20-23 09:42AM	RadNet, Inc. to Present at the Sidoti & Company Fall 2023 Virtual Conference on Wednesday, September 20th (GlobeNewswire)
Sep-19-23 09:00AM	Sidoti Events, LLCs Virtual September Small-Cap Conference (ACCESSWIRE)
Sep-05-23 07:54AM	Zacks Industry Outlook Highlights DaVita, Encompass Health, Option Care Health and RadNet (Zacks)
Sep-01-23 11:19AM	4 Stocks to Buy in a Booming Outpatient Home Health Industry (Zacks)
Aug-17-23 10:21AM	3 Super Speculative AI Stocks Not Worth the Risk (InvestorPlace)
Aug-08-23 07:15AM	RadNet (RDNT) Q2 Earnings and Revenues Top Estimates (Zacks) -6.04%
06:12AM	RadNet: Q2 Earnings Snapshot (AP Finance)
06:00AM	RadNet Reports Second Quarter Financial Results, with Record Quarterly Revenue and Adjusted EBITDA(1), and Updates 2023 Financial Guidance Ranges (GlobeNewswire)
Jul-31-23 06:00AM	RadNet, Inc. Announces the Addition of Sham Sokka and Sanjog Misra to Drive Further Growth Within its Digital Health Initiatives (GlobeNewswire)
Jul-26-23 04:24PM	Biotech Stocks Join AI-Fueled Rally (The Wall Street Journal)
Jul-21-23 06:00AM	RadNet, Inc. Announces Date of its Second Quarter 2023 Financial Results Conference Call (GlobeNewswire)
Jun-21-23 08:00PM	RDNT: Raising target price to $34.00 (Argus Research)
Jun-16-23 04:01PM	RadNet Announces Closing Of Upsized Public Offering Of Common Stock (GlobeNewswire)
Jun-15-23 08:46AM	Is There Now An Opportunity In RadNet, Inc. (NASDAQ:RDNT)? (Simply Wall St.)
Jun-13-23 11:36PM	RadNet Announces Pricing of Upsized Public Offering of Common Stock (GlobeNewswire) -8.80%
04:01PM	RADNET ANNOUNCES PROPOSED $175 MILLION UNDERWRITTEN PUBLIC OFFERING OF COMMON STOCK (PR Newswire)
Jun-05-23 06:00AM	RadNet, Inc. to Present at the Jefferies 2023 Global Healthcare Conference on June 8, 2023 (GlobeNewswire)
May-24-23 06:31AM	Are Investors Undervaluing RadNet, Inc. (NASDAQ:RDNT) By 42%? (Simply Wall St.)

RadNet, Inc. provides freestanding, fixed-site outpatient diagnostic imaging services in the United States. Its centers provide physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders and reduce unnecessary invasive procedures. The firm offers magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures. RadNet was founded by Howard G. Berger in 1980 and is headquartered in Los Angeles, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Murdock Michael N	EVP, Mergers and Acquisitions	Aug 21 '24	Sale	62.78	15,000	941,702	48,144	Aug 22 05:12 PM
Murdock Michael N	Officer	Aug 20 '24	Proposed Sale	62.50	15,000	937,500		Aug 20 03:28 PM
Patel Mital	EVP, Chief Admin Officer	Jun 18 '24	Sale	59.00	29,800	1,758,200	202,146	Jun 20 05:00 PM
Patel Mital	EVP, Chief Admin Officer	Jun 17 '24	Sale	60.00	10,200	612,000	231,946	Jun 20 05:00 PM
SPURLOCK GREGORY E.	Director	Jun 18 '24	Sale	59.75	7,167	428,228	2,591	Jun 18 06:23 PM
SPURLOCK GREGORY E.	Director	Jun 17 '24	Sale	59.75	7,167	428,228	9,758	Jun 18 06:23 PM
Murdock Michael N	EVP, Mergers and Acquisitions	Jun 12 '24	Sale	62.51	10,000	625,100	63,144	Jun 14 05:00 PM
Levitt Lawrence L	Director	Jun 14 '24	Sale	57.77	4,000	231,080	172,657	Jun 14 05:00 PM
Forthuber Stephen M	Pres & COO-Eastern Operations	Jun 12 '24	Sale	62.33	40,000	2,493,200	523,561	Jun 13 05:30 PM
Sorensen Alma Gregory	EVP, Chief Science Officer	Jun 12 '24	Sale	62.34	10,000	623,400	1,239,205	Jun 13 05:30 PM
Sorensen Alma Gregory	EVP, Chief Science Officer	Jun 11 '24	Sale	61.24	5,000	306,200	1,249,205	Jun 13 05:30 PM
SWARTZ DAVID L	Director	Jun 10 '24	Sale	60.43	20,934	1,265,042	200,542	Jun 12 05:36 PM
SWARTZ DAVID L	Director	Jun 12 '24	Sale	62.42	4,066	253,800	196,476	Jun 12 05:36 PM
STOLPER MARK	EVP, Chief Financial Officer	Jun 10 '24	Sale	61.27	25,000	1,531,750	80,398	Jun 12 05:36 PM
Levitt Lawrence L	Director	Jun 10 '24	Sale	60.85	16,000	973,600	174,066	Jun 12 05:35 PM
HAMES NORMAN R	Pres and COO-West Operations	Jun 11 '24	Sale	61.40	35,000	2,149,000	245,919	Jun 12 05:33 PM
HAMES NORMAN R	Pres and COO-West Operations	Jun 12 '24	Sale	63.08	18,597	1,173,099	227,322	Jun 12 05:33 PM
HAMES NORMAN R	Pres and COO-West Operations	Jun 10 '24	Sale	61.15	15,000	917,250	280,919	Jun 12 05:33 PM
HAMES NORMAN R	Pres and COO-West Operations	Jun 10 '24	Sale	61.09	5,000	305,450	24,889	Jun 12 05:33 PM
Katz David Jeffrey	EVP and Chief Legal Officer	Jun 07 '24	Sale	61.26	16,400	1,004,664	65,441	Jun 11 05:00 PM
Gordon Christine Nayoma	Director	Jun 07 '24	Sale	61.30	3,000	183,900	12,379	Jun 11 05:00 PM
Gordon Christine Nayoma	Director	Jun 10 '24	Sale	61.03	1,500	91,545	10,879	Jun 11 05:00 PM
Murdock Michael N	EVP & Chief Development Offcr	Dec 05 '23	Sale	35.02	10,115	354,227	68,432	Dec 07 04:05 PM
Gordon Christine Nayoma	Director	Nov 27 '23	Sale	32.40	3,000	97,200	10,385	Nov 28 04:02 PM

Open in Screener

PSNL

Personalis Inc

Sep 06 • 04:00PM ET

5.37

Dollar change +0.21
Percentage change 4.07	%

Healthcare • Diagnostics & Research • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

Held by: ARKG VTI VXF IWC AVSC DFAS DCOR DFUS DFAU

Index	-	P/E	-	EPS (ttm)	-1.63	Insider Own	41.46%	Shs Outstand	50.48M	Perf Week	-7.41%
Market Cap	285.68M	Forward P/E	-	EPS next Y	-1.24	Insider Trans	18.71%	Shs Float	31.14M	Perf Month	86.46%
Income	-81.45M	PEG	-	EPS next Q	-0.35	Inst Own	48.63%	Short Float	6.36%	Perf Quarter	283.57%
Sales	80.03M	P/S	3.57	EPS this Y	45.48%	Inst Trans	-2.99%	Short Ratio	1.46	Perf Half Y	219.64%
Book/sh	2.12	P/B	2.54	EPS next Y	-1.36%	ROA	-37.49%	Short Interest	1.98M	Perf Year	235.62%
Cash/sh	1.63	P/C	3.28	EPS next 5Y	-13.70%	ROE	-56.49%	52W Range	0.89 - 7.20	Perf YTD	155.71%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-28.46%	ROI	-54.48%	52W High	-25.42%	Beta	1.92
Dividend TTM	-	Quick Ratio	3.05	Sales past 5Y	18.20%	Gross Margin	27.76%	52W Low	502.96%	ATR (14)	0.66
Dividend Ex-Date	-	Current Ratio	3.18	EPS Y/Y TTM	30.89%	Oper. Margin	-101.13%	RSI (14)	57.35	Volatility	13.49% 16.01%
Employees	225	Debt/Eq	0.42	Sales Y/Y TTM	19.20%	Profit Margin	-101.78%	Recom	1.33	Target Price	7.05
Option/Short	Yes / Yes	LT Debt/Eq	0.33	EPS Q/Q	51.38%	Payout	-	Rel Volume	0.51	Prev Close	5.16
Sales Surprise	17.20%	EPS Surprise	35.71%	Sales Q/Q	35.22%	Earnings	Aug 07 AMC	Avg Volume	1.36M	Price	5.37
SMA20	2.45%	SMA50	53.80%	SMA200	170.68%	Trades		Volume	695,207	Change	4.07%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-06-23	Upgrade	Needham	Hold → Buy	$8
Feb-06-23	Upgrade	Needham	Hold → Buy
Jan-07-22	Upgrade	BofA Securities	Neutral → Buy	$27 → $23
Nov-05-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Nov-03-21	Downgrade	Needham	Buy → Hold
Oct-15-21	Resumed	Cowen	Outperform
Sep-20-21	Reiterated	Needham	Buy	$33 → $28
May-06-21	Upgrade	Oppenheimer	Perform → Outperform	$28
Jan-28-21	Initiated	Truist	Buy	$50
Jan-04-21	Downgrade	BofA Securities	Buy → Neutral	$40
Nov-12-20	Reiterated	Needham	Buy	$25 → $32
Nov-06-20	Downgrade	Oppenheimer	Outperform → Perform
Oct-19-20	Initiated	Citigroup	Buy	$35
Oct-08-20	Initiated	BTIG Research	Buy	$35
Aug-27-20	Initiated	H.C. Wainwright	Buy	$30
Aug-18-20	Initiated	Needham	Buy	$25
Sep-26-19	Upgrade	BofA/Merrill	Neutral → Buy	$22
Jul-15-19	Initiated	Oppenheimer	Outperform	$29
Jul-15-19	Initiated	Morgan Stanley	Overweight	$28
Jul-15-19	Initiated	Cowen	Outperform

Show Previous Ratings

Aug-22-24 04:01PM	Personalis to Participate at Upcoming Investor Conferences (Business Wire) -9.94%
Aug-21-24 06:13PM	Why Tempus AI Stock Skyrocketed Nearly 22% Today (Motley Fool) +11.42%
Aug-19-24 04:05PM	Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-16-24 08:30AM	Personalis and Tempus Announce Expanded Collaboration (Business Wire) +18.15%
Aug-13-24 09:15AM	Personalis, Inc. (PSNL) Hit a 52 Week High, Can the Run Continue? (Zacks) +8.12%
05:30PM	Loading…
Aug-07-24 05:30PM	Personalis (PSNL) Reports Q2 Loss, Tops Revenue Estimates (Zacks) -10.00% +19.10%
04:35PM	Personalis: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Personalis Reports Second Quarter 2024 Financial Results (Business Wire)
Aug-06-24 04:05PM	Myriad Genetics Reports Strong Second Quarter 2024 Financial Results, including 15% Revenue Growth Year-Over-Year; Raises 2024 Financial Guidance and Long-Term Revenue Growth Target to 12% (GlobeNewswire)
Jul-31-24 04:01PM	Personalis to Participate at the 9th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference (Business Wire) +10.58%
Jul-24-24 04:01PM	Personalis to Announce Second Quarter 2024 Financial Results (Business Wire)
Jul-11-24 09:00AM	Myriad Genetics and Personalis Cross-License Foundational MRD Intellectual Property to Broaden Patient Access to Testing (GlobeNewswire) +9.68%
Jun-18-24 04:01PM	Personalis to Participate at the TD Cowen 3rd Annual Tools / Dx Revolution Conference (Business Wire)
Jun-13-24 08:00AM	Personalis Provides Dial-in and Updated Date for ASCO Highlights Conference Call (Business Wire)
Jun-04-24 04:05PM	ASCO Data Highlights NeXT Personal Ultra-sensitive MRD Performance in Early-stage Breast Cancer Recurrence Detection and Immunotherapy Monitoring (Business Wire) -6.90% +8.89%
09:05AM	Loading…
May-31-24 09:05AM	Personalis Announces Start of Cancer MRD Testing Commercialization Collaboration with Tempus (Business Wire)
May-22-24 09:05AM	Personalis Announces Podium Presentations and Abstracts Accepted at ASCO 2024 (Business Wire) +7.24%
May-17-24 04:05PM	Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-09-24 12:31PM	Personalis, Inc. (NASDAQ:PSNL) Q1 2024 Earnings Call Transcript (Insider Monkey) +5.43%
07:11AM	Q1 2024 Personalis Inc Earnings Call (Thomson Reuters StreetEvents)
04:00AM	Personalis Inc (PSNL) (Q1 2024) Earnings Call Transcript Highlights: Surpassing Revenue ... (GuruFocus.com)
May-08-24 08:59PM	PSNL Stock Earnings: Personalis Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
04:22PM	Personalis: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	Personalis Reports First Quarter 2024 Financial Results (Business Wire)
Apr-24-24 04:01PM	Personalis to Announce First Quarter 2024 Financial Results (Business Wire) -5.80%
Mar-28-24 04:01PM	Personalis to Present at the 23rd Annual Needham Virtual Healthcare Conference (Business Wire)
09:00AM	Data Showcasing NeXT Personal MRD Test to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting (Business Wire)
Mar-26-24 09:00AM	Personalis Announces Publication Validating NeXT Personal Test for Ultra-sensitive MRD Detection and Cancer Treatment Response Monitoring (Business Wire)
Mar-19-24 04:43PM	Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -6.79%
Feb-29-24 09:44AM	Personalis, Inc. (NASDAQ:PSNL) Q4 2023 Earnings Call Transcript (Insider Monkey) +6.16%
05:00PM	Loading…
Feb-28-24 05:00PM	Personalis: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Personalis Reports Fourth Quarter and Full Year 2023 Financial Results (Business Wire)
Feb-14-24 04:01PM	Personalis to Announce Fourth Quarter and Full Year 2023 Financial Results (Business Wire) +10.46%
Jan-31-24 04:01PM	Personalis to Participate at Upcoming Investor Conferences (Business Wire)
Jan-30-24 09:00AM	Personalis and ClearNote Health Announce Partnership to Advance Epigenomic Technology (Business Wire) -8.50%
Jan-17-24 04:15PM	Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +6.06% -7.43%
Jan-16-24 09:05AM	Personalis Announces Medicare Coverage for NeXT Dx(R) Comprehensive Genomic Tumor Profiling Assay (Business Wire) -5.17%
Jan-05-24 09:05AM	Personalis Reports Preliminary Fourth Quarter and Full Year 2023 Revenue and Cash Balance (Business Wire) +7.00%
Dec-04-23 09:15AM	Personalis Extends Cash Position Into 2026, Provides Update on Key Initiatives (Business Wire) +6.80%
Nov-28-23 04:15PM	Personalis and Tempus Enter into a Strategic Collaboration to Advance Cancer Testing (Business Wire) -8.33% -9.09%
Nov-16-23 04:05PM	Myriad Genetics and Personalis Partner to Market Solutions to Pharma Customers (GlobeNewswire) -7.21% +6.80%
03:03PM	Meet the biotech company Cathie Wood bought half a million shares of this month (TheStreet.com)
Nov-08-23 01:45PM	Personalis, Inc. (NASDAQ:PSNL) Q3 2023 Earnings Call Transcript (Insider Monkey) +21.52%
Nov-07-23 04:50PM	Personalis: Q3 Earnings Snapshot (Associated Press Finance) -9.17%
04:01PM	Personalis Reports Third Quarter 2023 Financial Results (Business Wire)
Oct-26-23 08:15AM	Personalis Launches NeXT Personal Dx for Early Access Clinical Use in Residual Disease and Recurrence Detection in Cancer (Business Wire)
Oct-24-23 04:01PM	Personalis to Announce Third Quarter 2023 Financial Results (Business Wire) +15.04% -8.41%
Oct-21-23 04:25AM	Analysis from TRACERx Study Reveals More Sensitive and Earlier ctDNA Detection in Lung Cancer Patients by Personalis' MRD Technology (Business Wire)
Oct-19-23 07:15AM	Personalis Announces Late-Breaking NeXT Personal Abstract and Proffered Paper Presentation at ESMO 2023 (Business Wire)
Oct-18-23 07:15AM	Personalis Appoints Former Roche Diagnostics and GRAIL Executive Deepshikha Bhandari as SVP, Regulatory, Quality and Clinical Compliance (Business Wire)
Aug-29-23 04:01PM	Personalis to Present at the 21st Annual Morgan Stanley Global Healthcare Conference (Business Wire) +7.95%
Aug-24-23 07:01PM	Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -9.41%
Aug-15-23 10:20AM	Sidoti Events, LLCs Virtual August Micro-Cap Conference (ACCESSWIRE)
Aug-08-23 05:40PM	Personalis (PSNL) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:32PM	Personalis: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Personalis Reports Second Quarter 2023 Financial Results (Business Wire)
Aug-01-23 04:01PM	Personalis to Participate at Upcoming Investor Conferences (Business Wire)
Jul-25-23 04:01PM	Personalis to Announce Second Quarter 2023 Financial Results (Business Wire)
Jul-13-23 06:51AM	Personalis (NASDAQ:PSNL) adds US$23m to market cap in the past 7 days, though investors from three years ago are still down 86% (Simply Wall St.)
Jun-26-23 05:00PM	Personalis Files Second Patent Infringement Suit Against Foresight Diagnostics (Business Wire)
Jun-13-23 07:01PM	Dr. Kenneth J. Widder Joins Personalis Board of Directors (Business Wire) -6.93%
Jun-08-23 10:49AM	Not Many Are Piling Into Personalis, Inc. (NASDAQ:PSNL) Just Yet (Simply Wall St.)
May-30-23 08:00AM	Personalis Announces Two Abstracts Accepted for Presentation at ASCO 2023 (Business Wire) -6.22%
May-16-23 08:00AM	Personalis, National Cancer Center Hospital East, and Ono Collaborate to Better Predict Immunotherapy Response for Rectal Cancer (Business Wire) -6.36%
May-07-23 03:07PM	Personalis, Inc. (NASDAQ:PSNL) Q1 2023 Earnings Call Transcript (Insider Monkey)
May-05-23 12:03PM	Companies Like Personalis (NASDAQ:PSNL) Could Be Quite Risky (Simply Wall St.)
May-04-23 01:03PM	Q1 2023 Personalis Inc Earnings Call (Thomson Reuters StreetEvents)
May-03-23 05:45PM	Personalis (PSNL) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +10.00%
04:37PM	Personalis: Q1 Earnings Snapshot (AP Finance)
04:01PM	Personalis Reports First Quarter 2023 Financial Results (Business Wire)
May-02-23 08:00AM	Personalis, ABRCC, and Criterium Announce Major Prospective Clinical Trial for Residual and Recurrent Disease Detection in Triple Negative Breast Cancer (Business Wire) -5.17%
Apr-19-23 04:01PM	Personalis to Announce First Quarter 2023 Financial Results (Business Wire) -7.17%
Apr-08-23 08:10AM	Personalis, Inc. (NASDAQ:PSNL) is favoured by institutional owners who hold 62% of the company (Simply Wall St.)
Apr-05-23 04:01PM	Personalis to Participate at the 22nd Annual Needham Virtual Healthcare Conference (Business Wire)
08:45AM	Personalis Joins Top UK Cancer Research Organizations to Evaluate Earlier Cancer Recurrence Detection Through Groundbreaking Study (Business Wire)
Mar-22-23 08:55AM	Personalis Announces Four Abstracts Accepted for Presentation at AACR Annual Meeting 2023 (Business Wire)
Mar-07-23 08:55AM	Personalis Selected for Clinical Research After Successful Evaluation of Whole Genome-Based Molecular Residual Disease Assay (Business Wire)
Mar-02-23 04:05PM	Personalis Appoints Christopher Hall as Chief Executive Officer (Business Wire) +7.25%
Feb-28-23 12:00PM	Personalis (PSNL) Upgraded to Buy: Here's What You Should Know (Zacks)
Feb-26-23 07:31AM	Personalis Full Year 2022 Earnings: EPS Misses Expectations (Simply Wall St.)
Feb-24-23 01:32PM	Q4 2022 Personalis Inc Earnings Call (Thomson Reuters StreetEvents) -7.23%
Feb-23-23 04:01PM	Personalis Reports Fourth Quarter and Full Year 2022 Financial Results (Business Wire)
Feb-09-23 04:01PM	Personalis to Announce Fourth Quarter and Full Year 2022 Financial Results (Business Wire)
Feb-07-23 10:07AM	15 Worst Stock Picks of Cathie Wood in 2022 (Insider Monkey) +7.47%
Feb-06-23 04:01PM	Personalis to Participate at Upcoming Investor Conferences (Business Wire)
01:41PM	Analyst Upgrades Personalis; Says Biopharma Is Strong, Cash Burn Is Down (Benzinga)
Feb-03-23 12:38PM	Why Personalis Shares Are Trading Higher Today (Benzinga) +28.29%
08:45AM	Personalis and Moderna Sign New Agreement to Leverage NeXT Platform in Personalized mRNA Cancer Vaccine Clinical Trials (Business Wire)
Jan-19-23 10:17AM	Fremont cancer test business Personalis to cut staff by one-third (American City Business Journals) -9.43%
04:31AM	Cancer Genomics-Focused Personalis To Reduce Nearly One-Third Of Its Workforce (Benzinga)
Jan-05-23 05:21AM	Strong week for Personalis (NASDAQ:PSNL) shareholders doesn't alleviate pain of one-year loss (Simply Wall St.)
Jan-04-23 04:01PM	Personalis Reports Preliminary Fourth Quarter and Full Year 2022 Revenue (Business Wire) +8.46%
Dec-16-22 04:05PM	Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -6.52% -8.84%
Dec-14-22 04:02PM	Personalis Announces CEO Retirement and Transition (Business Wire) -14.81%
Nov-30-22 08:55AM	Personalis and UCSF to Study Clinical Utility of ctDNA for Treatment Response in Colorectal Cancer (Business Wire) +9.96%
Nov-21-22 04:01PM	Personalis to Present at the 34th Annual Piper Sandler Healthcare Conference (Business Wire)
Nov-07-22 04:05PM	Personalis Presents Data from New Platform Features at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting (Business Wire) -8.30%
02:16PM	Here's Why Personalis (NASDAQ:PSNL) Must Use Its Cash Wisely (Simply Wall St.)
Nov-02-22 05:15PM	Personalis (PSNL) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
04:01PM	Personalis Reports Third Quarter 2022 Financial Results (Business Wire)

Personalis, Inc. engages in the provision of advanced genomic tests for cancer. The firm is also involved in providing sequencing and data analysis services to support population sequencing initiatives. The company was founded by Euan A. Ashley, Michael Snyder, Atul J. Butte, John S. West, and Russ B. Altman in February 2011 and is headquartered in Fremont, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Tempus AI, Inc.	10% Owner	Aug 16 '24	Buy	5.07	3,500,000	17,745,000	12,718,800	Aug 20 04:17 PM
Chen Richard	CHIEF MEDICAL OFFICER AND EVP	Jul 30 '24	Sale	2.97	524	1,556	127,227	Aug 01 05:16 PM
Tachibana Aaron	CFO AND COO	Jul 30 '24	Sale	2.97	742	2,204	175,270	Aug 01 05:13 PM
Chen Richard	CHIEF MEDICAL OFFICER AND EVP	Jun 17 '24	Sale	1.29	5,055	6,521	127,751	Jun 20 04:55 PM
Tachibana Aaron	CFO AND COO	Jun 17 '24	Sale	1.29	7,176	9,257	176,012	Jun 20 04:54 PM
Moore Stephen Michael	SVP and Chief Legal Officer	Jun 17 '24	Sale	1.29	1,585	2,045	69,081	Jun 20 04:53 PM
Chen Richard	CHIEF MEDICAL OFFICER AND EVP	May 17 '24	Sale	1.38	940	1,297	132,806	May 21 09:14 PM
Tachibana Aaron	CFO AND COO	May 17 '24	Sale	1.38	1,333	1,840	183,188	May 21 09:13 PM
Moore Stephen Michael	SVP and Chief Legal Officer	May 17 '24	Sale	1.38	1,731	2,389	70,666	May 21 09:11 PM
Moore Stephen Michael	SVP and Chief Legal Officer	Apr 30 '24	Sale	1.37	4,523	6,197	72,397	May 02 05:52 PM
MYERS WOODROW A JR	Director	Mar 01 '24	Buy	1.67	10,000	16,700	26,116	Mar 05 05:15 PM
Chen Richard	CHIEF MEDICAL OFFICER AND EVP	Jan 29 '24	Sale	1.37	526	721	128,870	Jan 31 04:30 PM
Tachibana Aaron	CFO AND COO	Jan 29 '24	Sale	1.37	716	981	184,521	Jan 31 04:27 PM
Chen Richard	Chief Medical Officer and EVP	Dec 15 '23	Sale	1.47	4,708	6,921	129,396	Dec 19 06:09 PM
Tachibana Aaron	CFO and COO	Dec 15 '23	Sale	1.47	6,747	9,918	185,237	Dec 19 06:07 PM
Moore Stephen Michael	General Counsel	Dec 15 '23	Sale	1.47	1,476	2,170	76,920	Dec 19 06:02 PM
Moore Stephen Michael	General Counsel	Nov 16 '23	Sale	1.04	1,722	1,791	78,396	Nov 20 04:30 PM
Tachibana Aaron	CFO and COO	Nov 16 '23	Sale	1.04	1,344	1,398	191,984	Nov 20 04:30 PM
Chen Richard	Chief Medical Officer and EVP	Nov 16 '23	Sale	1.04	940	978	124,104	Nov 20 04:30 PM
Hall Christopher M	President and CEO	Nov 01 '23	Sale	0.93	20,459	19,027	204,541	Nov 03 09:00 PM

Open in Screener

FTRE

Fortrea Holdings Inc

Sep 06 • 04:00PM ET

20.09

Dollar change -0.71
Percentage change -3.41	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

FTRE Fortrea Holdings Inc daily Stock Chart

Held by: IJR VTI VB VBR VXF IJS SPSM IBB SLYV VIOO

Index	-	P/E	-	EPS (ttm)	-2.97	Insider Own	0.36%	Shs Outstand	89.60M	Perf Week	-13.22%
Market Cap	1.80B	Forward P/E	14.67	EPS next Y	1.37	Insider Trans	3.86%	Shs Float	89.28M	Perf Month	-18.23%
Income	-265.30M	PEG	-	EPS next Q	0.25	Inst Own	116.27%	Short Float	7.47%	Perf Quarter	-27.24%
Sales	2.88B	P/S	0.63	EPS this Y	-59.78%	Inst Trans	-	Short Ratio	4.72	Perf Half Y	-45.23%
Book/sh	16.33	P/B	1.23	EPS next Y	143.16%	ROA	-5.76%	Short Interest	6.67M	Perf Year	-22.70%
Cash/sh	1.41	P/C	14.26	EPS next 5Y	-8.80%	ROE	-14.21%	52W Range	18.07 - 41.02	Perf YTD	-42.44%
Dividend Est.	-	P/FCF	7.95	EPS past 5Y	-	ROI	-10.01%	52W High	-51.02%	Beta	0.65
Dividend TTM	-	Quick Ratio	1.19	Sales past 5Y	6.72%	Gross Margin	13.98%	52W Low	11.18%	ATR (14)	1.24
Dividend Ex-Date	-	Current Ratio	1.19	EPS Y/Y TTM	-	Oper. Margin	-1.81%	RSI (14)	33.68	Volatility	5.72% 6.54%
Employees	18000	Debt/Eq	0.82	Sales Y/Y TTM	-	Profit Margin	-9.22%	Recom	2.46	Target Price	24.10
Option/Short	Yes / Yes	LT Debt/Eq	0.81	EPS Q/Q	-504.33%	Payout	-	Rel Volume	0.73	Prev Close	20.80
Sales Surprise	-3.87%	EPS Surprise	-144.44%	Sales Q/Q	-16.47%	Earnings	Aug 12 BMO	Avg Volume	1.41M	Price	20.09
SMA20	-10.46%	SMA50	-17.07%	SMA200	-34.73%	Trades		Volume	1,030,319	Change	-3.41%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-08-24	Downgrade	Evercore ISI	Outperform → In-line	$31 → $27
Jul-24-24	Resumed	Barclays	Equal Weight	$30
Jun-06-24	Initiated	Goldman	Neutral	$28
May-29-24	Initiated	TD Cowen	Hold	$27
May-28-24	Initiated	Mizuho	Neutral	$27
Mar-22-24	Initiated	Robert W. Baird	Neutral	$43
Mar-06-24	Initiated	Deutsche Bank	Hold	$36
Jan-05-24	Initiated	William Blair	Mkt Perform
Jan-04-24	Initiated	Jefferies	Buy	$44
Dec-11-23	Upgrade	Citigroup	Neutral → Buy	$34 → $40
Dec-01-23	Upgrade	Evercore ISI	In-line → Outperform	$32 → $36
Nov-14-23	Upgrade	Barclays	Equal Weight → Overweight	$29 → $38
Oct-19-23	Initiated	Citigroup	Neutral	$32
Sep-14-23	Initiated	Evercore ISI	In-line	$31
Aug-16-23	Initiated	Barclays	Equal Weight	$29
Aug-07-23	Initiated	BofA Securities	Underperform	$27

Show Previous Ratings

Aug-13-24 12:58PM	Analyst Report: Fortrea Holdings Inc. (Morningstar Research) +10.88%
Aug-12-24 07:04PM	Analyst Report: Fortrea Holdings Inc. (Morningstar Research) -20.35%
07:00AM	Fortrea Reports Second Quarter 2024 Results (GlobeNewswire)
Jul-17-24 07:00AM	Fortrea Announces Date for Second Quarter 2024 Financial Results and Conference Call (GlobeNewswire)
Jul-11-24 08:42AM	Do Options Traders Know Something About Fortrea (FTRE) Stock We Don't? (Zacks) +5.36%
08:00AM	Loading…
08:00AM	Fortrea Appoints Robert Parks as Chief Accounting Officer (GlobeNewswire)
Jun-27-24 07:00AM	Fortrea Launches AI Innovation Studio to Galvanize Technology and Human Solutions to Improve Clinical Trial Delivery (GlobeNewswire)
Jun-19-24 05:02PM	Fortrea to Participate in Virtual Fireside Chat with Evercore ISI (GlobeNewswire)
Jun-04-24 07:00AM	Fortrea Completes Divestiture of Endpoint Clinical and Patient Access Businesses to Arsenal Capital Partners (GlobeNewswire)
Jun-03-24 07:00AM	Fortrea to Present at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-30-24 07:01PM	Fortrea Holdings Inc (FTRE) CEO Acquires Additional Shares (GuruFocus.com)
07:00AM	Fortrea Introduces Comprehensive Solution to Improve Diversity and Inclusion in Clinical Research (GlobeNewswire)
May-21-24 09:48AM	Seth Klarman 2024 Portfolio: Top New Stock Picks (Insider Monkey)
May-17-24 10:15PM	Morningstar \| A Weekly Summary of Stock Ideas and Developments in the Companies We Cover (Morningstar Research)
May-16-24 04:05PM	Fortrea Appoints Machelle Sanders to Board of Directors (GlobeNewswire)
03:56PM	Loading…
May-15-24 03:56PM	Klarman's Baupost Group Buys Stake in SoundHound, Cuts Position in Warner Bros Discovery (Investopedia)
May-14-24 06:43PM	Analyst Report: Fortrea Holdings Inc. (Morningstar Research)
03:01AM	Fortrea Holdings Inc (FTRE) (Q1 2024) Earnings Call Transcript Highlights: Navigating ... (GuruFocus.com)
May-13-24 06:50PM	Analyst Report: Fortrea Holdings Inc. (Morningstar Research) -14.90%
10:52AM	FTRE Stock Earnings: Fortrea Holdings Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
06:30AM	Fortrea Reports First Quarter 2024 Results (GlobeNewswire)
May-06-24 08:22AM	Fortrea Reschedules Release of First Quarter 2024 Financial Results and Conference Call (GlobeNewswire)
Apr-30-24 01:58PM	Laboratory Corporation of America Holdings (NYSE:LH) Q1 2024 Earnings Call Transcript (Insider Monkey)
Apr-11-24 07:00AM	Fortrea Announces Date for First Quarter 2024 Financial Results and Conference Call (GlobeNewswire)
Mar-12-24 11:24AM	Analyst Report: Fortrea Holdings Inc. (Morningstar Research)
Mar-11-24 06:30AM	Fortrea Signs Definitive Agreement to Divest Endpoint Clinical and Patient Access Businesses to Arsenal Capital Partners (GlobeNewswire)
06:30AM	Fortrea Reports Fourth Quarter and Full-Year 2023 Results; Issues Full-Year 2024 Guidance (GlobeNewswire)
Feb-20-24 04:05PM	Fortrea Increases Patient Access Capabilities and Cold Chain Expertise with FortreaRx Expansion (GlobeNewswire)
07:00AM	Fortrea to Present at the Barclays 26th Annual Global Healthcare Conference (GlobeNewswire)
Jan-29-24 07:00AM	Fortrea Announces Date for Fourth Quarter and Full Year 2023 Financial Results and Conference Call (GlobeNewswire)
04:22PM	Loading…
Jan-09-24 04:22PM	Fortrea Establishes Industry Partnership with Veeva and Advarra to Streamline Patient and Site Clinical Trial Experience (GlobeNewswire)
Jan-08-24 07:00AM	Fortrea Previews J.P. Morgan Healthcare Conference Updates (GlobeNewswire)
Jan-05-24 04:53AM	Vltava Fund Sold Fortrea Holdings (FTRE) for an Attractive Price (Insider Monkey)
Jan-04-24 08:00AM	FORTREA SELECTS COGNIZANT AS ITS TECHNOLOGY TRANSFORMATION PROVIDER (PR Newswire)
Jan-02-24 07:00AM	Fortrea to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-13-23 07:00AM	Fortrea Convenes New Site Advisory Board (GlobeNewswire)
Nov-20-23 07:00AM	Fortrea Announces AI-Driven Partnership with Medidata to Increase Diversity in Clinical Trials (GlobeNewswire)
Nov-14-23 08:33PM	Analyst Report: Fortrea Holdings Inc. (Morningstar Research) +5.05%
Nov-13-23 11:07AM	Fortrea Holdings Inc (FTRE) Reports Mixed Q3 Results Amidst Transformation (GuruFocus.com) +9.61%
06:30AM	Fortrea Reports Third Quarter 2023 Results (GlobeNewswire)
Nov-02-23 07:00AM	Fortrea Completes Expansion of Clinical Pharmacology Solutions Following Targeted Investments at its Four Clinical Research Units in U.S. and U.K. (GlobeNewswire)
Oct-18-23 05:40AM	Here's Why Madison Mid Cap Fund Elected to Sell Fortrea Holdings (FTRE) (Insider Monkey)
Oct-17-23 01:35PM	Hedge Fund and Insider Trading News: John Paulson, Ray Dalio, Starboard Value, Trian Fund Management, ExodusPoint Capital Management, JAT Capital, Lexicon Pharmaceuticals, Inc. (LXRX), Omnicom Group Inc. (OMC), and More (Insider Monkey)
09:05AM	Starboard Value Issues Presentation Delivered at 13D Monitors 2023 Active-Passive Investor Summit (Business Wire)
Oct-16-23 08:30PM	Starboard Takes 5%-Plus Stake in Contract-Research Firm Fortrea (The Wall Street Journal)
Oct-13-23 07:00AM	Fortrea Appoints Life Science Executive Dr. John Doyle to Lead Consulting Team (GlobeNewswire)
Oct-11-23 07:00AM	Fortrea Announces Date for Third Quarter 2023 Financial Results and Conference Call (GlobeNewswire)
Oct-10-23 07:00AM	Fortrea's Jim Cameli Named a Top 100 Global Chief Information Security Officer by HotTopics (GlobeNewswire)
Oct-06-23 04:52AM	Here's Why Vltava Fund Sold Fortrea Holdings (FTRE) (Insider Monkey)
Sep-15-23 08:45PM	Morningstar \| A Weekly Summary of Stock Ideas and Developments in the Companies We Cover (Morningstar Research)
Sep-06-23 11:00AM	Fortrea to Present at the Morgan Stanley 21st Annual Global Healthcare Conference (GlobeNewswire)
11:00AM	Fortrea to Present at the Baird 2023 Global Healthcare Conference (GlobeNewswire)
Aug-16-23 10:00AM	Chevron upgraded, SolarEdge downgraded: Wall Street's top analyst calls (The Fly)
Aug-15-23 07:03AM	Fortrea: The Number One Hurdle to Focus on Now Is Growth (GuruFocus.com)
07:03AM	Fortrea: The Main Hurdle to Focus on Now Is Growth (GuruFocus.com)
Aug-14-23 07:00AM	Fortrea Reports Second Quarter 2023 Results and Provides Full-Year 2023 Guidance (GlobeNewswire) -12.21%
Aug-07-23 09:57AM	American downgraded, United upgraded: Wall Street's top analyst calls (The Fly)
09:57AM	American Airlines downgraded, United upgraded: Wall Street's top analys (The Fly)
Jul-20-23 07:00AM	Fortrea Announces Date for Second Quarter 2023 Financial Results and Conference Call (GlobeNewswire)
Jul-18-23 07:40AM	Incannex engages Fortrea to Manage its FDA IND Opening Phase 2/3 Clinical Trial Investigating IHL-42X for Treatment of Obstructive Sleep Apnoea (GlobeNewswire)
Jul-07-23 12:00PM	Fortrea Stock Drops, Headed For Weekly Loss (The Wall Street Journal) -5.21%
Jun-28-23 06:08PM	Fortrea Holdings and PHINIA Set to Join S&P SmallCap 600 (PR Newswire)

Fortrea Holdings, Inc. engages in the provision of clinical development and commercialization services. It operates under the Clinical Services and Enabling Services Segments. The Clinical Services segment provides services across the clinical pharmacology, clinical development, and other clinical service spectrum utilizing enabling services and technology through multiple delivery models. The Enabling Services segment provides technology solutions directly to customers that streamline complex randomization and optimize the trial drug supply process, while minimizing operational costs and supporting timely and accurate patient dosing. The company was founded on January 31, 2023 and is headquartered in Durham, NC.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Morais Mark A.	Chief Operating Officer	Aug 19 '24	Option Exercise	0.00	11,312	0	36,464	Aug 20 05:37 PM
Mcconnell Jill G.	Chief Financial Officer	Aug 19 '24	Option Exercise	0.00	11,312	0	38,194	Aug 20 05:36 PM
Pike Thomas	Chief Executive Officer	Aug 19 '24	Option Exercise	0.00	125,691	0	183,518	Aug 20 05:34 PM
Smith David Ross	Director	Jul 18 '24	Option Exercise	0.00	6,354	0	6,354	Jul 19 05:24 PM
NEUPERT PETER M	Director	Jul 18 '24	Option Exercise	0.00	6,354	0	28,350	Jul 19 05:23 PM
Pesicka Edward A	Director	Jul 18 '24	Option Exercise	0.00	6,354	0	6,354	Jul 19 05:23 PM
ECKERT R ANDREW	Director	Jul 18 '24	Option Exercise	0.00	6,354	0	6,354	Jul 19 05:22 PM
Ray Amrit	Director	Jul 18 '24	Option Exercise	0.00	6,354	0	6,354	Jul 19 05:21 PM
Hanson James S.	General Counsel	Jun 12 '24	Buy	25.30	2,000	50,600	7,475	Jun 12 06:28 PM
Hanson James S.	General Counsel	Jun 03 '24	Option Exercise	0.00	7,706	0	7,706	Jun 03 07:08 PM
Warren Amanda M.	Chief Accounting Officer	Jun 03 '24	Option Exercise	0.00	3,842	0	6,411	Jun 03 07:05 PM
Mcconnell Jill G.	Chief Financial Officer	Jun 03 '24	Option Exercise	0.00	11,000	0	31,717	Jun 03 07:03 PM
Morais Mark A.	Chief Operating Officer	Jun 03 '24	Option Exercise	0.00	11,000	0	29,406	Jun 03 07:01 PM
Pike Thomas	Chief Executive Officer	May 29 '24	Buy	24.81	10,000	248,066	57,827	May 30 04:34 PM
Larson Betty D	Former Director	Mar 30 '24	Option Exercise	0.00	6,354	0	6,354	Apr 01 06:33 AM
Mcconnell Jill G.	Chief Financial Officer	Mar 04 '24	Option Exercise	0.00	20,776	0	26,815	Mar 06 06:42 PM
Morais Mark A.	Chief Operating Officer	Mar 04 '24	Option Exercise	0.00	15,368	0	22,856	Mar 06 06:40 PM
Mcconnell Jill G.	Chief Financial Officer	Feb 11 '24	Option Exercise	0.00	1,544	0	6,486	Feb 13 05:05 PM
Warren Amanda M.	Chief Accounting Officer	Feb 11 '24	Option Exercise	0.00	1,068	0	2,935	Feb 13 05:03 PM
Morais Mark A.	Chief Operating Officer	Feb 11 '24	Option Exercise	0.00	1,210	0	7,839	Feb 13 05:01 PM
Mcconnell Jill G.	Chief Financial Officer	Feb 07 '24	Option Exercise	0.00	1,680	0	5,437	Feb 08 07:00 PM
Warren Amanda M.	Chief Accounting Officer	Feb 07 '24	Option Exercise	0.00	1,182	0	2,272	Feb 08 06:58 PM
Morais Mark A.	Chief Operating Officer	Feb 07 '24	Option Exercise	0.00	2,249	0	7,280	Feb 08 06:55 PM
Mcconnell Jill G.	Chief Financial Officer	Feb 02 '24	Option Exercise	0.00	1,708	0	4,262	Feb 05 05:19 PM
Warren Amanda M.	Chief Accounting Officer	Feb 02 '24	Option Exercise	0.00	1,046	0	1,449	Feb 05 05:17 PM
Morais Mark A.	Chief Operating Officer	Feb 02 '24	Option Exercise	0.00	1,787	0	5,183	Feb 05 05:17 PM
Pike Thomas	Chief Executive Officer	Jan 09 '24	Option Exercise	0.00	40,220	0	60,220	Jan 11 06:12 PM
Morais Mark A.	Chief Operating Officer	Dec 15 '23	Option Exercise	0.00	406	0	3,891	Dec 15 05:41 PM

Open in Screener

SERA

Sera Prognostics Inc

Sep 06 • 04:00PM ET

7.25

Dollar change +0.03
Percentage change 0.42	%

Healthcare • Medical Devices • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

SERA Sera Prognostics Inc daily Stock Chart

Held by: VTI IWM VXF IWO VTWO IWC VTWG RSSL DFAS AVSC

Index	RUT	P/E	-	EPS (ttm)	-0.99	Insider Own	41.80%	Shs Outstand	30.74M	Perf Week	3.72%
Market Cap	241.93M	Forward P/E	-	EPS next Y	-0.94	Insider Trans	-2.06%	Shs Float	19.42M	Perf Month	-2.03%
Income	-31.54M	PEG	-	EPS next Q	-0.23	Inst Own	44.74%	Short Float	4.05%	Perf Quarter	-14.00%
Sales	0.11M	P/S	2199.39	EPS this Y	16.81%	Inst Trans	0.25%	Short Ratio	4.11	Perf Half Y	-19.71%
Book/sh	1.79	P/B	4.05	EPS next Y	2.07%	ROA	-34.74%	Short Interest	0.79M	Perf Year	331.55%
Cash/sh	1.53	P/C	4.75	EPS next 5Y	-	ROE	-44.77%	52W Range	1.52 - 12.35	Perf YTD	21.24%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-21.21%	ROI	-52.47%	52W High	-41.32%	Beta	1.05
Dividend TTM	-	Quick Ratio	2.08	Sales past 5Y	109.61%	Gross Margin	-1029.91%	52W Low	376.97%	ATR (14)	0.48
Dividend Ex-Date	-	Current Ratio	2.08	EPS Y/Y TTM	26.38%	Oper. Margin	-32957.94%	RSI (14)	49.79	Volatility	6.90% 5.90%
Employees	57	Debt/Eq	0.02	Sales Y/Y TTM	-71.47%	Profit Margin	-29471.96%	Recom	1.67	Target Price	2.75
Option/Short	Yes / Yes	LT Debt/Eq	0.01	EPS Q/Q	25.68%	Payout	-	Rel Volume	0.26	Prev Close	7.22
Sales Surprise	-76.56%	EPS Surprise	5.27%	Sales Q/Q	-80.49%	Earnings	Aug 07 AMC	Avg Volume	191.62K	Price	7.25
SMA20	1.09%	SMA50	2.62%	SMA200	-3.43%	Trades		Volume	49,759	Change	0.42%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-30-22	Downgrade	Citigroup	Buy → Neutral	$18 → $4
Nov-19-21	Initiated	Oppenheimer	Outperform	$19
Oct-15-21	Resumed	Cowen	Outperform

Sep-04-24 04:53PM	Sera Prognostics to Present at H.C. Wainwright 26th Annual Global Investment Conference (PR Newswire)
Aug-08-24 08:30AM	Sera Prognostics to Participate in Panel Discussion at UBS Genomic Medicine Summit on August 14, 2024 (PR Newswire)
Aug-07-24 05:50PM	Sera Prognostics, Inc. (SERA) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:05PM	SERA PROGNOSTICS REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS (PR Newswire)
Jul-25-24 08:30AM	Sera Prognostics Announces Conference Call and Webcast of Second Quarter Fiscal Year 2024 Financial Results on August 7, 2024 (PR Newswire)
08:30AM	Loading…
Jul-09-24 08:30AM	Sera Prognostics PreTRM Test Prevention Strategy Demonstrates 18% Reduction in Severe Neonatal Morbidity and Mortality in Newly Published AVERT Trial (PR Newswire)
Jul-01-24 08:30AM	SERA PROGNOSTICS ADDED TO RUSSELL 2000 AND 3000 INDEXES FOLLOWING CONCLUSION OF 2024 INDEXES ANNUAL RECONSTITUTION (PR Newswire)
Jun-16-24 06:17AM	3 Stocks Under $10 With the Potential to Make You a Millionaire (InvestorPlace)
May-28-24 08:30AM	SERA PROGNOSTICS EXPECTED TO BE ADDED TO RUSSELL 2000 AND 3000 INDEXES (PR Newswire)
May-10-24 03:10PM	Sera Prognostics Inc Reports Q1 2024 Results: A Closer Look at Financials and Strategic Moves (GuruFocus.com) -5.41%
May-09-24 10:44AM	Sera Prognostics, Inc. (NASDAQ:SERA) Q1 2024 Earnings Call Transcript (Insider Monkey) +5.27%
May-08-24 08:57PM	SERA Stock Earnings: Sera Prognostics Beats EPS for Q1 2024 (InvestorPlace)
04:05PM	SERA PROGNOSTICS REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS (PR Newswire)
Apr-29-24 02:15PM	Sera Prognostics Announces Conference Call and Webcast of First Quarter Fiscal Year 2024 Financial Results on May 8, 2024 (PR Newswire)
Mar-29-24 01:32AM	Chief Scientific Officer John Boniface Sells 77,136 Shares of Sera Prognostics Inc (SERA) (GuruFocus.com)
01:27AM	Loading…
Mar-27-24 01:27AM	Chief Scientific Officer John Boniface Sells 22,163 Shares of Sera Prognostics Inc (SERA) (GuruFocus.com)
Mar-25-24 12:00PM	Sera Prognostics (SERA) Upgraded to Buy: Here's What You Should Know (Zacks) -8.50%
Mar-21-24 09:57AM	Sera Prognostics, Inc. (NASDAQ:SERA) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-20-24 08:54PM	SERA Stock Earnings: Sera Prognostics Beats EPS, Misses Revenue for Q4 2023 (InvestorPlace)
05:33PM	Sera Prognostics Inc Reports Modest Revenue Growth Amid Operational Streamlining (GuruFocus.com)
05:20PM	Sera Prognostics, Inc. (SERA) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:05PM	SERA PROGNOSTICS REPORTS FOURTH QUARTER 2023 FINANCIAL RESULTS (PR Newswire)
Mar-12-24 11:40AM	25 Countries With Highest Abortion Rates (Insider Monkey)
Mar-04-24 08:30AM	Sera Prognostics Announces Conference Call and Webcast of Fourth Quarter and Fiscal Year 2023 Financial Results on March 20, 2024 (PR Newswire)
Feb-29-24 11:14AM	Sera Prognostics To Present at TD Cowen 44th Annual Healthcare Conference (PR Newswire)
Dec-11-23 12:00PM	Here's Why Sera Prognostics, Inc. (SERA) is a Great Momentum Stock to Buy (Zacks)
Dec-06-23 01:19PM	Why Is Sera Prognostics (SERA) Stock Up 260% Today? (InvestorPlace) +161.43%
08:30AM	SERA PROGNOSTICS ANNOUNCES PRIMARY ENDPOINT CRITERIA MET IN PIVOTAL PRIME STUDY INTERIM LOOK - ENROLLMENT TO STOP DUE TO SUCCESS (PR Newswire)
Nov-22-23 01:00PM	SERA PROGNOSTICS TO PRESENT AT 35TH ANNUAL PIPER SANDLER HEALTHCARE CONFERENCE (PR Newswire)
Nov-12-23 10:59AM	Sera Prognostics, Inc. (NASDAQ:SERA) Q3 2023 Earnings Call Transcript (Insider Monkey)
06:29PM	Loading…
Nov-08-23 06:29PM	Sera Prognostics Inc (SERA) Reports Q3 2023 Financial Results: Revenue Declines as Cost ... (GuruFocus.com) -7.61%
04:05PM	SERA PROGNOSTICS REPORTS THIRD QUARTER 2023 FINANCIAL RESULTS (PR Newswire)
Oct-25-23 08:30AM	Sera Prognostics Announces Conference Call and Webcast of Third Quarter Fiscal Year 2023 Financial Results on November 8, 2023 (PR Newswire) +6.06%
Sep-21-23 08:30AM	SERA PROGNOSTICS TO PRESENT AT CANTOR FITZGERALD GLOBAL HEALTHCARE CONFERENCE 2023 (PR Newswire)
Aug-31-23 09:35AM	Sera Prognostics, Inc. (SERA) Loses -32.38% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks) -6.32%
Aug-30-23 09:35AM	Sera Prognostics, Inc. (SERA) Loses -38.49% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Aug-09-23 05:50PM	Sera Prognostics, Inc. (SERA) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:05PM	SERA PROGNOSTICS REPORTS SECOND QUARTER 2023 FINANCIAL RESULTS (PR Newswire)
Jul-31-23 08:30AM	Sera Prognostics Announces Conference Call and Webcast of Second Quarter Fiscal Year 2023 Financial Results on August 9, 2023 (PR Newswire)
May-25-23 04:15PM	Sera Prognostics Announces Commercial Changes and Actions to Optimize Business for Market Success Toward Accelerating Test Adoption and Revenue (PR Newswire) -5.08%
May-15-23 05:15PM	Sera Prognostics Announces Retirement of President and CEO Dr. Greg Critchfield and Appointment of Board Member Zhenya Lindgardt as Interim CEO (PR Newswire)
May-10-23 06:05PM	Sera Prognostics, Inc. (SERA) Reports Q1 Loss (Zacks)
04:05PM	SERA PROGNOSTICS REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS (PR Newswire)
May-04-23 07:31AM	We're Not Very Worried About Sera Prognostics' (NASDAQ:SERA) Cash Burn Rate (Simply Wall St.)
Apr-27-23 08:30AM	Sera Prognostics Announces Conference Call and Webcast of First Quarter Fiscal Year 2023 Financial Results on May 10, 2023 (PR Newswire)
Apr-24-23 09:35AM	Sera Prognostics, Inc. (SERA) Loses -13.03% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Mar-27-23 12:00PM	All You Need to Know About Sera Prognostics, Inc. (SERA) Rating Upgrade to Buy (Zacks)
02:27AM	Sera Prognostics, Inc. (NASDAQ:SERA) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-24-23 06:29AM	Sera Prognostics Full Year 2022 Earnings: Revenues Miss Expectations (Simply Wall St.)
Mar-22-23 05:35PM	Sera Prognostics, Inc. (SERA) Reports Q4 Loss, Lags Revenue Estimates (Zacks) -6.77%
04:05PM	SERA PROGNOSTICS REPORTS FOURTH QUARTER 2022 FINANCIAL RESULTS (PR Newswire)
Mar-09-23 04:05PM	Sera Prognostics Announces Conference Call and Webcast of Fourth Quarter and Fiscal Year 2022 Financial Results on March 22, 2023 (PR Newswire)
Feb-23-23 04:20PM	SERA PROGNOSTICS TO PRESENT AT UPCOMING MARCH INVESTOR CONFERENCES (PR Newswire) -7.22%
Feb-18-23 07:43AM	Individual investors in Sera Prognostics, Inc. (NASDAQ:SERA) are its biggest bettors, and their bets paid off as stock gained 179% last week (Simply Wall St.)
Feb-15-23 08:30AM	Sera Prognostics Announces Positive Top-line Data from AVERT PRETERM TRIAL (PR Newswire) +73.28%
Nov-29-22 08:30AM	FORS MARSH TO INCLUDE THE PreTRM® TEST IN ITS EMPLOYEE MATERNITY BENEFITS PACKAGE IN COLLABORATION WITH SERA PROGNOSTICS (PR Newswire) -7.63%
Nov-15-22 08:30AM	SERA PROGNOSTICS ANNOUNCES PUBLICATION OF DATA PREDICTING CLINICAL UTILITY AND COST EFFECTIVENESS OF THE PRETRM® TEST-AND-TREAT STRATEGY ACROSS DIVERSE POPULATIONS (PR Newswire)
Nov-09-22 06:15PM	Sera Prognostics, Inc. (SERA) Reports Q3 Loss, Tops Revenue Estimates (Zacks) +10.77%
04:05PM	SERA PROGNOSTICS REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS (PR Newswire)
Nov-04-22 04:00PM	Sera Prognostics Announces Conference Call and Webcast of Third Quarter Fiscal Year 2022 Financial Results on November 9 (PR Newswire) -10.37%
Oct-04-22 08:30AM	SONRAVA HEALTH TO INCLUDE THE PreTRM® TEST IN ITS EMPLOYEE MATERNITY BENEFITS PACKAGE IN COLLABORATION WITH CEREBRAE AND SERA PROGNOSTICS (PR Newswire) +7.78%
Sep-22-22 08:30AM	BANNER HEALTH, SERA PROGNOSTICS TEAM UP TO PROVIDE PreTRM® TEST TO COVERED PREGNANT MEMBERS (PR Newswire)
Sep-20-22 07:19AM	Is Sera Prognostics (NASDAQ:SERA) In A Good Position To Invest In Growth? (Simply Wall St.)
Aug-11-22 07:00AM	Sera Prognostics, Inc. (SERA) Q2 2022 Earnings Call Transcript (Motley Fool)
Aug-10-22 05:55PM	Sera Prognostics, Inc. (SERA) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -6.64%
04:05PM	SERA PROGNOSTICS REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS (PR Newswire)
Aug-03-22 10:00AM	Sera Prognostics, Inc. (SERA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Jul-28-22 08:30AM	Sera Prognostics Announces Conference Call and Webcast of Second Quarter Fiscal Year 2022 Financial Results on August 10 (PR Newswire)
Jun-06-22 02:15PM	SERA PROGNOSTICS TO PRESENT AT 42nd ANNUAL WILLIAM BLAIR GROWTH STOCK CONFERENCE (PR Newswire)
May-19-22 04:15PM	SERA PROGNOSTICS ANNOUNCES PUBLICATION OF DATA DEMONSTRATING IMPROVED PERFORMANCE OF ITS PRETRM® TEST WITH MORE PRECISE GESTATIONAL AGE (PR Newswire)
May-18-22 03:03PM	SERA PROGNOSTICS PRESENTS DATA DEMONSTRATING THE HEALTH AND ECONOMIC BENEFIT OF PRETRM® TESTING AT ISPOR ANNUAL MEETING (PR Newswire)
May-10-22 04:05PM	SERA PROGNOSTICS REPORTS FIRST QUARTER 2022 FINANCIAL RESULTS (PR Newswire) -7.11%
May-05-22 08:30AM	SERA PROGNOSTICS AND NEWBORN FOUNDATION PARTNER TO REDUCE RISKS ASSOCIATED WITH PRETERM BIRTH AND IMPROVE HEALTH EQUITY THROUGH THE "EVERY MOTHER, EVERY BABY" PROJECT (PR Newswire)
May-02-22 08:30AM	Sera Prognostics Announces Conference Call and Webcast of First Quarter Fiscal Year 2022 Financial Results on May 10 (PR Newswire)
Apr-12-22 08:30AM	SERA PROGNOSTICS ANNOUNCES THE APPOINTMENT OF DR. JANE F. BARLOW TO THE SERA PROGNOSTICS BOARD (PR Newswire) -11.31%
Mar-30-22 07:30AM	Sera Prognostics, Inc. (SERA) Q4 2021 Earnings Call Transcript (Motley Fool) -7.65%
Mar-29-22 04:00PM	SERA PROGNOSTICS REPORTS FOURTH QUARTER 2021 FINANCIAL RESULTS (PR Newswire) +12.19%
Mar-18-22 12:00PM	Sera Prognostics Presents Data Demonstrating Prediction of Preeclampsia Utilizing Protein Biomarker and Clinical Factors at SRI Annual Meeting (PR Newswire) -14.45%
07:00AM	Sera Prognostics Announces Conference Call and Webcast of Fourth Quarter and Fiscal Year 2021 Financial Results on March 29 (PR Newswire)
Mar-03-22 08:30AM	SERA PROGNOSTICS TO PRESENT AT UPCOMING MARCH INVESTOR CONFERENCES (PR Newswire) -6.05%
Feb-17-22 08:30AM	SERA PROGNOSTICS PRESENTATION RESCHEDULED FOR CITI 2022 HEALTHCARE CONFERENCE (PR Newswire)
Feb-07-22 08:30AM	SERA PROGNOSTICS TO PRESENT AT UPCOMING FEBRUARY INVESTOR CONFERENCES (PR Newswire)
Feb-01-22 08:30AM	SERA PROGNOSTICS ANNOUNCES NEW AGREEMENT WITH MULTIPLAN, EXPANDING PATIENT ACCESS TO THE PRETRM® TEST (PR Newswire)
Dec-15-21 08:30AM	SERA PROGNOSTICS ADDED TO NASDAQ BIOTECHNOLOGY INDEX (PR Newswire)
Dec-02-21 08:00AM	Sera Prognostics Announces Pricing For PreTRM® Test, The Only Broadly Validated Blood Test To Assess Risk Of Preterm Birth (PR Newswire)
Dec-01-21 11:40AM	Sera Prognostics Announces Publication Of Data Confirming The Performance Of The IBP4/SHBG Biomarkers In Diverse Non-U.S. Populations (PR Newswire)
Nov-30-21 08:00AM	Sera Prognostics Announces The Appointment Of Sandra A.J. Lawrence To The Sera Prognostics Board (PR Newswire)
Nov-10-21 09:01AM	Sera Prognostics, Inc. (SERA) Q3 2021 Earnings Call Transcript (Motley Fool)
Nov-09-21 04:01PM	Sera Prognostics Reports Third Quarter 2021 Financial Results (PR Newswire)
Nov-08-21 04:20PM	Sera Prognostics Announces The Appointment Of Zhenya Lindgardt To The Board (PR Newswire)
Nov-04-21 08:00AM	Sera Prognostics Appoints Woodrow Myers, MD, MBA As Advisor Of Public And Political Affairs (PR Newswire) +5.63%
Nov-03-21 08:00AM	Sera Prognostics Announces Publication of the Clinical Validation of PreTRM® Threshold for Clinical Action (PR Newswire)
Nov-02-21 08:00AM	Sera Prognostics Announces Collaboration To Help Underserved Communities Make Informed Decisions About Prenatal Health (PR Newswire)
Oct-27-21 08:30AM	Sera Prognostics Announces Conference Call and Webcast of Third Quarter 2021 Financial Results on November 9 (PR Newswire)
Oct-15-21 10:59AM	We're Not Very Worried About Sera Prognostics' (NASDAQ:SERA) Cash Burn Rate (Simply Wall St.)
Sep-28-21 08:30AM	Sera Prognostics Appoints Dr. Paul Kearney as Chief Data Officer (GlobeNewswire)
Sep-20-21 08:30AM	Sera Prognostics to be Added to Russell 2000 Index (GlobeNewswire)
Sep-15-21 08:00AM	Sera Prognostics Appoints Dr. Michael R. Foley as Chief Medical Officer (GlobeNewswire) -6.73%
Sep-14-21 08:00AM	Sera Prognostics Announces Publication of Health Economic Analysis Supporting PreTRM® Test-and-Treat Strategy to Improve Maternal and Infant Health (GlobeNewswire)
Sep-13-21 08:00AM	Sera Prognostics to Present at Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit (GlobeNewswire)

Sera Prognostics, Inc. engages in the provision of personalized diagnostics to predict and manage pregnancy complications. It focuses on developing blood tests to predict the risks of preterm birth, preeclampsia and other pregnancy complications. The company was founded by Steven W. Graves, Dennis Farrar and M. Sean Esplin in 2008 and is headquartered in Salt Lake City, UT.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Lindgardt Zhenya	Officer	Aug 07 '24	Proposed Sale	7.42	12,327	91,405		Aug 08 05:07 PM
Harrison Robert Gardner	Officer	Aug 07 '24	Proposed Sale	7.41	5,022	37,238		Aug 08 05:05 PM
Kearney Paul	Officer	Aug 07 '24	Proposed Sale	7.41	4,333	32,129		Aug 08 05:04 PM
Mirza Mansoor Raza	Director	Aug 07 '24	Proposed Sale	7.42	101	749		Aug 08 05:02 PM
Boniface John J.	Officer	Aug 07 '24	Proposed Sale	7.41	5,022	37,238		Aug 08 05:01 PM
Jackson Benjamin	Officer	Aug 07 '24	Proposed Sale	7.41	5,022	37,238		Aug 08 05:00 PM
Aerts Austin	Officer	Aug 07 '24	Proposed Sale	7.41	6,760	50,125		Aug 08 04:58 PM
Boniface John J.	Chief Scientific Officer	Aug 07 '24	Sale	7.42	5,022	37,263	129,847	Aug 08 04:51 PM
Harrison Robert Gardner	Chief Information Officer	Aug 07 '24	Sale	7.42	5,022	37,263	135,773	Aug 08 04:50 PM
Kearney Paul	Chief Data Officer	Aug 07 '24	Sale	7.42	4,333	32,151	180,967	Aug 08 04:50 PM
Lindgardt Zhenya	Chief Executive Officer	Aug 07 '24	Sale	7.42	12,327	91,466	856,918	Aug 08 04:50 PM
Mirza Mansoor Raza	Director	Aug 07 '24	Sale	7.42	101	749	7,016	Aug 08 04:50 PM
Jackson Benjamin	General Counsel	Aug 07 '24	Sale	7.42	5,022	37,263	140,255	Aug 08 04:50 PM
Aerts Austin	Chief Financial Officer	Aug 07 '24	Sale	7.42	6,760	50,159	303,721	Aug 08 04:49 PM
Lindgardt Zhenya	Chief Executive Officer	Jun 10 '24	Sale	8.11	26,867	217,891	869,245	Jun 11 04:50 PM
Aerts Austin	Chief Financial Officer	Jun 10 '24	Sale	8.11	5,415	43,916	310,481	Jun 11 04:50 PM
Kearney Paul	Chief Data Officer	May 15 '24	Sale	8.24	10,387	85,589	185,300	May 15 06:23 PM
Kearney Paul	Chief Data Officer	May 08 '24	Sale	9.59	4,205	40,326	154,833	May 10 05:42 PM
Boniface John J.	Chief Scientific Officer	May 08 '24	Sale	9.59	4,902	47,010	134,869	May 10 05:41 PM
Jackson Benjamin	General Counsel	May 08 '24	Sale	9.59	4,902	47,010	145,277	May 10 05:41 PM
Aerts Austin	Chief Financial Officer	May 08 '24	Sale	9.59	6,592	63,217	315,896	May 10 05:41 PM
Lindgardt Zhenya	Chief Executive Officer	May 08 '24	Sale	9.59	11,992	115,003	896,112	May 10 05:41 PM
Harrison Robert Gardner	Chief Information Officer	May 08 '24	Sale	9.59	4,902	47,010	140,795	May 10 05:40 PM
Boniface John J.	Chief Scientific Officer	Mar 27 '24	Option Exercise	0.91	48,909	44,507	188,680	Mar 28 05:56 PM
Boniface John J.	Chief Scientific Officer	Mar 28 '24	Option Exercise	0.91	24,474	22,271	164,245	Mar 28 05:56 PM
Boniface John J.	Chief Scientific Officer	Mar 27 '24	Sale	9.62	52,662	506,608	139,771	Mar 28 05:56 PM
Boniface John J.	Chief Scientific Officer	Mar 28 '24	Sale	9.04	24,474	221,245	139,771	Mar 28 05:56 PM
Lindgardt Zhenya	Chief Executive Officer	Mar 26 '24	Sale	9.37	38,899	364,484	908,104	Mar 26 08:00 PM
Aerts Austin	Chief Financial Officer	Mar 26 '24	Sale	9.37	8,092	75,822	322,488	Mar 26 08:00 PM
Boniface John J.	Chief Scientific Officer	Mar 26 '24	Sale	9.55	21,438	204,733	143,524	Mar 26 05:38 PM
Boniface John J.	Chief Scientific Officer	Mar 25 '24	Sale	9.10	22,163	201,683	164,962	Mar 26 04:20 PM
Boniface John J.	Chief Scientific Officer	Mar 06 '24	Sale	9.02	1,664	15,009	187,125	Mar 07 04:16 PM
Aerts Austin	Chief Financial Officer	Mar 06 '24	Sale	9.02	444	4,005	330,580	Mar 07 04:16 PM
Kearney Paul	Chief Data Officer	Mar 06 '24	Sale	9.02	1,028	9,273	159,038	Mar 07 04:16 PM
Harrison Robert Gardner	Chief Information Officer	Mar 06 '24	Sale	9.02	2,138	19,285	145,697	Mar 07 04:15 PM
Jackson Benjamin	General Counsel	Mar 06 '24	Sale	9.02	1,856	16,741	150,179	Mar 07 04:15 PM
Jackson Benjamin	General Counsel	Feb 06 '24	Sale	8.03	5,665	45,490	152,035	Feb 07 04:57 PM
Boniface John J.	Chief Scientific Officer	Feb 06 '24	Sale	8.03	5,665	45,490	188,789	Feb 07 04:57 PM
Kearney Paul	Chief Data Officer	Feb 06 '24	Sale	8.03	4,984	40,022	160,066	Feb 07 04:56 PM
Harrison Robert Gardner	Chief Information Officer	Feb 06 '24	Sale	8.03	5,665	45,490	147,835	Feb 07 04:56 PM
Lindgardt Zhenya	Chief Executive Officer	Feb 06 '24	Sale	8.03	27,997	224,816	947,003	Feb 07 04:56 PM
Aerts Austin	Chief Financial Officer	Feb 06 '24	Sale	8.03	9,786	78,582	331,024	Feb 07 04:56 PM
Jackson Benjamin	General Counsel	Dec 07 '23	Sale	5.22	10,000	52,200	157,700	Dec 07 09:35 PM
Boniface John J.	Chief Scientific Officer	Dec 07 '23	Sale	4.80	5,000	24,000	194,454	Dec 07 09:35 PM

Open in Screener

GH

Guardant Health Inc

Sep 06 • 04:00PM ET

23.73

Dollar change -0.60
Percentage change -2.47	%

Healthcare • Diagnostics & Research • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

GH Guardant Health Inc daily Stock Chart

Held by: VTI VB IWM VXF VBK ARKG IWO VTWO VHT SCHA

Index	RUT	P/E	-	EPS (ttm)	-4.09	Insider Own	4.99%	Shs Outstand	121.63M	Perf Week	-8.48%
Market Cap	2.92B	Forward P/E	-	EPS next Y	-2.85	Insider Trans	0.03%	Shs Float	116.88M	Perf Month	-30.12%
Income	-490.76M	PEG	-	EPS next Q	-0.75	Inst Own	95.30%	Short Float	8.03%	Perf Quarter	-18.23%
Sales	643.81M	P/S	4.53	EPS this Y	23.73%	Inst Trans	1.88%	Short Ratio	4.59	Perf Half Y	28.55%
Book/sh	-0.01	P/B	-	EPS next Y	12.83%	ROA	-28.46%	Short Interest	9.39M	Perf Year	-32.80%
Cash/sh	8.42	P/C	2.82	EPS next 5Y	29.20%	ROE	-337.16%	52W Range	15.81 - 37.04	Perf YTD	-12.27%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-8.88%	ROI	-37.41%	52W High	-35.93%	Beta	1.11
Dividend TTM	-	Quick Ratio	6.07	Sales past 5Y	49.27%	Gross Margin	59.87%	52W Low	50.09%	ATR (14)	1.45
Dividend Ex-Date	-	Current Ratio	6.40	EPS Y/Y TTM	16.79%	Oper. Margin	-79.30%	RSI (14)	31.06	Volatility	3.99% 4.87%
Employees	1779	Debt/Eq	-	Sales Y/Y TTM	26.20%	Profit Margin	-76.23%	Recom	1.38	Target Price	41.50
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	-25.31%	Payout	-	Rel Volume	1.29	Prev Close	24.33
Sales Surprise	9.01%	EPS Surprise	-11.48%	Sales Q/Q	29.23%	Earnings	Aug 07 AMC	Avg Volume	2.05M	Price	23.73
SMA20	-13.72%	SMA50	-20.11%	SMA200	-3.80%	Trades		Volume	2,645,831	Change	-2.47%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-28-24	Upgrade	Guggenheim	Neutral → Buy	$36
Jun-03-24	Resumed	Jefferies	Buy	$32
Apr-24-24	Resumed	Craig Hallum	Buy	$28
Dec-14-23	Initiated	Guggenheim	Neutral
Dec-13-23	Initiated	Wolfe Research	Peer Perform
Nov-13-23	Upgrade	Raymond James	Mkt Perform → Outperform	$27
Sep-28-23	Initiated	Bernstein	Outperform	$34
Sep-27-23	Upgrade	Piper Sandler	Neutral → Overweight	$40
Jul-05-23	Resumed	JP Morgan	Overweight	$65
May-26-23	Upgrade	Citigroup	Neutral → Buy	$28 → $40
May-05-23	Initiated	UBS	Buy	$40
Mar-09-23	Downgrade	Citigroup	Buy → Neutral	$60 → $33
Jan-05-23	Initiated	Scotiabank	Sector Outperform	$36
Nov-01-22	Downgrade	Piper Sandler	Overweight → Neutral	$65 → $50
Oct-19-22	Initiated	Craig Hallum	Buy	$88
Oct-06-22	Initiated	Stephens	Overweight	$99
Aug-25-22	Initiated	Credit Suisse	Outperform	$80
Jun-03-22	Initiated	Piper Sandler	Overweight	$65
Apr-28-22	Resumed	BTIG Research	Buy	$135 → $115
Feb-24-22	Reiterated	Wells Fargo	Overweight	$150 → $115

Show Previous Ratings

Aug-27-24 04:05PM	Guardant Health to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference (Business Wire)
Aug-26-24 12:56PM	Midday movers: PDD Holdings, NVIDIA fall; Xpeng gains (Investing.com) -7.86%
10:40AM	Why Guardant Health Stock Just Crashed 10% (Motley Fool)
Aug-23-24 10:45AM	Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought (Motley Fool)
06:00AM	Sector Spotlight: Top 4 Basket of Diagnostic Stocks (EXAS, GH, ILMN, LUDG) (News Direct)
05:00PM	Loading…
Aug-22-24 05:00PM	Guardant Health to Ring the Nasdaq Opening Bell on August 28 to Celebrate the Launch of Shield Blood Test for Colorectal Cancer Screening (Business Wire)
Aug-12-24 11:45AM	Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought (Motley Fool) +5.07%
Aug-09-24 04:48PM	Analyst Report: Guardant Health, Inc. (Morningstar Research)
Aug-08-24 04:05PM	Guardant Health to Participate in Upcoming Investor Conferences (Business Wire) -10.87%
09:35AM	Guardant Health (GH) Recently Broke Out Above the 20-Day Moving Average (Zacks)
Aug-07-24 07:30PM	Guardant Health (GH) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks) +5.60%
06:50PM	Guardant Health (GH) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
05:49PM	Guardant Health: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Guardant Health Reports Second Quarter 2024 Financial Results and Increases 2024 Revenue Guidance (Business Wire)
08:05AM	Guardant Health COSMOS Study Published in Clinical Cancer Research Validates Utility of Guardant Reveal Liquid Biopsy Test for Predicting Recurrence in Colorectal Cancer (Business Wire)
09:15AM	Loading…
Aug-06-24 09:15AM	What Analyst Projections for Key Metrics Reveal About Guardant Health (GH) Q2 Earnings (Zacks) +5.27%
Aug-01-24 04:02PM	Why Exact Sciences, Up 27%, Is 'Coiled To Snap Back' After Quarterly Beat (Investor's Business Daily) -5.04%
08:30AM	Guardant Healths FDA-approved Shield Blood Test Now Commercially Available in U.S. as a Primary Screening Option for Colorectal Cancer (Business Wire)
08:00AM	Guardant Health Outcomes Model Confirms the Public Health Importance of Enhanced Colorectal Cancer Screening Outcomes with High Adherence Strategies (Business Wire)
Jul-31-24 09:45AM	Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought (Motley Fool)
Jul-30-24 06:32AM	Guardant Health secures FDA approval for Shield test (Medical Device Network)
05:17AM	Guardant Health (GH) Moves 6.9% Higher: Will This Strength Last? (Zacks)
Jul-29-24 04:06PM	FDA approves Guardant Health's blood test for colon cancer (Yahoo Finance Video) +6.91%
02:16PM	Guardant Health Gets FDA Nod on Colorectal Cancer Blood Test (Investopedia)
07:58AM	Guardant wins FDA approval for colon cancer blood test (MedTech Dive)
06:30AM	Guardant Healths Shield Blood Test Approved by FDA as a Primary Screening Option, Clearing Path for Medicare Reimbursement and a New Era of Colorectal Cancer Screening (Business Wire)
Jul-24-24 04:05PM	Guardant Health to Report Second Quarter 2024 Financial Results on August 7, 2024 (Business Wire)
Jul-23-24 08:05AM	Guardant Health Introduces Major Smart Liquid Biopsy Upgrade to Market-Leading Guardant360 Test, Further Extending Its Best-in-Class Performance (Business Wire)
01:38AM	Guardant settles allegations it violated the False Claims Act (MedTech Dive)
Jul-21-24 06:00AM	3 Precision Medicine Stocks Tailoring Treatments (InvestorPlace)
05:00PM	Loading…
Jul-18-24 05:00PM	Dr. Manuel Hidalgo Medina Joins Guardant Health Board of Directors (Business Wire)
Jul-05-24 03:01PM	Baillie Gifford Reduces Stake in Guardant Health Inc. (GuruFocus.com)
Jul-03-24 11:11AM	3 Biotech Moonshots With Imminent Catalyst Potential (InvestorPlace)
07:00AM	The 3 Best Personalized Medicine Stocks to Buy in July 2024 (InvestorPlace)
Jul-02-24 06:15AM	From Sell' to Strong Buy': 3 Dramatic Analyst U-Turns to Watch (InvestorPlace)
Jun-27-24 03:28PM	American Cancer Society Projects Over 2 Million New Cases in 2024: Biotech Innovations Respond (PR Newswire)
Jun-26-24 09:35AM	Guardant Health (GH) Just Overtook the 20-Day Moving Average (Zacks)
Jun-25-24 09:55AM	Guardant Health (GH) Now Trades Above Golden Cross: Time to Buy? (Zacks)
Jun-04-24 08:05AM	Guardant Health introduces new Guardant360 TissueNext test with nearly 500 biomarkers to identify more treatment options for patients with advanced cancer (Business Wire)
Jun-03-24 09:18AM	Guardant Health and Washington University to present study at 2024 ASCO meeting highlighting utility of ctDNA to address racial inequities in the use of targeted therapies and enrollment in clinical trials (Business Wire)
May-31-24 08:05AM	Guardant Health Named to TIME100 Most Influential Companies (Business Wire)
May-30-24 08:05AM	Guardant Health to Present Studies at 2024 ASCO Annual Meeting Highlighting Contributions of Its Blood Tests and Real-World Data to Advancing Precision Oncology and Cancer Screening (Business Wire) +5.29%
May-27-24 11:34AM	Bull Market Blastoff: 3 Stocks Targeting 56% to 91% Returns (InvestorPlace)
09:30AM	Guardant Health (GH) Recently Broke Out Above the 200-Day Moving Average (Zacks)
May-24-24 04:06PM	Guardant Health Jumps As Exact Sciences Slumps On A Key FDA Move For Blood Tests (Investor's Business Daily) +13.37%
01:16PM	Guardant Health Stock Jumps 12% (Barrons.com)
01:15PM	Guardant Health Stock Jumps. Blood Test for Cancer Moves Toward FDA Approval. (Barrons.com)
10:28AM	Guardant Stock Climbs As Cancer Test Strides Towards FDA Ok (The Wall Street Journal)
09:03AM	Guardant Health Rockets After FDA Panel Recommends Approval For Blood-Based Colon Cancer Test (Investor's Business Daily)
08:37AM	Guardant wins FDA AdCom backing for colon cancer test (Medical Device Network)
May-23-24 07:03PM	FDA Advisory Committee Panel Strongly Recommends Approval of Shield Blood Test for Colorectal Cancer Screening as a Primary Non-Invasive Screening Option (Business Wire)
10:52AM	Guardant Health's blood test to detect deadly colon cancer is under review by the FDA (Quartz)
07:05AM	Guardant Health Stock Trading Temporarily Halted; FDA Panel to Assess Premarket Approval Application for Shield Blood Test for Colorectal Cancer Screening (Business Wire)
May-22-24 04:05PM	Guardant Health to Participate in Upcoming Investor Conferences (Business Wire) +13.37%
08:15AM	Guardant colon cancer test struggles to detect non-cancerous tumors, FDA says (MedTech Dive)
May-21-24 04:36PM	What's Going On With Colorectal Cancer Diagnostic-Focused Guardant Health Stock On Tuesday? (Benzinga)
09:53AM	Guardant Health Gets EU Certification for Blood-Based Test for Comprehensive Genomic Profiling of Solid Cancers (MT Newswires)
08:05AM	Guardant Health Receives EU IVDR Certification for Guardant360 CDx Liquid Biopsy for Tumor Mutation Profiling Across All Solid Cancers and Companion Diagnostic Indications (Business Wire)
May-17-24 08:05AM	Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-16-24 08:05AM	Guardant Health to present real-world data supporting performance of Shield blood test for colorectal cancer screening at 2024 Digestive Disease Week (Business Wire)
May-15-24 06:45PM	Analyst Report: Guardant Health, Inc. (Morningstar Research)
May-13-24 10:03AM	Guardant Health, Inc. (NASDAQ:GH) Q1 2024 Earnings Call Transcript (Insider Monkey) +7.29%
May-10-24 06:16PM	Analyst Report: Guardant Health, Inc. (Morningstar Research) +15.07%
01:58PM	Guardant Health Shares Rise After Q1 Adjusted Loss Shrinks, Revenue Rises; 2024 Revenue Guidance Raised (MT Newswires)
01:09PM	Guardant Health Inc (GH) Reports Strong Q1 2024 Earnings, Surpasses Revenue Estimates (GuruFocus.com)
May-09-24 06:30PM	Compared to Estimates, Guardant Health (GH) Q1 Earnings: A Look at Key Metrics (Zacks)
06:05PM	Guardant Health (GH) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:58PM	Guardant Health: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Guardant Health Reports First Quarter 2024 Financial Results and Increases 2024 Revenue Guidance (Business Wire)
May-07-24 04:05PM	Guardant Health to Participate in Upcoming Investor Conferences (Business Wire)
11:29AM	Guardant (GH) Gears Up for Q1 Earnings: Here's What to Expect (Zacks)
08:00AM	Guardant Health Surpasses 500 Peer-Reviewed Publications Milestone (Business Wire)
May-06-24 09:15AM	Curious about Guardant Health (GH) Q1 Performance? Explore Wall Street Estimates for Key Metrics (Zacks)
Apr-29-24 04:01PM	Ginkgo Bioworks Announces Nomination of Myrtle Potter and Ross Fubini to Board of Directors (PR Newswire)
11:18AM	Canaccord Genuity Adjusts Price Target on Guardant Health to $30 From $45, Maintains Buy Rating (MT Newswires)
Apr-22-24 08:52AM	FDA Advisory Panel Review of Guardant Healths Shield Blood Test to Screen for Colorectal Cancer to Be Held on May 23 (Business Wire) +9.46%
Apr-18-24 04:05PM	Guardant Health to Report First Quarter 2024 Financial Results on May 9, 2024 (Business Wire)
Apr-03-24 08:05AM	Guardant Health to Present Data Highlighting Application of Epigenomics to Advance Precision Oncology at 2024 AACR Annual Meeting (Business Wire) -5.24%
Apr-02-24 04:02PM	Exact Sciences, A Cathie Wood Stock, Surges As Rival Colon Cancer Test Pales (Investor's Business Daily)
Apr-01-24 08:35AM	Better Than ChatGPT? New Super AI Bot Says Buy These 3 Stocks. (InvestorPlace)
Mar-30-24 07:43PM	20 Foods To Reduce Cancer Risk (Insider Monkey)
Mar-13-24 05:09PM	A blood test for colon cancer performed well in a study, expanding options for screening (Associated Press Finance)
05:00PM	Guardant Health ECLIPSE Study Data Demonstrating Efficacy of Shield Blood-based Test for Colorectal Cancer Screening to be Published in The New England Journal of Medicine (Business Wire)
Mar-06-24 04:30PM	Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +7.58%
Mar-01-24 05:30AM	New Survey: Patients and Physicians Overwhelmingly Agree Blood Tests Could Help Close the Colorectal Cancer Screening Gap (Business Wire)
Feb-28-24 06:46PM	21 Countries that Have the Highest Rates of Cancer Deaths (Insider Monkey)
Feb-26-24 02:13AM	Analyst Report: Guardant Health, Inc. (Morningstar Research)
Feb-23-24 11:48AM	Guardant Health, Inc. (NASDAQ:GH) Q4 2023 Earnings Call Transcript (Insider Monkey) -12.80%
Feb-22-24 07:00PM	Guardant Health (GH) Reports Q4 Earnings: What Key Metrics Have to Say (Zacks)
06:20PM	Guardant Health (GH) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
05:23PM	Guardant Health: Q4 Earnings Snapshot (Associated Press Finance)
04:38PM	Guardant Health Inc (GH) Reports 25% Revenue Growth in Full Year 2023 (GuruFocus.com)
04:05PM	Guardant Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Outlook (Business Wire)
09:55AM	Wall Street Analysts Think Guardant Health (GH) Could Surge 109.89%: Read This Before Placing a Bet (Zacks)
Feb-16-24 03:10AM	15 Best Hospitals for Cancer Treatment in the US (Insider Monkey)
Feb-15-24 04:05PM	Guardant Health to Participate in Upcoming Investor Conferences (Business Wire)
10:00AM	Guardant Health (GH) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Feb-07-24 09:00AM	Cathie Wood Is Selling This Stock: Should You? (Motley Fool)
Feb-02-24 09:35AM	Down -12.91% in 4 Weeks, Here's Why Guardant Health (GH) Looks Ripe for a Turnaround (Zacks)
Feb-01-24 04:05PM	Guardant Health to Report Fourth Quarter and Full Year 2023 Financial Results on February 22, 2024 (Business Wire)

Guardant Health, Inc. is a precision oncology company engaged in the treatment of cancer through the use of proprietary blood-based tests, vast data sets, and advanced analytics. Its solutions include treatment selection, recurrence detection, and early detection. The company was founded by Helmy Eltoukhy, AmirAli H. Talasaz, and Michael Joseph Wiley in 2011 and is headquartered in Palo Alto, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Joyce Meghan V.	Director	Sep 04 '24	Option Exercise	0.00	67	0	10,412	Sep 05 04:52 PM
Saia John G.	Chief Legal Officer	Sep 01 '24	Option Exercise	0.00	263	0	29,306	Sep 03 04:47 PM
Kalia Kumud	Chief Information Officer	Sep 01 '24	Option Exercise	0.00	710	0	18,666	Sep 03 04:46 PM
Chudova Darya	Chief Technology Officer	Sep 01 '24	Option Exercise	0.00	316	0	44,379	Sep 03 04:45 PM
Krognes Steve E.	Director	Aug 31 '24	Option Exercise	0.00	155	0	9,603	Sep 03 04:43 PM
Tariq Musa	Director	Aug 15 '24	Option Exercise	0.00	250	0	4,247	Aug 19 05:18 PM
POTTER MYRTLE S	Director	Aug 15 '24	Option Exercise	0.00	68	0	13,448	Aug 19 05:17 PM
Joyce Meghan V.	Director	Aug 04 '24	Option Exercise	0.00	66	0	10,345	Aug 05 06:10 PM
Krognes Steve E.	Director	Jul 31 '24	Option Exercise	0.00	154	0	9,448	Aug 01 06:46 PM
Tariq Musa	Director	Jul 15 '24	Option Exercise	0.00	250	0	3,997	Jul 16 04:35 PM
POTTER MYRTLE S	Director	Jul 15 '24	Option Exercise	0.00	69	0	13,380	Jul 16 04:33 PM
Joyce Meghan V.	Director	Jul 04 '24	Option Exercise	0.00	66	0	10,279	Jul 08 05:29 PM
Saia John G.	Chief Legal Officer	Jul 01 '24	Option Exercise	0.00	974	0	29,391	Jul 02 04:58 PM
Kalia Kumud	Chief Information Officer	Jul 01 '24	Option Exercise	0.00	1,607	0	18,530	Jul 02 04:57 PM
Freeman Chris	Chief Commercial Officer	Jul 01 '24	Option Exercise	0.00	1,928	0	26,527	Jul 02 04:55 PM
EAGLE CRAIG	Chief Medical Officer	Jul 01 '24	Option Exercise	0.00	1,714	0	19,108	Jul 02 04:54 PM
Chudova Darya	Chief Technology Officer	Jul 01 '24	Option Exercise	0.00	1,339	0	44,541	Jul 02 04:53 PM
Talasaz AmirAli	Co-Chief Executive Officer	Jun 30 '24	Option Exercise	0.00	11,462	0	2,204,589	Jul 02 04:51 PM
Krognes Steve E.	Director	Jun 30 '24	Option Exercise	0.00	154	0	9,294	Jul 02 04:49 PM
Eltoukhy Helmy	Co-Chief Executive Officer	Jun 30 '24	Option Exercise	0.00	11,462	0	2,304,423	Jul 02 04:47 PM
Tariq Musa	Director	Jun 15 '24	Option Exercise	0.00	250	0	3,747	Jun 17 06:44 PM
Saia John G.	Chief Legal Officer	Jun 15 '24	Option Exercise	0.00	4,017	0	29,851	Jun 17 06:43 PM
POTTER MYRTLE S	Director	Jun 15 '24	Option Exercise	0.00	68	0	13,311	Jun 17 06:42 PM
Kalia Kumud	Chief Information Officer	Jun 15 '24	Option Exercise	0.00	2,510	0	17,819	Jun 17 06:41 PM
Freeman Chris	Chief Commercial Officer	Jun 15 '24	Option Exercise	0.00	10,402	0	27,469	Jun 17 06:40 PM
EAGLE CRAIG	Chief Medical Officer	Jun 15 '24	Option Exercise	0.00	5,523	0	19,365	Jun 17 06:38 PM
Bell Michael Brian	Chief Financial Officer	Jun 15 '24	Option Exercise	0.00	9,267	0	21,720	Jun 17 06:37 PM
POTTER MYRTLE S	Director	Jun 12 '24	Option Exercise	0.00	5,592	0	13,243	Jun 13 08:58 PM
Krognes Steve E.	Director	Jun 12 '24	Option Exercise	0.00	5,592	0	9,140	Jun 13 08:56 PM
Joyce Meghan V.	Director	Jun 12 '24	Option Exercise	0.00	5,592	0	10,213	Jun 13 08:54 PM
Gadde Vijaya	Director	Jun 12 '24	Option Exercise	0.00	5,592	0	17,640	Jun 13 08:53 PM
CLARK IAN T	Director	Jun 12 '24	Option Exercise	0.00	6,776	0	15,677	Jun 13 08:51 PM
Joyce Meghan V.	Director	Jun 04 '24	Option Exercise	0.00	67	0	4,721	Jun 05 04:56 PM
Joyce Meghan V.	Director	Jun 04 '24	Sale	27.87	100	2,787	4,621	Jun 05 04:56 PM
Saia John G.	Chief Legal Officer	Jun 01 '24	Option Exercise	0.00	263	0	25,928	Jun 03 06:25 PM
Kalia Kumud	Chief Information Officer	Jun 01 '24	Option Exercise	0.00	711	0	15,563	Jun 03 06:23 PM
Chudova Darya	Chief Technology Officer	Jun 01 '24	Option Exercise	0.00	315	0	43,315	Jun 03 06:21 PM
Krognes Steve E.	Director	May 31 '24	Option Exercise	0.00	155	0	3,548	Jun 03 06:20 PM
Tariq Musa	Director	May 15 '24	Option Exercise	0.00	250	0	3,497	May 16 06:17 PM
POTTER MYRTLE S	Director	May 15 '24	Option Exercise	0.00	69	0	7,651	May 16 06:15 PM
EAGLE CRAIG	Chief Medical Officer	May 15 '24	Option Exercise	0.00	3,717	0	15,169	May 16 06:14 PM
Chudova Darya	Chief Technology Officer	May 15 '24	Option Exercise	0.00	8,705	0	46,106	May 16 06:12 PM
Joyce Meghan V.	Director	May 04 '24	Option Exercise	0.00	66	0	4,654	May 06 05:06 PM
Eltoukhy Helmy	Co-Chief Executive Officer	May 03 '24	Option Exercise	4.18	200,000	836,000	2,292,961	May 06 05:05 PM
Talasaz AmirAli	Co-Chief Executive Officer	May 02 '24	Option Exercise	4.18	283,830	1,186,409	2,193,127	May 06 05:03 PM
Krognes Steve E.	Director	Apr 30 '24	Option Exercise	0.00	154	0	3,393	May 02 05:03 PM
Tariq Musa	Director	Apr 15 '24	Option Exercise	0.00	249	0	3,247	Apr 16 06:36 PM
Saia John G.	Chief Legal Officer	Apr 15 '24	Option Exercise	0.00	7,569	0	28,366	Apr 16 06:35 PM
POTTER MYRTLE S	Director	Apr 15 '24	Option Exercise	0.00	68	0	7,582	Apr 16 06:33 PM
Joyce Meghan V.	Director	Apr 04 '24	Option Exercise	0.00	67	0	4,588	Apr 05 06:29 PM
Saia John G.	Chief Legal Officer	Apr 01 '24	Option Exercise	0.00	974	0	22,305	Apr 02 06:09 PM
Kalia Kumud	Chief Information Officer	Apr 01 '24	Option Exercise	0.00	1,607	0	14,329	Apr 02 06:08 PM
Freeman Chris	Chief Commercial Officer	Apr 01 '24	Option Exercise	0.00	1,929	0	16,502	Apr 02 06:06 PM
EAGLE CRAIG	Chief Medical Officer	Apr 01 '24	Option Exercise	0.00	1,714	0	12,073	Apr 02 06:05 PM
Chudova Darya	Chief Technology Officer	Apr 01 '24	Option Exercise	0.00	1,340	0	36,831	Apr 02 06:04 PM
Krognes Steve E.	Director	Mar 31 '24	Option Exercise	0.00	154	0	3,239	Apr 01 05:25 PM
Talasaz AmirAli	Co-Chief Executive Officer	Mar 31 '24	Option Exercise	0.00	11,461	0	1,913,806	Apr 01 05:23 PM
Eltoukhy Helmy	Co-Chief Executive Officer	Mar 31 '24	Option Exercise	0.00	11,461	0	2,097,470	Apr 01 05:20 PM
Kalia Kumud	Chief Information Officer	Mar 18 '24	Buy	17.82	2,187	38,963	12,722	Mar 19 05:29 PM
Tariq Musa	Director	Mar 15 '24	Option Exercise	0.00	2,998	0	2,998	Mar 18 06:16 PM
POTTER MYRTLE S	Director	Mar 15 '24	Option Exercise	0.00	68	0	7,514	Mar 18 06:14 PM
Bell Michael Brian	Chief Financial Officer	Mar 15 '24	Option Exercise	0.00	1,233	0	12,882	Mar 18 06:12 PM
Joyce Meghan V.	Director	Mar 04 '24	Option Exercise	0.00	66	0	4,621	Mar 05 08:01 PM
Joyce Meghan V.	Director	Mar 04 '24	Sale	19.05	100	1,905	4,521	Mar 05 08:01 PM
Saia John G.	Chief Legal Officer	Mar 01 '24	Option Exercise	0.00	263	0	21,439	Mar 04 06:39 PM
Merrill Amelia	SVP, People	Mar 01 '24	Option Exercise	0.00	158	0	27,540	Mar 04 06:37 PM
Kalia Kumud	Chief Information Officer	Mar 01 '24	Option Exercise	0.00	710	0	10,789	Mar 04 06:35 PM
Chudova Darya	Chief Technology Officer	Mar 01 '24	Option Exercise	0.00	316	0	35,621	Mar 04 06:34 PM
Krognes Steve E.	Director	Feb 29 '24	Option Exercise	0.00	154	0	3,085	Mar 01 05:08 PM
POTTER MYRTLE S	Director	Feb 15 '24	Option Exercise	0.00	69	0	7,446	Feb 16 07:10 PM
Joyce Meghan V.	Director	Feb 04 '24	Option Exercise	0.00	66	0	4,555	Feb 05 08:12 PM
Krognes Steve E.	Director	Jan 31 '24	Option Exercise	0.00	155	0	2,931	Feb 01 05:38 PM
Chudova Darya	Chief Technology Officer	Jan 16 '24	Option Exercise	8.80	6,626	58,309	35,305	Jan 16 07:44 PM
POTTER MYRTLE S	Director	Jan 15 '24	Option Exercise	0.00	68	0	7,377	Jan 16 07:43 PM
Bell Michael Brian	Chief Financial Officer	Jan 15 '24	Option Exercise	0.00	3,308	0	13,005	Jan 16 07:41 PM
Kalia Kumud	Chief Information Officer	Jan 07 '24	Option Exercise	0.00	5,376	0	12,250	Jan 08 07:45 PM
Joyce Meghan V.	Director	Jan 04 '24	Option Exercise	0.00	67	0	4,489	Jan 05 04:58 PM
Saia John G.	Chief Legal Officer	Jan 01 '24	Option Exercise	0.00	974	0	21,576	Jan 03 07:51 PM
Merrill Amelia	SVP, People	Jan 01 '24	Option Exercise	0.00	482	0	27,580	Jan 03 07:49 PM
Kalia Kumud	Chief Information Officer	Jan 01 '24	Option Exercise	0.00	1,607	0	7,533	Jan 03 07:48 PM
Freeman Chris	Chief Commercial Officer	Jan 01 '24	Option Exercise	0.00	1,928	0	15,207	Jan 03 07:45 PM
EAGLE CRAIG	Chief Medical Officer	Jan 01 '24	Option Exercise	0.00	1,714	0	11,062	Jan 03 07:44 PM
Chudova Darya	Chief Technology Officer	Jan 01 '24	Option Exercise	0.00	1,339	0	29,228	Jan 03 07:42 PM
Krognes Steve E.	Director	Dec 31 '23	Option Exercise	0.00	154	0	2,776	Jan 02 06:06 PM
POTTER MYRTLE S	Director	Dec 15 '23	Option Exercise	0.00	69	0	7,309	Dec 18 05:39 PM
Bell Michael Brian	Chief Financial Officer	Dec 15 '23	Option Exercise	0.00	1,233	0	10,124	Dec 18 05:37 PM
Joyce Meghan V.	Director	Dec 04 '23	Option Exercise	0.00	66	0	4,522	Dec 05 05:01 PM
Joyce Meghan V.	Director	Dec 04 '23	Sale	26.34	100	2,634	4,422	Dec 05 05:01 PM
Saia John G.	Chief Legal Officer	Dec 01 '23	Option Exercise	0.00	263	0	20,733	Dec 04 06:28 PM
Merrill Amelia	SVP, People	Dec 01 '23	Option Exercise	0.00	158	0	27,153	Dec 04 06:26 PM
Kalia Kumud	Chief Information Officer	Dec 01 '23	Option Exercise	0.00	710	0	12,079	Dec 04 06:25 PM
Kalia Kumud	Chief Information Officer	Dec 01 '23	Sale	26.37	5,800	152,954	5,926	Dec 04 06:25 PM
Chudova Darya	Chief Technology Officer	Dec 01 '23	Option Exercise	0.00	315	0	27,998	Dec 04 06:24 PM
Krognes Steve E.	Director	Nov 30 '23	Option Exercise	0.00	154	0	2,622	Dec 04 06:22 PM
Chudova Darya	Chief Technology Officer	Nov 15 '23	Option Exercise	8.80	4,000	35,200	27,683	Nov 16 05:04 PM
POTTER MYRTLE S	Director	Nov 15 '23	Option Exercise	0.00	68	0	7,240	Nov 16 05:02 PM
Joyce Meghan V.	Director	Nov 04 '23	Option Exercise	0.00	66	0	4,456	Nov 06 05:40 PM
Krognes Steve E.	Director	Oct 31 '23	Option Exercise	0.00	154	0	2,468	Nov 01 08:07 PM
POTTER MYRTLE S	Director	Oct 15 '23	Option Exercise	0.00	68	0	7,172	Oct 16 06:28 PM
Joyce Meghan V.	Director	Oct 04 '23	Option Exercise	0.00	67	0	4,390	Oct 05 06:02 PM

Open in Screener

XGN

Exagen Inc

Sep 06 • 04:00PM ET

3.14

Dollar change -0.28
Percentage change -8.19	%

Healthcare • Diagnostics & Research • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

Held by: VTI VXF

Index	-	P/E	-	EPS (ttm)	-0.97	Insider Own	51.22%	Shs Outstand	17.05M	Perf Week	5.02%
Market Cap	54.60M	Forward P/E	-	EPS next Y	-0.83	Insider Trans	0.46%	Shs Float	8.48M	Perf Month	28.16%
Income	-17.31M	PEG	-	EPS next Q	-0.29	Inst Own	36.15%	Short Float	0.19%	Perf Quarter	53.92%
Sales	56.66M	P/S	0.96	EPS this Y	28.48%	Inst Trans	-0.85%	Short Ratio	0.31	Perf Half Y	60.20%
Book/sh	1.01	P/B	3.10	EPS next Y	12.87%	ROA	-30.51%	Short Interest	0.02M	Perf Year	24.11%
Cash/sh	1.41	P/C	2.23	EPS next 5Y	-	ROE	-69.97%	52W Range	1.30 - 3.71	Perf YTD	57.79%
Dividend Est.	-	P/FCF	-	EPS past 5Y	2.69%	ROI	-43.68%	52W High	-15.36%	Beta	1.27
Dividend TTM	-	Quick Ratio	4.01	Sales past 5Y	10.63%	Gross Margin	59.13%	52W Low	141.48%	ATR (14)	0.28
Dividend Ex-Date	-	Current Ratio	4.32	EPS Y/Y TTM	52.30%	Oper. Margin	-27.90%	RSI (14)	58.37	Volatility	9.13% 11.68%
Employees	179	Debt/Eq	1.36	Sales Y/Y TTM	7.05%	Profit Margin	-30.56%	Recom	1.33	Target Price	6.25
Option/Short	Yes / Yes	LT Debt/Eq	1.25	EPS Q/Q	42.51%	Payout	-	Rel Volume	1.20	Prev Close	3.42
Sales Surprise	14.76%	EPS Surprise	52.94%	Sales Q/Q	6.56%	Earnings	Aug 05 BMO	Avg Volume	51.65K	Price	3.14
SMA20	2.89%	SMA50	30.49%	SMA200	61.51%	Trades		Volume	62,014	Change	-8.19%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-05-22	Downgrade	KeyBanc Capital Markets	Overweight → Sector Weight
Oct-15-21	Resumed	Cowen	Outperform	$26
Apr-15-21	Initiated	Canaccord Genuity	Buy	$25
Nov-10-20	Initiated	KeyBanc Capital Markets	Overweight	$32
Oct-08-20	Initiated	BTIG Research	Buy	$18
Jun-02-20	Resumed	Cantor Fitzgerald	Overweight	$19 → $20
Oct-14-19	Initiated	William Blair	Outperform
Oct-14-19	Initiated	Cowen	Outperform	$17
Oct-14-19	Initiated	Cantor Fitzgerald	Overweight	$18

Sep-04-24 04:05PM	Exagen Inc. to Participate in the 2024 Cantor Global Healthcare Conference (GlobeNewswire) +15.93%
Aug-29-24 09:55AM	Bears are Losing Control Over Exagen (XGN), Here's Why It's a 'Buy' Now (Zacks)
Aug-26-24 08:50AM	Exagen (XGN) Shows Fast-paced Momentum But Is Still a Bargain Stock (Zacks)
Aug-09-24 09:15AM	Exagen Inc. (XGN) Soars to 52-Week High, Time to Cash Out? (Zacks) +22.46%
Aug-08-24 08:50AM	Fast-paced Momentum Stock Exagen (XGN) Is Still Trading at a Bargain (Zacks) +12.65%
12:53PM	Loading…
Aug-05-24 12:53PM	XGN Stock Earnings: Exagen Beats EPS, Beats Revenue for Q2 2024 (InvestorPlace) +17.65%
09:10AM	Exagen Inc. (XGN) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
08:00AM	Exagen Inc. Reports Strong Second Quarter 2024 Results: Raises Guidance due to Record Performance (GlobeNewswire)
Aug-02-24 09:00AM	Exagen Inc. to Participate in the Canaccord Genuity 44th Annual Growth Conference (GlobeNewswire)
Aug-01-24 09:00AM	Exagen Appoints Jeffrey G. Black as New Chief Financial Officer (GlobeNewswire)
Jul-22-24 09:00AM	Exagen to Announce Second Quarter 2024 Results on August 5, 2024 (GlobeNewswire)
Jun-13-24 08:50AM	Why Fast-paced Mover Exagen (XGN) Is a Great Choice for Value Investors (Zacks)
May-15-24 05:01AM	Exagen Inc (XGN) Q1 2024 Earnings Call Transcript Highlights: Strong Revenue Growth and Margin ... (GuruFocus.com) +8.52%
May-13-24 12:53PM	XGN Stock Earnings: Exagen Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
09:10AM	Exagen Inc. (XGN) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
08:00AM	Loading…
08:00AM	Exagen Inc. Reports Strong First Quarter 2024 Results: Raises Guidance for Full Year (GlobeNewswire)
May-06-24 04:05PM	Exagen Announces Campaign for Lupus Awareness Month (GlobeNewswire)
Apr-30-24 04:05PM	Exagen to Announce First Quarter 2024 Results on May 13, 2024 (GlobeNewswire)
Apr-26-24 08:30AM	Exagen Inc. Announces Changes to the Board of Directors (GlobeNewswire)
Mar-19-24 09:37AM	Exagen Inc. (NASDAQ:XGN) Q4 2023 Earnings Call Transcript (Insider Monkey) -12.99%
01:55AM	Q4 2023 Exagen Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-18-24 12:52PM	XGN Stock Earnings: Exagen Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace) +9.26%
09:25AM	Exagen Inc. (XGN) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
08:00AM	Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2023 Results (GlobeNewswire)
Mar-08-24 09:00AM	Exagen Inc. to Participate in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum (GlobeNewswire)
Mar-07-24 04:05PM	Exagen to Announce Fourth Quarter 2023 and Full-Year Financial Results on March 18, 2024 (GlobeNewswire)
Feb-06-24 08:50AM	Despite Fast-paced Momentum, Exagen Inc. (XGN) Is Still a Bargain Stock (Zacks)
Jan-30-24 04:05PM	Exagen Inc. to Participate in the 2024 BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference (GlobeNewswire) -6.52%
Jan-07-24 12:00PM	Exagen Inc. Announces Select Preliminary Full-Year 2023 Results and Reaffirms Guidance (GlobeNewswire)
Nov-13-23 04:05PM	Exagen Inc. Reports Strong Third Quarter 2023 Results (GlobeNewswire) +16.44%
04:05PM	Loading…
Nov-09-23 04:05PM	Exagen Inc. and Johns Hopkins University Announce License Agreement for Novel Patented Lupus Nephritis Biomarkers (GlobeNewswire) -6.25%
Nov-02-23 04:05PM	Exagen Inc. to Participate in the 2023 Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum (GlobeNewswire)
Oct-30-23 04:05PM	Exagen to Announce Third Quarter 2023 Financial Results on November 13, 2023 (GlobeNewswire) +6.75% +6.08%
Sep-28-23 04:05PM	Exagen Announces Acceptance of Multiple Abstracts at ACR 2023 Annual Meeting (GlobeNewswire)
Sep-12-23 04:05PM	Exagen Inc. to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference (GlobeNewswire)
Aug-09-23 10:47AM	Exagen Inc. (NASDAQ:XGN) Q2 2023 Earnings Call Transcript (Insider Monkey) -7.22%
Aug-08-23 04:13AM	Q2 2023 Exagen Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-07-23 09:15AM	Exagen Inc. (XGN) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +8.76%
08:00AM	Exagen Inc. Reports Strong Second Quarter 2023 Results (GlobeNewswire)
Jul-26-23 04:05PM	Exagen Inc. to Participate in the Canaccord Genuity 43rd Annual Growth Conference (GlobeNewswire)
Jul-25-23 04:05PM	Exagen to Announce Second Quarter 2023 Financial Results on August 7, 2023 (GlobeNewswire) -6.51%
Jul-24-23 04:05PM	Exagen Inc. Appoints Paul Kim to Board of Directors (GlobeNewswire)
07:33AM	This Exagen Insider Increased Their Holding In The Last Year (Simply Wall St.)
Jun-13-23 08:19AM	Exagen Inc.'s (NASDAQ:XGN) Low P/S No Reason For Excitement (Simply Wall St.) -8.36%
May-30-23 09:00AM	Exagen Inc. to Participate in the William Blair 43rd Annual Growth Stock Conference (GlobeNewswire)
May-17-23 07:11AM	Exagen (NASDAQ:XGN) shareholders are up 20% this past week, but still in the red over the last three years (Simply Wall St.) -6.90%
May-16-23 11:03AM	Q1 2023 Exagen Inc Earnings Call (Thomson Reuters StreetEvents) +19.51%
May-15-23 05:55PM	Exagen Inc. (XGN) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Exagen Inc. Reports First Quarter 2023 Results (GlobeNewswire)
May-01-23 04:05PM	Exagen Announces Campaign for Lupus Awareness Month (GlobeNewswire)
Apr-24-23 04:05PM	Exagen to Announce First Quarter 2023 Financial Results on May 15, 2023 (GlobeNewswire)
Mar-24-23 08:16AM	Exagen Inc. (NASDAQ:XGN) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-22-23 06:12AM	Exagen Full Year 2022 Earnings: Revenues Beat Expectations, EPS Lags (Simply Wall St.)
Mar-21-23 07:40AM	Q4 2022 Exagen Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-20-23 05:25PM	Exagen Inc. (XGN) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Exagen Inc. Reports Fourth Quarter and Full Year 2022 Results (GlobeNewswire)
Mar-06-23 04:05PM	Exagen to Announce Fourth Quarter and Full Year Financial Results on March 20, 2023 (GlobeNewswire) +5.31%
Feb-27-23 09:00AM	Exagen Inc. to Participate in Upcoming March Conferences (GlobeNewswire)
Feb-14-23 06:19AM	Exagen Inc. (NASDAQ:XGN) insider upped their holding earlier this year (Simply Wall St.)
Jan-30-23 04:05PM	Exagen Inc. to Participate in the 2023 BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference (GlobeNewswire)
Jan-23-23 09:00AM	Exagen Inc. Elects Tina S. Nova, Ph.D. as Executive Chair of the Board of Directors (GlobeNewswire)
Nov-14-22 07:55PM	Exagen Inc. (XGN) Reports Q3 Loss, Tops Revenue Estimates (Zacks) -7.49% +42.38%
04:05PM	Exagen Inc. Reports Third Quarter 2022 Results (GlobeNewswire)
Nov-08-22 04:05PM	Exagen Inc. to Participate in Fourth Quarter Investor Conferences (GlobeNewswire)
Oct-31-22 04:05PM	Exagen to Announce Third Quarter 2022 Financial Results on November 14, 2022 (GlobeNewswire)
Oct-17-22 09:00AM	Exagen Announces Appointment of John Aballi as CEO (GlobeNewswire)
Oct-04-22 08:25AM	Exagen Announces Appointment of Andrew L. Concoff MD, FACR, CAQSM, as Chief Innovation Officer (GlobeNewswire)
Sep-20-22 04:05PM	Exagen Announces Acceptance of Multiple Abstracts at ACR 2022 Annual Meeting (GlobeNewswire) -10.02%
Sep-19-22 10:20AM	The past three years for Exagen (NASDAQ:XGN) investors has not been profitable (Simply Wall St.) -8.67%
Sep-01-22 04:05PM	Exagen Inc. Collaboration Leads to Characterization of Broad Autoreactivity in Severe COVID-19 Patients (GlobeNewswire)
Aug-05-22 12:00PM	Exagen Inc. (XGN) Q2 2022 Earnings Call Transcript (Motley Fool) -23.61%
Aug-04-22 06:55PM	Exagen Inc. (XGN) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:06PM	Exagen Initiates Study to Predict Rheumatoid Arthritis Drug Response (RADR) in Patients with RA (GlobeNewswire)
04:05PM	Exagen Inc. Reports Second Quarter 2022 Results (GlobeNewswire)
Jul-25-22 04:05PM	Exagen Inc. to Participate in the Canaccord Genuity 42nd Annual Growth Conference (GlobeNewswire) +8.23% -6.11%
Jul-21-22 04:05PM	Exagen to Announce Second Quarter 2022 Financial Results on August 4, 2022 (GlobeNewswire)
Jul-05-22 08:25AM	Exagen Releases Largest Comparative Utility Study in Lupus Diagnostics Confirming AVISE® Lupus Delivers Unparalleled Utility (GlobeNewswire)
Jun-21-22 08:10AM	Does Exagen (NASDAQ:XGN) Have A Healthy Balance Sheet? (Simply Wall St.) +8.65%
Jun-09-22 08:25AM	Exagen Inc. Expands Coverage with MediNcrease (GlobeNewswire) +10.78%
May-26-22 04:05PM	Exagen Inc. to Participate in the William Blair 42nd Annual Growth Stock Conference (GlobeNewswire) +9.50%
May-16-22 04:05PM	Exagen Inc. Expands Coverage with Alivio Health, Partnering to Provide More Accurate Diagnostic Testing with AVISE® CTD and AVISE® Lupus (GlobeNewswire)
May-11-22 05:55PM	Exagen Inc. (XGN) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -16.16%
04:06PM	Exagen Inc. Announces New PLA Code and Medicare Pricing for Proprietary AVISE® Lupus Test (GlobeNewswire)
04:05PM	Exagen Inc. Reports First Quarter 2022 Results (GlobeNewswire)
May-10-22 10:45AM	AdaptHealth Corp. (AHCO) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +10.25%
May-03-22 05:15PM	MacroGenics (MGNX) Reports Q1 Loss, Lags Revenue Estimates (Zacks) +9.25%
May-01-22 12:00PM	Exagen Announces Five-Week Campaign for Lupus Awareness Month (GlobeNewswire)
Apr-25-22 04:05PM	Exagen to Announce First Quarter 2022 Financial Results on May 11, 2022 (GlobeNewswire)
Apr-20-22 04:05PM	Exagen Inc. to Participate in Investor Summit Groups Q2 Conference (GlobeNewswire) -5.64%
Apr-12-22 07:22AM	Shareholders in Exagen (NASDAQ:XGN) have lost 61%, as stock drops 15% this past week (Simply Wall St.)
Mar-30-22 08:25AM	Exagen Inc. Expands In-Network Access with Evolutions Healthcare Systems (GlobeNewswire)
Mar-22-22 10:00PM	Exagen Inc. (XGN) Q4 2021 Earnings Call Transcript (Motley Fool)
05:25PM	Exagen Inc. (XGN) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:06PM	Exagen Inc. Expands In-Network Benefit with Additional 22.7 Million Lives (GlobeNewswire)
04:05PM	Exagen Inc. Reports Fourth Quarter and Full Year 2021 Results (GlobeNewswire)
Mar-16-22 04:05PM	Exagen Announces New Rheumatoid Arthritis Scientific Advisory Board (GlobeNewswire) +6.52%
Mar-09-22 05:35PM	Myomo, Inc. (MYO) Reports Q4 Loss, Tops Revenue Estimates (Zacks) +13.31%
04:05PM	Exagen Inc. to Participate in the 2022 KeyBanc Capital Markets Life Sciences and MedTech Investor Forum (GlobeNewswire)
Mar-08-22 04:05PM	Exagen to Announce Fourth Quarter and Full Year Financial Results on March 22, 2022 (GlobeNewswire)
Mar-07-22 08:05AM	Eagle Pharmaceuticals (EGRX) Lags Q4 Earnings and Revenue Estimates (Zacks)

Exagen, Inc. is a commercial-stage diagnostics company, which engages in transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. It operates under the Avise brand. The company was founded by Waneta C. Tuttle and Cole Harris in 2002 and is headquartered in Vista, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Adawi Kamal	Officer	Aug 09 '24	Proposed Sale	2.76	52,624	145,242		Aug 09 05:08 PM
ABALLI JOHN	President and CEO	May 16 '24	Buy	1.92	40,401	77,570	40,401	May 16 08:02 PM
Adawi Kamal	CFO and Corporate Secretary	Mar 04 '24	Sale	1.91	12,784	24,407	243,749	Mar 06 04:05 PM
Adawi Kamal	CFO and Corporate Secretary	Feb 06 '24	Sale	1.95	6,738	13,133	181,533	Feb 08 04:05 PM
ABALLI JOHN	President and CEO	Oct 17 '23	Sale	1.75	33,819	59,018	415,984	Oct 18 04:05 PM

Open in Screener

LH

Labcorp Holdings Inc.

Sep 06 • 04:00PM ET

223.91

Dollar change -3.43
Percentage change -1.51	%

Healthcare • Diagnostics & Research • USA • NYSE

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

LH Labcorp Holdings Inc. daily Stock Chart

Held by: VTI VOO VO SPY IVV VTV XLV RSP VOE SPLV

Index	S&P 500	P/E	42.52	EPS (ttm)	5.27	Insider Own	0.35%	Shs Outstand	83.90M	Perf Week	-2.52%
Market Cap	18.80B	Forward P/E	14.09	EPS next Y	15.89	Insider Trans	-15.48%	Shs Float	83.67M	Perf Month	2.07%
Income	449.50M	PEG	4.61	EPS next Q	3.53	Inst Own	96.44%	Short Float	2.00%	Perf Quarter	12.85%
Sales	12.49B	P/S	1.51	EPS this Y	7.97%	Inst Trans	-2.81%	Short Ratio	2.95	Perf Half Y	2.54%
Book/sh	95.53	P/B	2.34	EPS next Y	8.55%	ROA	2.61%	Short Interest	1.67M	Perf Year	9.44%
Cash/sh	3.16	P/C	70.91	EPS next 5Y	9.23%	ROE	5.35%	52W Range	191.97 - 238.46	Perf YTD	-1.49%
Dividend Est.	2.93 (1.31%)	P/FCF	22.06	EPS past 5Y	-11.14%	ROI	3.82%	52W High	-6.10%	Beta	1.05
Dividend TTM	2.88 (1.29%)	Quick Ratio	0.77	Sales past 5Y	2.87%	Gross Margin	26.10%	52W Low	16.64%	ATR (14)	4.35
Dividend Ex-Date	Aug 29, 2024	Current Ratio	0.88	EPS Y/Y TTM	-43.06%	Oper. Margin	9.09%	RSI (14)	47.77	Volatility	1.83% 1.76%
Employees	67000	Debt/Eq	0.75	Sales Y/Y TTM	-11.38%	Profit Margin	3.60%	Recom	1.78	Target Price	254.64
Option/Short	Yes / Yes	LT Debt/Eq	0.47	EPS Q/Q	14.74%	Payout	60.36%	Rel Volume	0.86	Prev Close	227.34
Sales Surprise	1.11%	EPS Surprise	4.34%	Sales Q/Q	6.17%	Earnings	Aug 01 BMO	Avg Volume	566.81K	Price	223.91
SMA20	-1.58%	SMA50	2.80%	SMA200	4.46%	Trades		Volume	488,211	Change	-1.51%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-25-24	Upgrade	Argus	Hold → Buy	$250
Feb-26-24	Initiated	Leerink Partners	Outperform	$260
Feb-09-24	Initiated	Evercore ISI	In-line	$240
Jan-03-24	Initiated	Barclays	Equal Weight	$222
Sep-06-23	Initiated	HSBC Securities	Hold	$210
Dec-12-22	Downgrade	Citigroup	Buy → Neutral	$275 → $250
Sep-19-22	Downgrade	Argus	Buy → Hold
Aug-22-22	Resumed	Morgan Stanley	Overweight	$300
Jan-28-22	Downgrade	Deutsche Bank	Buy → Hold	$330 → $294
Jan-11-21	Upgrade	Argus	Hold → Buy	$245
Jan-11-21	Downgrade	Wolfe Research	Peer Perform → Underperform
Jan-08-21	Downgrade	Wolfe Research	Outperform → Peer Perform
Jul-14-20	Upgrade	BofA Securities	Neutral → Buy	$194 → $220
Jul-13-20	Upgrade	Wolfe Research	Peer Perform → Outperform
Jun-02-20	Resumed	Deutsche Bank	Buy	$210
May-15-20	Upgrade	Mizuho	Neutral → Buy	$158 → $186
Apr-29-20	Downgrade	KeyBanc Capital Markets	Overweight → Sector Weight
Apr-27-20	Upgrade	Wolfe Research	Underperform → Peer Perform
Apr-27-20	Upgrade	Citigroup	Neutral → Buy	$204 → $214
Jan-08-20	Initiated	Wells Fargo	Overweight	$210

Show Previous Ratings

Sep-03-24 04:09PM	Labcorp to Speak at the Baird 2024 Global Healthcare Conference (PR Newswire)
Aug-27-24 07:05AM	Should You Invest in Labcorp Holdings (LH)? (Insider Monkey)
Aug-22-24 08:52AM	Should You Hold Labcorp (LH) Stock in Your Portfolio Now? (Zacks)
Aug-21-24 01:01PM	Insider Sale: EVP, Chief Legal Officer Sandra D van der Vaart Sells 2,000 Shares of Labcorp ... (GuruFocus.com)
Aug-19-24 01:01PM	Insider Sale: CFO Glenn Eisenberg Sells 15,000 Shares of Labcorp Holdings Inc (LH) (GuruFocus.com)
12:42PM	Loading…
Aug-14-24 12:42PM	Labcorp (LH) Gains From New Collaborations Amid FX Issues (Zacks)
Aug-07-24 11:00AM	Insider Sale: EVP, CIO & CTO Lance Berberian Sells 12,093 Shares of Labcorp Holdings Inc (LH) (GuruFocus.com)
Aug-06-24 12:47AM	Labcorp wins FDA OK for pan-solid tumor liquid biopsy (MedTech Dive)
Aug-05-24 07:00AM	Labcorp Finalizes Acquisition of Select Assets of Invitae (PR Newswire)
04:12AM	FDA grants De Novo authorisation for Labcorps liquid biopsy test (Medical Device Network)
Aug-03-24 01:05AM	Decoding Labcorp Holdings Inc (LH): A Strategic SWOT Insight (GuruFocus.com)
Aug-02-24 01:12PM	Health Care Stock Soars Past Buy Point After Boosting Buyback (Investor's Business Daily)
08:30AM	Labcorp Receives FDA De Novo Marketing Authorization for PGDx elio plasma focus Dx (PR Newswire)
06:31AM	Q2 2024 Labcorp Holdings Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-01-24 07:21PM	Analyst Report: Labcorp Holdings Inc. (Morningstar Research) +8.33%
03:02PM	Loading…
03:02PM	Labcorp (LH) Q2 Earnings Surpass Estimates (revised) (Zacks)
01:31PM	LabCorp's Stock Soars After Q2 Performance, Analyst Highlights Strong Position In Healthcare Sector (Benzinga)
11:49AM	Midday movers: Meta Platforms, Lilly rise; Arm, Moderna fall (Investing.com)
09:47AM	Labcorp (LH) Q2 Earnings Surpass Estimates, Margins Increase (Zacks)
09:30AM	Compared to Estimates, Labcorp (LH) Q2 Earnings: A Look at Key Metrics (Zacks)
08:10AM	Labcorp (LH) Beats Q2 Earnings and Revenue Estimates (Zacks)
07:28AM	Labcorp beats Q2 profit and revenue estimates on demand for health tests (Reuters)
07:08AM	Labcorp: Q2 Earnings Snapshot (Associated Press Finance)
06:57AM	Labcorp Announces 2024 Second Quarter Results (PR Newswire)
Jul-31-24 06:00AM	Labcorp expands Ultima pact to boost genomic diagnostics (MedTech Dive)
Jul-30-24 07:00AM	Labcorp Expands Collaboration with Ultima Genomics to Advance Whole Genome Sequencing Applications and Oncology Testing Capabilities (PR Newswire)
Jul-25-24 10:02AM	Labcorp (LH) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
06:59AM	Labcorp Declares Quarterly Dividend (PR Newswire)
Jul-22-24 09:27AM	Here's How Labcorp (LH) is Placed Ahead of Q2 Earnings Release (Zacks)
Jul-12-24 08:36AM	Implied Volatility Surging for Labcorp (LH) Stock Options (Zacks)
10:00AM	Loading…
Jul-09-24 10:00AM	Here's Why Labcorp (LH) is a Strong Value Stock (Zacks)
Jul-02-24 07:36AM	Is It the Right Time to Hold Labcorp (LH) in Your Portfolio? (Zacks)
Jul-01-24 07:00AM	Labcorp to Announce Second Quarter Financial Results on August 1, 2024 (PR Newswire)
Jun-20-24 02:20PM	Analyst Report: Labcorp Holdings Inc. (Morningstar Research)
Jun-18-24 06:53AM	Labcorp launches suite of laboratory solutions designed to expedite clinical trials (Clinical Trials Arena)
06:13AM	Ranking the top ten clinical research organisations in the world (Pharmaceutical Technology)
Jun-17-24 08:00AM	Labcorp Launches Global Trial Connect to Accelerate Clinical Trials (PR Newswire)
Jun-04-24 07:54AM	Labcorp Holdings (LH) is Trading at an Attractive Valuation (Insider Monkey)
07:32AM	Here's Why Diamond Hill Large Cap Strategy Sold BorgWarner (BWA) in Q1 (Insider Monkey)
Jun-03-24 07:00AM	Labcorp Announces New Strategic Service Offerings within Precision Oncology Portfolio (PR Newswire)
May-30-24 07:00AM	Labcorp to Present Multiple Abstracts across Precision Oncology at the 2024 ASCO Annual Meeting (PR Newswire)
May-28-24 06:59AM	Labcorp to Speak at the 44th Annual William Blair Growth Stock Conference (PR Newswire)
May-21-24 09:40AM	Why Labcorp (LH) is a Top Value Stock for the Long-Term (Zacks)
May-16-24 11:00AM	Insider Sale: EVP, Chief Legal Officer van der Vaart Sandra D Sells Shares of Laboratory Corp ... (GuruFocus.com)
09:49AM	Labcorp (LH) to Assess Preeclampsia Risk With New Test (Zacks)
06:22AM	Labcorp launches first trimester preeclampsia screening test (Medical Device Network)
05:42AM	Baird Adjusts Price Target on Laboratory Corp of America Holdings to $256 From $255, Keeps Outperform Rating (MT Newswires)
May-15-24 08:00AM	Labcorp Introduces First Trimester Screening Test to Assess Preeclampsia Risk during Pregnancy (PR Newswire)
May-09-24 10:41AM	Here's Why Investors Should Retain Labcorp (LH) Stock for Now (Zacks)
May-08-24 06:59AM	Labcorp to Webcast Its Annual Meeting of Shareholders (PR Newswire)
06:56AM	Q1 2024 OPKO Health Inc Earnings Call (Thomson Reuters StreetEvents)
03:44AM	OPKO Health Inc (OPK) Q1 2024 Earnings Call Transcript Highlights: Strategic Moves Amid ... (GuruFocus.com)
May-07-24 04:05PM	Invitae Receives Court Approval for Sale to Labcorp (PR Newswire)
May-02-24 02:22AM	Insider Sale at Laboratory Corp of America Holdings (LH) (GuruFocus.com)
May-01-24 01:03AM	Decoding Laboratory Corp of America Holdings (LH): A Strategic SWOT Insight (GuruFocus.com)
Apr-30-24 01:58PM	Laboratory Corporation of America Holdings (NYSE:LH) Q1 2024 Earnings Call Transcript (Insider Monkey)
08:41AM	Baird Adjusts Laboratory Corp of America Holdings' Price Target to $255 From $244 (MT Newswires)
Apr-29-24 10:17AM	Labcorp Receives US FDA's Approval for Companion Diagnostic Device for Use With Pfizer's Hemophilia B Gene Therapy (MT Newswires)
07:00AM	Labcorp Receives FDA Approval for First Companion Diagnostic for Use with Pfizer's Newly Approved Gene Therapy to Treat Patients with Hemophilia B (PR Newswire)
Apr-26-24 11:14AM	Baird Adjusts Laboratory Corp of America Holdings' Price Target to $244 From $255 (MT Newswires)
10:34AM	Barclays Adjusts Price Target on Laboratory Corp of America Holdings to $213 From $234 (MT Newswires)
07:55AM	Truist Cuts Price Target on Laboratory Corp of America Holdings to $255 From $270, Keeps Buy Rating (MT Newswires)
01:06AM	Q1 2024 Laboratory Corporation of America Holdings Earnings Call (Thomson Reuters StreetEvents)
Apr-25-24 01:41PM	Analyst Report: Laboratory Corporation of America Holdings (Morningstar Research)
01:11PM	Labcorp to acquire Invitaes assets for $239M (MedTech Dive)
12:45PM	Leerink Partners Adjusts Laboratory Corp of America Price Target to $242 From $260, Keeps Outperform Rating (MT Newswires)
10:18AM	Labcorp (LH) Tops Q1 Earnings Estimates, Raises 2024 EPS View (Zacks)
09:30AM	Compared to Estimates, Labcorp (LH) Q1 Earnings: A Look at Key Metrics (Zacks)
09:22AM	Laboratory Corp of America Q1 Adjusted Earnings, Revenue Increase; 2024 Adjusted EPS Outlook Updated (MT Newswires)
08:35AM	Laboratory Corp of America Holdings (LH) Q1 Earnings: Surpasses Revenue Forecasts and Updates ... (GuruFocus.com)
07:09AM	Labcorp beats quarterly estimates on strong testing demand (Reuters)
07:06AM	Labcorp: Q1 Earnings Snapshot (Associated Press Finance)
06:58AM	Labcorp Announces 2024 First Quarter Results (PR Newswire)
Apr-24-24 10:25PM	Clinical lab operator Labcorp to buy bankrupt genetic test maker Invitae for $239 million (Reuters)
10:23PM	Clinical lab operator Labcorp to buy bankrupt genetic test maker Invitae for $239 mln (Reuters)
09:27PM	Labcorp Announces Winning Bid for Select Assets of Invitae (PR Newswire)
09:19PM	Invitae Enters into Agreement with Labcorp for Sale of Business (PR Newswire)
Apr-22-24 09:16AM	Exploring Analyst Estimates for Labcorp (LH) Q1 Earnings, Beyond Revenue and EPS (Zacks)
Apr-19-24 05:34AM	Labcorp (LH) Expected to Beat Earnings Estimates: Should You Buy? (Revised) (Zacks)
Apr-18-24 12:10PM	Why Labcorp (LH) Could Beat Earnings Estimates Again (Zacks)
10:01AM	Labcorp (LH) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Apr-16-24 08:42AM	Labcorp (LH) to Report Q1 Earnings: What's in the Cards? (Zacks)
Apr-15-24 07:00AM	Labcorp Announces First-of-Its-Kind Test for Early Indication of Neurodegenerative Diseases and Brain Injuries Using a Blood Draw (PR Newswire)
Apr-12-24 09:10AM	Labcorp's (LH) At-Home Mpox Testing Kit Gets the FDA's EUA Nod (Zacks)
Apr-11-24 06:59AM	Labcorp Declares Quarterly Dividend (PR Newswire)
Apr-10-24 06:49AM	Labcorp Receives FDA Emergency Use Authorization for Mpox PCR Test Home Collection Kit (PR Newswire)
Apr-09-24 09:03AM	Labcorp's (LH) Strategic Alliances Aid Amid Macroeconomic Woes (Zacks)
Apr-08-24 09:34AM	Labcorp (LH) Extends MRD Clinical Research With New Launch (Zacks)
07:09AM	Do You Think Laboratory Corporation of America Holdings (LH) Valuation is Not Attractive Anymore? (Insider Monkey)
07:03AM	Heres Why Vltava Fund Sold Lockheed Martin Corporation (LMT) (Insider Monkey)
07:00AM	Labcorp Announces Expansion of Precision Oncology Portfolio to Support Pharmaceutical, Biopharma, and Clinical Research in Advancing Drug Development Programs (PR Newswire)
Apr-05-24 07:00AM	Labcorp Launches Labcorp Plasma Detect Extending Leadership into Molecular Residual Disease (MRD) Clinical Research (PR Newswire)
Apr-03-24 11:01AM	Insider Sell: EVP, President Diagnostics & COO Mark Schroeder Sells Shares of Laboratory ... (GuruFocus.com)
11:00AM	Insider Sell: EVP, Chief Marketing Officer Amy Summy Sells 3,500 Shares of Laboratory Corp of ... (GuruFocus.com)
Apr-02-24 11:20AM	Here's Why Investors Should Retain Labcorp (LH) Stock for Now (Zacks)
07:00AM	Labcorp to Present Diverse Portfolio of Precision Oncology Research at the Annual Meeting of the American Association for Cancer Research (PR Newswire)
Apr-01-24 12:42PM	Labcorp (LH) to Boost Clinical Diagnostics With New Deal (Zacks)
08:00AM	Xcell Biosciences Strengthens Cell and Gene Therapy Collaboration With Labcorp (Business Wire)
Mar-30-24 01:30AM	Insider Sell: EVP, Chief Legal Officer van der Vaart Sandra D Sells 3,553 Shares of Laboratory ... (GuruFocus.com)
Mar-29-24 09:00AM	The Prelude Network Names Labcorp Its Preferred Genetic Carrier Screening Lab (PR Newswire)

Labcorp Holdings, Inc. engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
DiVincenzo Jonathan P.	Officer	Sep 03 '24	Proposed Sale	229.66	5,460	1,253,956		Sep 03 02:23 PM
van der Vaart Sandra D	EVP, Chief Legal Officer	Aug 19 '24	Sale	227.05	2,000	454,100	3,670	Aug 21 09:08 AM
van der Vaart Sandra D	Officer	Aug 19 '24	Proposed Sale	227.05	2,000	454,100		Aug 19 11:44 AM
EISENBERG GLENN A	Chief Financial Officer, EVP	Aug 15 '24	Sale	223.99	15,000	3,359,825	31,289	Aug 19 10:22 AM
EISENBERG GLENN A	Officer	Aug 15 '24	Proposed Sale	223.99	15,000	3,359,825		Aug 15 06:02 PM
ANDERSON KERRII B	Director	Aug 08 '24	Sale	225.00	586	131,850	14,722	Aug 09 10:16 AM
ANDERSON KERRII B	Director	Aug 07 '24	Sale	225.00	414	93,150	15,308	Aug 09 10:16 AM
KERRII B ANDERSON	Director	Aug 07 '24	Proposed Sale	225.87	1,000	225,870		Aug 07 04:12 PM
BERBERIAN LANCE	EVP, CIO & CTO	Aug 05 '24	Sale	229.10	12,093	2,770,552	15,921	Aug 07 08:47 AM
BERBERIAN LANCE	Officer	Aug 05 '24	Proposed Sale	229.10	12,093	2,770,554		Aug 05 05:13 PM
van der Vaart Sandra D	EVP, Chief Legal Officer	May 14 '24	Sale	210.83	2,000	421,655	5,637	May 16 08:02 AM
ANDERSON KERRII B	Director	Apr 30 '24	Sale	204.13	250	51,034	15,972	May 02 04:29 PM
ANDERSON KERRII B	Director	May 02 '24	Sale	200.10	250	50,025	15,722	May 02 04:29 PM
Wilkinson Peter J	SVP, Chief Accounting Officer	Apr 29 '24	Sale	204.33	2,439	498,358	2,087	May 01 06:29 PM
Schroeder Mark S	EVP, Pres Diagnostics & COO	Apr 01 '24	Sale	217.29	6,477	1,407,387	5,036	Apr 03 08:35 AM
Summy Amy B.	EVP, Chief Marketing Officer	Apr 01 '24	Sale	217.29	3,500	760,515	3,975	Apr 03 08:34 AM
van der Vaart Sandra D	EVP, Chief Legal Officer	Mar 28 '24	Sale	216.74	3,553	770,077	7,637	Mar 29 05:54 PM
Schroeder Mark S	EVP, Pres Diagnostics & COO	Mar 07 '24	Option Exercise	117.09	2,119	248,114	10,084	Mar 11 08:59 AM
Schroeder Mark S	EVP, Pres Diagnostics & COO	Mar 07 '24	Sale	218.45	5,048	1,102,736	5,036	Mar 11 08:59 AM
Summy Amy B.	EVP, Chief Marketing Officer	Mar 07 '24	Sale	218.45	227	49,588	3,859	Mar 11 08:56 AM
EISENBERG GLENN A	Chief Financial Officer, EVP	Feb 21 '24	Option Exercise	163.63	14,054	2,299,656	58,099	Feb 22 03:05 PM
EISENBERG GLENN A	Chief Financial Officer, EVP	Feb 21 '24	Sale	215.97	34,504	7,451,866	23,595	Feb 22 03:05 PM
DiVincenzo Jonathan P.	EVP, Pres, Central Labs & Intl	Feb 21 '24	Sale	215.49	500	107,745	3,401	Feb 22 03:04 PM
van der Vaart Sandra D	EVP, Chief Legal Officer	Feb 13 '24	Sale	226.45	237	53,669	7,637	Feb 15 08:32 AM
van der Vaart Sandra D	EVP, Chief Legal Officer	Feb 08 '24	Sale	222.06	259	57,514	7,637	Feb 09 12:19 PM
van der Vaart Sandra D	EVP, Chief Legal Officer	Feb 05 '24	Sale	220.57	193	42,570	7,637	Feb 06 03:47 PM
Wilkinson Peter J	SVP, Chief Accounting Officer	Nov 16 '23	Sale	210.71	1,384	291,627	2,087	Nov 20 12:23 PM

Open in Screener

BDSX

Biodesix Inc

Sep 06 • 04:00PM ET

1.85

Dollar change 0.00
Percentage change 0.00	%

Healthcare • Diagnostics & Research • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

Held by: VTI VXF IWC

Index	-	P/E	-	EPS (ttm)	-0.46	Insider Own	59.89%	Shs Outstand	96.24M	Perf Week	0.00%
Market Cap	268.58M	Forward P/E	-	EPS next Y	-0.22	Insider Trans	-0.01%	Shs Float	58.23M	Perf Month	16.35%
Income	-44.51M	PEG	-	EPS next Q	-0.07	Inst Own	36.81%	Short Float	0.73%	Perf Quarter	42.31%
Sales	60.90M	P/S	4.41	EPS this Y	45.63%	Inst Trans	12.06%	Short Ratio	2.90	Perf Half Y	23.33%
Book/sh	0.25	P/B	7.41	EPS next Y	37.93%	ROA	-46.01%	Short Interest	0.42M	Perf Year	30.74%
Cash/sh	0.29	P/C	6.35	EPS next 5Y	-	ROE	-304.17%	52W Range	1.15 - 2.21	Perf YTD	0.54%
Dividend Est.	-	P/FCF	-	EPS past 5Y	8.42%	ROI	-45.63%	52W High	-16.29%	Beta	1.22
Dividend TTM	-	Quick Ratio	3.21	Sales past 5Y	24.79%	Gross Margin	77.58%	52W Low	60.87%	ATR (14)	0.10
Dividend Ex-Date	-	Current Ratio	3.28	EPS Y/Y TTM	58.10%	Oper. Margin	-54.42%	RSI (14)	57.56	Volatility	7.38% 6.23%
Employees	217	Debt/Eq	1.70	Sales Y/Y TTM	46.25%	Profit Margin	-73.08%	Recom	1.00	Target Price	3.12
Option/Short	Yes / Yes	LT Debt/Eq	1.69	EPS Q/Q	50.03%	Payout	-	Rel Volume	0.63	Prev Close	1.85
Sales Surprise	10.94%	EPS Surprise	13.14%	Sales Q/Q	50.99%	Earnings	Aug 07 AMC	Avg Volume	146.05K	Price	1.85
SMA20	4.01%	SMA50	9.16%	SMA200	15.53%	Trades		Volume	92,363	Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-26-24	Initiated	Craig Hallum	Buy	$3
May-13-24	Initiated	TD Cowen	Buy	$2.80
May-03-24	Initiated	Lake Street	Buy	$3
Nov-17-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$21 → $11
Nov-23-20	Initiated	William Blair	Outperform
Nov-23-20	Initiated	Morgan Stanley	Overweight	$20
Nov-23-20	Initiated	Canaccord Genuity	Buy	$26
Nov-23-20	Initiated	BTIG Research	Buy	$22

Sep-05-24 06:00AM	Biodesix to Present at Two Investor Conferences in September (Business Wire)
Aug-08-24 10:23AM	Q2 2024 Biodesix Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-07-24 06:05PM	Biodesix, Inc. (BDSX) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Biodesix Announces Second Quarter 2024 Results and Highlights (Business Wire)
Aug-06-24 06:00AM	Biodesix to Present at Canaccord Genuitys 44th Annual Growth Conference (Business Wire)
06:00AM	Loading…
Jul-24-24 06:00AM	Biodesix to Report Second Quarter 2024 Financial Results on August 7, 2024 (Business Wire)
Jun-18-24 08:13AM	Biodesix Named to Inc. Magazine's 2024 "Best Workplaces" (Business Wire)
May-28-24 06:00AM	Biodesix to Participate in Two Investor Conferences in June (Business Wire)
May-21-24 06:00AM	Biodesix to Present New Data on the Nodify XL2 Test at ATS 2024 Annual Meeting (Business Wire)
May-10-24 05:59PM	Biodesix, Inc. (NASDAQ:BDSX) Q1 2024 Earnings Call Transcript (Insider Monkey)
03:55PM	Biodesix Inc (BDSX) Surpasses Analyst Revenue Forecasts with Strong Q1 2024 Performance (GuruFocus.com)
May-09-24 03:46AM	Biodesix Inc (BDSX) Q1 2024 Earnings Call Transcript Highlights: Strong Revenue Growth and ... (GuruFocus.com)
May-08-24 09:00PM	BDSX Stock Earnings: Biodesix Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
05:20PM	Biodesix, Inc. (BDSX) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Biodesix Announces First Quarter 2024 Results Driven by Growth in Lung Diagnostic Testing for Lung Nodule Management (Business Wire)
06:00AM	Loading…
May-07-24 06:00AM	Biodesix to Participate in the 2024 RBCCM Global Healthcare Conference (Business Wire)
Apr-24-24 06:00AM	Biodesix to Report First Quarter 2024 Financial Results on May 8, 2024 (Business Wire)
Apr-09-24 05:00PM	Biodesix to Present New Data on Liquid Biopsy Technologies at AACR 2024 Annual Meeting (Business Wire) -9.93%
Apr-05-24 07:17AM	Biodesix Announces Pricing of Oversubscribed and Upsized Underwritten Offering of Common Stock and Concurrent Private Placement (Business Wire) -7.28%
Mar-25-24 06:00AM	Biodesix Announces New Master Collaborative Research Agreement with Leading US Cancer Center (Business Wire)
Mar-04-24 09:04AM	Biodesix, Inc. (NASDAQ:BDSX) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-01-24 10:40PM	Q4 2023 Biodesix Inc Earnings Call (Thomson Reuters StreetEvents)
06:31AM	Biodesix Inc (BDSX) Reports Strong Growth in Lung Diagnostic Test Volume and Gross Profit Margin (GuruFocus.com)
06:00AM	Biodesix Announces Fourth Quarter and Fiscal Year 2023 Results and Business Highlights (Business Wire)
Feb-26-24 06:00AM	Biodesix to Participate in the TD Cowen 44th Annual Health Care Conference (Business Wire)
Feb-16-24 06:00AM	Biodesix to Report Fourth Quarter and Full Year 2023 Financial Results on March 1, 2024 (Business Wire) -5.73%
Feb-13-24 03:00AM	Biodesix Inc CEO Scott Hutton Sells 64,390 Shares (GuruFocus.com)
Jan-26-24 09:04AM	3 Penny Stocks to Turn $999 Into $1 Million: January 2024 (InvestorPlace)
Nov-14-23 06:00AM	Biodesix Enhances Access to Nodify Lung Testing with Launch of New Blood Draw Method (Business Wire)
Nov-09-23 06:00AM	Biodesix to Participate in Two Upcoming Investor Conferences in November (Business Wire) -6.39%
04:01PM	Loading…
Nov-07-23 04:01PM	Biodesix Announces Third Quarter 2023 Results and Highlights (Business Wire) -10.14%
Oct-24-23 06:00AM	Biodesix to Report Third Quarter 2023 Financial Results on November 7, 2023 (Business Wire) -5.00%
Oct-03-23 06:00AM	Biodesix to Present New Data on Nodify Lung® Testing at CHEST 2023 Annual Meeting (Business Wire)
Sep-07-23 06:00AM	Biodesix Announces Two Presentations on Lung Cancer Treatment Guidance Tests at the IASLC 2023 World Lung Conference on Lung Cancer (Business Wire)
Sep-05-23 06:00AM	Biodesix to Participate in Two Upcoming Investor Conferences in September (Business Wire) -11.76%
Aug-22-23 06:00AM	Biodesix Announces Presentation of New Nodify XL2® Data at AABIP Conference Highlighting Increased Proportion of Biopsies Diagnosing Cancer (Business Wire)
Aug-09-23 10:25AM	Biodesix, Inc. (NASDAQ:BDSX) Q2 2023 Earnings Call Transcript (Insider Monkey) -15.62%
Aug-08-23 08:38AM	Q2 2023 Biodesix Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-07-23 05:15PM	Biodesix, Inc. (BDSX) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Biodesix Announces Second Quarter 2023 Results and Highlights (Business Wire)
Aug-01-23 06:00AM	Biodesix to Participate in the Canaccord Genuity 43rd Annual Growth Conference (Business Wire) +20.17%
Jul-26-23 07:58AM	Biodesix (NASDAQ:BDSX) investors are sitting on a loss of 49% if they invested a year ago (Simply Wall St.)
Jul-24-23 06:00AM	Biodesix to Report Second Quarter 2023 Financial Results on August 7, 2023 (Business Wire)
Jul-12-23 06:00AM	Biodesix Announces Publication of the ORACLE Clinical Utility Study with the Primary Endpoint Demonstrating that the Nodify XL2® Test Reduced Unnecessary Invasive Procedures on Benign Lung Nodules (Business Wire)
Jul-06-23 09:11AM	Biodesix Awarded Advanced Diagnostic Laboratory Test Status for its Nodify CDT® Test by the Center for Medicare and Medicaid Services (Business Wire)
Jun-27-23 06:00AM	Biodesix Completes Enrollment of INSIGHT Study Assessing Clinical Utility of the VeriStrat® Blood-Based Host Immune Classifier (Business Wire) -5.83%
Jun-01-23 06:00AM	Biodesix Announces Three Abstracts to Be Presented at ASCO 2023 Annual Meeting (Business Wire)
May-31-23 06:00AM	Biodesix to Participate in William Blairs 43rd Annual Growth Stock Conference (Business Wire)
May-28-23 08:09AM	Jack Schuler Spends US$65k On Biodesix Stock \ (Simply Wall St.)
May-25-23 06:00AM	Biodesix Announces Four Presentations of Health Economic Data Highlighting Cost Saving Potential of Nodify Lung® Testing (Business Wire) +5.30%
May-24-23 06:00AM	Biodesix, Inc. Chief Financial Officer Robin Harper Cowie Appointed to Colorado BioScience Association's Board of Directors (Business Wire) +12.68%
May-18-23 07:00AM	Biodesix Announces New Clinical Utility Evidence for the Nodify XL2® Nodule Risk Assessment Test to Be Presented at ATS 2023 International Conference (Business Wire) -5.79%
May-12-23 11:10AM	Q1 2023 Biodesix Inc Earnings Call (Thomson Reuters StreetEvents) -12.28%
May-11-23 05:25PM	Biodesix, Inc. (BDSX) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Biodesix Announces First Quarter 2023 Results and Highlights (Business Wire)
May-09-23 06:15PM	Natera (NTRA) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
Apr-27-23 06:00AM	Biodesix to Report First Quarter 2023 Financial Results on May 11, 2023 (Business Wire)
Apr-12-23 06:53AM	Insiders of Biodesix, Inc. (NASDAQ:BDSX) must be frustrated after market cap dropped US$16m since recent purchases (Simply Wall St.)
Mar-15-23 09:31AM	Bullish Biodesix, Inc. (NASDAQ:BDSX) insiders filled their treasuries with US$34m worth of stock over last year (Simply Wall St.) +15.24%
Mar-08-23 07:14AM	Biodesix, Inc. (NASDAQ:BDSX) Q4 2022 Earnings Call Transcript (Insider Monkey) -5.06%
Mar-06-23 07:25AM	Biodesix, Inc. (BDSX) Reports Q4 Loss, Misses Revenue Estimates (Zacks) -10.00%
06:00AM	Biodesix Announces Fourth Quarter and Fiscal Year End 2022 Results and Highlights (Business Wire)
Feb-28-23 06:00AM	Biodesix to Participate at Cowens 43rd Annual Healthcare Conference (Business Wire)
Feb-21-23 06:00AM	Biodesix to Report Fourth Quarter and Full Year 2022 Financial Results on March 6, 2023 (Business Wire)
Feb-16-23 06:27AM	Even after rising 15% this past week, Biodesix (NASDAQ:BDSX) shareholders are still down 39% over the past year (Simply Wall St.) +5.72%
Dec-19-22 06:00AM	Biodesix Announces First Four Private Payer Coverage Policies for the Nodify XL2® Test (Business Wire) +5.88%
Dec-16-22 04:01PM	Biodesix Announces Appointment of Lawrence (Lair) T. Kennedy, Jr. to Board of Directors (Business Wire)
Dec-12-22 06:00AM	Biodesix Ranked Top Proteomics Solutions Company by Life Sciences Review Magazine (Business Wire) +8.57%
Nov-21-22 04:01PM	Biodesix Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional Shares (Business Wire) -7.14% +13.85%
Nov-17-22 12:26AM	Biodesix Announces Pricing of $35.1 Million Upsized Public Offering of Common Stock (Business Wire) +23.48%
Nov-16-22 04:05PM	Biodesix Announces Proposed Public Offering of Common Stock (Business Wire) +8.49%
04:01PM	Biodesix Announces Senior Secured Financing Agreement with Perceptive Advisors for Up to $50 Million (Business Wire)
Nov-10-22 09:00AM	Biodesix Presents New Data from the INSIGHT Study at the 2022 Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting (Business Wire)
Nov-09-22 05:33AM	Biodesix Third Quarter 2022 Earnings: Revenues Beat Expectations, EPS Lags (Simply Wall St.) -6.42%
Nov-03-22 07:15AM	Biodesix, Inc. (BDSX) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
06:00AM	Biodesix Announces Third Quarter 2022 Results and Highlights (Business Wire)
Oct-20-22 06:00AM	Biodesix to Report Third Quarter 2022 Financial Results on November 3, 2022 (Business Wire)
Oct-17-22 05:05PM	Boulder's Biodesix snags $20M contract, plans move to larger space in Louisville (American City Business Journals)
06:00AM	Biodesix Awarded U.S. Federal Supply Schedule Contract for Its Comprehensive Lung Cancer Diagnostic Testing Solutions (Business Wire)
Oct-12-22 06:00AM	Biodesix to Present Data at the CHEST 2022 Annual Meeting Demonstrating High Sensitivity of the Nodify XL2® Blood-Based Lung Nodule Test in Various Patient Populations, Including Individuals Participating in Lung Cancer Screening Programs (Business Wire) -7.09%
Oct-11-22 06:00AM	Biodesix Announces Preliminary Revenue for Third Quarter 2022 (Business Wire)
Sep-06-22 06:00AM	Biodesix to Participate in Two Upcoming Investor Conferences in September (Business Wire) -6.56%
Aug-09-22 06:00AM	Biodesix Named a Top 100 Healthcare Technology Company of 2022 (Business Wire) -13.62%
Aug-06-22 04:30AM	Biodesix, Inc. (BDSX) Q2 2022 Earnings Call Transcript (Motley Fool)
Aug-04-22 07:15AM	Biodesix, Inc. (BDSX) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
06:00AM	Biodesix Announces Second Quarter 2022 Results and Highlights (Business Wire)
Aug-03-22 06:00AM	Biodesix to Present at the Canaccord Genuity 42nd Annual Growth Conference (Business Wire) +5.34%
Jul-30-22 10:44AM	Biodesix, Inc. (NASDAQ:BDSX) insiders placed bullish bets worth US$21m in the last 12 months (Simply Wall St.)
Jul-20-22 06:00AM	Biodesix to Present Data at IASLC 2022 World Conference Demonstrating that the VeriStrat® Test is Predictive of Progression Free Survival and Overall Survival in Patients with Low or Negative PD-L1 Treated with Immune Checkpoint Inhibitors (Business Wire)
Jul-19-22 06:00AM	Biodesix to Report Second Quarter 2022 Financial Results on August 4, 2022 (Business Wire)
Jun-22-22 09:19AM	Sotera Health Company (SHC) Stock Jumps 6.5%: Will It Continue to Soar? (Zacks)
Jun-15-22 10:11AM	Investors in Biodesix (NASDAQ:BDSX) have unfortunately lost 90% over the last year (Simply Wall St.)
Jun-07-22 06:00AM	Biodesix Obtains Medicare Coverage for the Nodify CDT® Lung Nodule Test (Business Wire) +16.23%
Jun-03-22 06:00AM	Biodesix Announces Research Agreement with Top US Cancer Center (Business Wire)
Jun-01-22 06:00AM	Biodesix to Present at the 42nd Annual William Blair Growth Stock Conference (Business Wire) -6.76%
May-17-22 06:00AM	Biodesix to Present at the H.C. Wainwright Global Investment Conference (Business Wire)
May-12-22 06:00AM	Biodesix Announces New Clinical Utility Evidence for the Nodify XL2® Nodule Risk Assessment Test to be Presented at ATS 2022 International Conference (Business Wire) +6.29%
May-11-22 07:15AM	Biodesix, Inc. (BDSX) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -15.41%
06:00AM	Biodesix Announces First Quarter 2022 Results and Highlights (Business Wire)
Apr-27-22 06:00AM	Biodesix to Report First Quarter 2022 Financial Results on May 11, 2022 (Business Wire)

Biodesix, Inc. provides blood-based diagnostics services for patients with lung disease. The firm offers GeneStrat, a genomic blood test for patients who have been diagnosed with advanced lung cancer and VeriStrat, a serum proteomic test that provides prognostic and predictive information for patients with non-small cell lung cancer. It also offers six diagnostic tests including: Nodify XL2, Nodify CDT, GeneStrat, VeriStrat, Bio-Rad SARS-CoV-2 ddPCR test and the Platelia SARS-CoV-2 test. The company was founded by David Brunel and Robert E. Cawthorn in 2005 and is headquartered in Louisville, CO.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Vazquez Chris	Chief Accounting Officer	Aug 09 '24	Sale	1.60	155	248	11,242	Aug 12 07:24 PM
Vazquez Chris	Chief Accounting Officer	Aug 12 '24	Sale	1.57	54	85	11,188	Aug 12 07:24 PM
Pestano Gary Anthony	Chief Development Officer	Aug 09 '24	Sale	1.60	320	512	126,187	Aug 12 07:24 PM
Pestano Gary Anthony	Chief Development Officer	Aug 12 '24	Sale	1.57	111	174	126,076	Aug 12 07:24 PM
O'Kane Kieran	Chief Commercial Officer	Aug 09 '24	Sale	1.60	345	552	89,748	Aug 12 07:24 PM
O'Kane Kieran	Chief Commercial Officer	Aug 12 '24	Sale	1.57	120	189	89,628	Aug 12 07:24 PM
Hutton Scott	President & CEO	Aug 09 '24	Sale	1.60	2,781	4,452	519,331	Aug 12 07:23 PM
Hutton Scott	President & CEO	Aug 12 '24	Sale	1.57	963	1,514	518,368	Aug 12 07:23 PM
Cowie Robin Harper	CFO, Sec'y & Treasurer	Aug 09 '24	Sale	1.60	724	1,159	191,402	Aug 12 07:23 PM
Cowie Robin Harper	CFO, Sec'y & Treasurer	Aug 12 '24	Sale	1.57	251	395	191,151	Aug 12 07:23 PM
Cowie Robin Harper	CFO, Sec'y & Treasurer	May 21 '24	Option Exercise	0.42	4,209	1,768	175,889	May 23 07:13 PM
Vazquez Chris	Chief Accounting Officer	May 09 '24	Sale	1.48	244	361	9,915	May 10 05:06 PM
Pestano Gary Anthony	Chief Development Officer	May 09 '24	Sale	1.48	434	642	124,248	May 10 05:06 PM
O'Kane Kieran	Chief Commercial Officer	May 09 '24	Sale	1.48	468	692	75,524	May 10 05:05 PM
Hutton Scott	President & CEO	May 09 '24	Sale	1.48	3,764	5,569	483,780	May 10 05:04 PM
Cowie Robin Harper	CFO, Sec'y & Treasurer	May 09 '24	Sale	1.48	980	1,450	171,680	May 10 05:04 PM
Vazquez Chris	Chief Accounting Officer	Feb 09 '24	Sale	1.92	1,077	2,064	10,470	Feb 12 09:46 PM
Vazquez Chris	Chief Accounting Officer	Feb 12 '24	Sale	1.66	922	1,535	9,548	Feb 12 09:46 PM
Pestano Gary Anthony	Chief Development Officer	Feb 09 '24	Sale	1.92	5,862	11,235	128,272	Feb 12 09:45 PM
Pestano Gary Anthony	Chief Development Officer	Feb 12 '24	Sale	1.66	5,022	8,360	123,250	Feb 12 09:45 PM
O'Kane Kieran	Chief Commercial Officer	Feb 09 '24	Sale	1.92	6,319	12,111	73,417	Feb 12 09:45 PM
O'Kane Kieran	Chief Commercial Officer	Feb 12 '24	Sale	1.66	5,412	9,009	68,005	Feb 12 09:45 PM
Hutton Scott	President & CEO	Feb 09 '24	Sale	1.92	34,682	66,472	494,719	Feb 12 09:45 PM
Hutton Scott	President & CEO	Feb 12 '24	Sale	1.66	29,708	49,455	465,011	Feb 12 09:45 PM
Cowie Robin Harper	CFO, Sec'y & Treasurer	Feb 09 '24	Sale	1.92	10,156	19,465	178,109	Feb 12 09:44 PM
Cowie Robin Harper	CFO, Sec'y & Treasurer	Feb 12 '24	Sale	1.66	8,699	14,481	169,410	Feb 12 09:44 PM
Vazquez Chris	Chief Accounting Officer	Nov 09 '23	Sale	1.27	107	136	6,359	Nov 13 04:51 PM
Vazquez Chris	Chief Accounting Officer	Nov 10 '23	Sale	1.23	108	132	6,251	Nov 13 04:51 PM
Pestano Gary Anthony	Chief Development Officer	Nov 09 '23	Sale	1.27	217	276	104,719	Nov 13 04:51 PM
Pestano Gary Anthony	Chief Development Officer	Nov 10 '23	Sale	1.23	218	267	104,501	Nov 13 04:51 PM
O'Kane Kieran	Chief Commercial Officer	Nov 09 '23	Sale	1.27	234	297	47,947	Nov 13 04:50 PM
O'Kane Kieran	Chief Commercial Officer	Nov 10 '23	Sale	1.23	235	288	47,712	Nov 13 04:50 PM
Hutton Scott	President & CEO	Nov 09 '23	Sale	1.27	1,882	2,391	331,311	Nov 13 04:50 PM
Hutton Scott	President & CEO	Nov 10 '23	Sale	1.23	1,883	2,308	329,428	Nov 13 04:50 PM
Cowie Robin Harper	CFO, Sec'y & Treasurer	Nov 09 '23	Sale	1.27	491	624	137,064	Nov 13 04:50 PM
Cowie Robin Harper	CFO, Sec'y & Treasurer	Nov 10 '23	Sale	1.23	491	602	136,573	Nov 13 04:50 PM

Open in Screener

EXAS

Exact Sciences Corp.

Sep 06 • 04:00PM ET

59.11

Dollar change -1.80
Percentage change -2.96	%

Healthcare • Diagnostics & Research • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

EXAS Exact Sciences Corp. daily Stock Chart

Held by: XBI VTI VB VXF VBK FBT IWR SCHM VHT LABU

Index	-	P/E	-	EPS (ttm)	-0.96	Insider Own	1.51%	Shs Outstand	184.77M	Perf Week	-5.06%
Market Cap	10.92B	Forward P/E	418.12	EPS next Y	0.14	Insider Trans	-0.24%	Shs Float	181.97M	Perf Month	5.57%
Income	-175.01M	PEG	-	EPS next Q	-0.19	Inst Own	97.21%	Short Float	7.59%	Perf Quarter	32.33%
Sales	2.61B	P/S	4.18	EPS this Y	17.44%	Inst Trans	-1.71%	Short Ratio	5.14	Perf Half Y	-3.82%
Book/sh	17.29	P/B	3.42	EPS next Y	115.15%	ROA	-2.69%	Short Interest	13.82M	Perf Year	-28.06%
Cash/sh	5.12	P/C	11.54	EPS next 5Y	-	ROE	-5.60%	52W Range	40.62 - 82.96	Perf YTD	-20.10%
Dividend Est.	-	P/FCF	-	EPS past 5Y	4.59%	ROI	-3.07%	52W High	-28.75%	Beta	1.26
Dividend TTM	-	Quick Ratio	1.98	Sales past 5Y	43.88%	Gross Margin	69.63%	52W Low	45.51%	ATR (14)	2.74
Dividend Ex-Date	-	Current Ratio	2.17	EPS Y/Y TTM	60.38%	Oper. Margin	-10.76%	RSI (14)	54.63	Volatility	5.70% 4.12%
Employees	6600	Debt/Eq	0.87	Sales Y/Y TTM	13.54%	Profit Margin	-6.70%	Recom	1.29	Target Price	76.14
Option/Short	Yes / Yes	LT Debt/Eq	0.78	EPS Q/Q	80.92%	Payout	-	Rel Volume	0.62	Prev Close	60.91
Sales Surprise	1.34%	EPS Surprise	73.55%	Sales Q/Q	12.41%	Earnings	Jul 31 AMC	Avg Volume	2.69M	Price	59.11
SMA20	-0.09%	SMA50	13.08%	SMA200	0.45%	Trades		Volume	1,661,506	Change	-2.96%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-28-24	Initiated	Wells Fargo	Overweight	$75
Jun-27-24	Initiated	Scotiabank	Sector Outperform	$70
Jun-03-24	Resumed	Jefferies	Buy	$75
Jan-02-24	Upgrade	The Benchmark Company	Hold → Buy	$91
Dec-14-23	Initiated	Guggenheim	Buy	$90
Dec-13-23	Initiated	Wolfe Research	Outperform	$95
Oct-10-23	Upgrade	Piper Sandler	Neutral → Overweight	$90
Sep-28-23	Initiated	Bernstein	Outperform	$83
Aug-02-23	Downgrade	The Benchmark Company	Buy → Hold
May-10-23	Upgrade	Craig Hallum	Hold → Buy	$55 → $85
May-05-23	Initiated	UBS	Neutral	$73
Mar-09-23	Upgrade	Citigroup	Neutral → Buy	$70 → $90
Feb-10-23	Downgrade	Credit Suisse	Outperform → Neutral	$50 → $70
Jan-18-23	Downgrade	Raymond James	Outperform → Mkt Perform
Oct-19-22	Downgrade	Craig Hallum	Buy → Hold	$60 → $35
Aug-25-22	Initiated	Credit Suisse	Outperform	$55
Jun-03-22	Initiated	Piper Sandler	Neutral	$50
Nov-03-21	Downgrade	Raymond James	Strong Buy → Outperform	$160 → $130
Jul-29-21	Reiterated	Stifel	Buy	$165 → $145
Jul-29-21	Reiterated	Oppenheimer	Outperform	$161 → $155

Show Previous Ratings

Aug-30-24 11:31AM	Exact Sciences (EXAS) Up 7.5% Since Last Earnings Report: Can It Continue? (Zacks)
Aug-28-24 06:00AM	Exact Sciences to Participate in September Investor Conferences (Business Wire)
Aug-23-24 08:26AM	Should You Believe in the Growth Potential of Exact Sciences Corporation (EXAS)? (Insider Monkey)
06:00AM	Sector Spotlight: Top 4 Basket of Diagnostic Stocks (EXAS, GH, ILMN, LUDG) (News Direct)
Aug-22-24 09:55AM	Does Exact Sciences (EXAS) Have the Potential to Rally 34.13% as Wall Street Analysts Expect? (Zacks)
09:23AM	Loading…
09:23AM	Exact Sciences (EXAS) Rides on Cologuard Sales, New Launches (Zacks)
08:41AM	Exact Sciences (EXAS) Enrolls First Patient in Pivotal MCED Study (Zacks)
Aug-21-24 11:08PM	Atlassian Corporation (TEAM): Short Sellers Are Bullish On This Advertising Stock Now (Insider Monkey)
08:08AM	Heres Why Baron Opportunity Fund Sold its Stake in Exact Sciences Corp (EXAS) (Insider Monkey)
07:13AM	Exact Sciences kicks off multi-cancer detection study (Medical Device Network)
Aug-20-24 07:00AM	Exact Sciences Announces First Patient Enrolled in its Multi-Cancer Early Detection (MCED) Falcon Registry Real-World Evidence Study (Business Wire)
Aug-16-24 07:13AM	Exact Sciences data finds Cologuard detected almost 600k cancer cases (Medical Device Network)
Aug-15-24 07:00AM	New Modeling Data Show the Cologuard Test Has Detected More Than 623,000 Cancers and Precancers Over Past Decade, Saving U.S. Health Care System $22 Billion (Business Wire)
Aug-14-24 09:19AM	Why You Should Add Exact Sciences (EXAS) to Your Portfolio (Zacks)
Aug-11-24 02:47PM	Atlassian Corporation (TEAM): Hedge Funds Are Bullish on This AdTech Stock Now (Insider Monkey)
09:22PM	Loading…
Aug-10-24 09:22PM	8 Best AdTech Stocks to Buy Now (Insider Monkey)
Aug-06-24 09:55AM	Wall Street Analysts Predict a 45.04% Upside in Exact Sciences (EXAS): Here's What You Should Know (Zacks)
Aug-02-24 01:08AM	Decoding Exact Sciences Corp (EXAS): A Strategic SWOT Insight (GuruFocus.com)
Aug-01-24 04:02PM	Why Exact Sciences, Up 27%, Is 'Coiled To Snap Back' After Quarterly Beat (Investor's Business Daily) +26.77%
10:49AM	Analyst Report: Exact Sciences Corporation (Morningstar Research)
09:03AM	Exact Sciences (EXAS) Q2 Loss Narrower Than Expected, Sales Beat (Zacks)
12:00AM	Exact Sciences (EXAS) Q2 2024 Earnings Call Transcript (Motley Fool)
Jul-31-24 07:30PM	Exact Sciences (EXAS) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
06:28PM	Exact Sciences: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	TwinStrand Biosciences and Exact Sciences Announce Exclusive License Agreement for Duplex Sequencing Technology (PR Newswire)
04:05PM	Exact Sciences Announces Second-Quarter 2024 Results (Business Wire)
Jul-24-24 10:01AM	Exact Sciences (EXAS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Jul-22-24 09:32AM	Goldman Sachs Says Buy These 3 Stocks for Double-Digit Returns (InvestorPlace)
Jul-16-24 06:06AM	Lattice Semiconductor Corporation (LSCC) Slipped Due to Cyclical Pressures (Insider Monkey) +5.57%
05:57AM	Exact Sciences Corporation (EXAS) Slipped Over Investors' Concerns (Insider Monkey)
05:53AM	Loading…
05:53AM	Should You Believe in the Upside Potential of Celsius Holdings (CELH)? (Insider Monkey)
Jul-11-24 06:33AM	Geneoscopys ColoSense deemed reliable in published study (Medical Device Network)
Jul-08-24 08:30AM	This Cathie Wood Growth Stock Could Soar by 93%, According to Wall Street (Motley Fool)
06:00AM	Exact Sciences schedules second quarter 2024 earnings call (Business Wire)
Jul-07-24 05:30AM	People Are Feeling Stuck in Their Jobs. Bosses Are Starting to Worry. (The Wall Street Journal)
Jul-03-24 07:00AM	The 3 Best Personalized Medicine Stocks to Buy in July 2024 (InvestorPlace)
Jun-20-24 10:13AM	NGS: the road to personalising cancer care (Medical Device Network)
Jun-17-24 12:54PM	MGI and SeqOne partner to create end-to-end genomic testing platform (Medical Device Network)
Jun-13-24 10:12AM	Jefferies Says Buy These 3 Stocks for More Than Double-Digit Returns (InvestorPlace)
06:45AM	Is It Time to Buy May's Worst-Performing Nasdaq Stocks? (Motley Fool)
Jun-07-24 11:30AM	Why Is Exact Sciences (EXAS) Down 17.5% Since Last Earnings Report? (Zacks)
Jun-04-24 07:06AM	Illumina names Everett Cunningham as chief commercial officer (MedTech Dive)
Jun-03-24 04:26PM	Is Exact Sciences Corporation (NASDAQ:EXAS) the Gene Therapy Stock with the Greatest Potential? (Insider Monkey)
04:17PM	9 Best Gene Therapy Stocks to Buy Now (Insider Monkey)
May-30-24 06:35AM	10 Buzzing AI Semiconductor Stocks in 2024 (Insider Monkey)
May-29-24 11:27AM	Exact Sciences (EXAS) Witnesses Rising Expenses, Competition (Zacks)
May-28-24 10:34AM	Exact Sciences (EXAS) to Showcase Favorable Research Outcome (Zacks) -5.66%
06:00AM	Exact Sciences to Participate in June Investor Conferences (Business Wire)
May-27-24 06:43PM	Hedge Funds are Bullish on This Cancer Stock (Insider Monkey)
06:13PM	7 Best Mid-Cap Healthcare Stocks To Buy Now (Insider Monkey)
11:34AM	Bull Market Blastoff: 3 Stocks Targeting 56% to 91% Returns (InvestorPlace)
May-24-24 10:28AM	Guardant Stock Climbs As Cancer Test Strides Towards FDA Ok (The Wall Street Journal) -7.84%
07:11AM	FDA panel backs Guardants blood test for colon cancer (MedTech Dive)
06:05AM	Exact Sciences Demonstrates Continued Leadership in Early Cancer Diagnosis and Improved Health Outcomes for Patients with Multiple Data Presentations at ASCO (Business Wire)
May-22-24 07:30AM	Exact Sciences Earns 2024 Great Place To Work Certification (Business Wire)
May-21-24 08:56AM	Exact Sciences Says Court Allows Patent Lawsuit Against Geneoscopy to Proceed (MT Newswires)
06:05AM	Court Ruling Enables Exact Sciences to Proceed with Lawsuit against Geneoscopy (Business Wire)
May-17-24 06:27AM	Wall Street Favorites: 3 Cathie Wood Stocks With Strong Buy Ratings for May 2024 (InvestorPlace)
May-10-24 12:27PM	Exact Sciences Corp (EXAS) Q1 2024 Earnings: Revenue Growth Amidst Increased Net Loss (GuruFocus.com)
09:22AM	UK NICE backs Exacts Oncotype cancer genomic test (Medical Device Network)
May-09-24 04:02PM	Exact Sciences Stock, A Cathie Wood Darling, Tumbles On 'Overblown' Growth Concerns (Investor's Business Daily) -8.96%
12:29PM	Analyst Report: Exact Sciences Corporation (Morningstar Research)
11:41AM	Exact Sciences Corporation (NASDAQ:EXAS) Q1 2024 Earnings Call Transcript (Insider Monkey)
11:02AM	Exact Sciences (EXAS) Q1 Revenues Rise Y/Y, Gross Margin Down (Zacks)
09:59AM	Q1 2024 Exact Sciences Corp Earnings Call (Thomson Reuters StreetEvents)
07:29AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday (InvestorPlace)
03:53AM	Exact Sciences Corp (EXAS) Q1 2024 Earnings Call Transcript Highlights: Navigating Growth ... (GuruFocus.com)
01:06AM	Decoding Exact Sciences Corp (EXAS): A Strategic SWOT Insight (GuruFocus.com)
May-08-24 11:30PM	Exact Sciences (EXAS) Q1 2024 Earnings Call Transcript (Motley Fool)
06:05PM	Exact Sciences (EXAS) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
05:02PM	Exact Sciences: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Exact Sciences Announces First-Quarter 2024 Results (Business Wire)
May-07-24 08:00AM	Exact Sciences Demonstrates Continued Scientific Advancement in Colorectal Cancer Screening with Multiple Data Presentations at DDW 2024 (Business Wire)
May-06-24 08:52AM	MDxHealth SA (NASDAQ:MDXH) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-01-24 06:00AM	Exact Sciences to Participate in May Investor Conference (Business Wire)
Apr-25-24 08:05PM	Analyst Report: Exact Sciences Corporation (Morningstar Research) -7.04%
Apr-24-24 06:15PM	Exact Sciences (EXAS) Stock Drops Despite Market Gains: Important Facts to Note (Zacks)
07:16AM	Here's Why Baron Health Care Fund Reduced Exact Sciences Corporation (EXAS) (Insider Monkey)
Apr-22-24 12:44PM	Should You Buy Exact Sciences (EXAS) Ahead of Q1 Earnings? (Zacks)
11:10AM	10 Best Performing Biotech ETFs in 2024 (Insider Monkey)
Apr-17-24 06:15PM	Why Exact Sciences (EXAS) Dipped More Than Broader Market Today (Zacks)
Apr-15-24 06:52AM	Exact Sciences names Aaron Bloomer CFO (MedTech Dive) -8.40%
06:00AM	Exact Sciences Names Aaron Bloomer as New Chief Financial Officer (Business Wire)
Apr-12-24 07:00AM	Here's Why Exact Sciences Corporation (EXAS) Declined in Q1 (Insider Monkey)
06:49AM	Should You Hold ON Semiconductor Corporation (ON)? (Insider Monkey)
06:40AM	Should You be Bullish on the Long-Term Growth of Atlassian Corporation (TEAM)? (Insider Monkey)
Apr-11-24 06:00AM	Exact Sciences Announces Debt Exchange Transaction and Private Placement of Convertible Senior Notes (Business Wire)
Apr-10-24 06:15PM	Exact Sciences (EXAS) Stock Moves -0.89%: What You Should Know (Zacks)
08:16AM	Search for Cancer Blood Test Continues Despite Illumina-Grail Deals Failure (Barrons.com)
12:00AM	ZTS, EXAS, AZN: Which Biotech Stock Is the Better Buy? (TipRanks)
Apr-09-24 07:37AM	11 Best Biotech ETFs To Buy (Insider Monkey)
Apr-08-24 12:05PM	Exact Sciences to Present Late-Breaking Data from ASCEND-2 Study Validating Its Investigational Multi-Cancer Early Detection Test at AACR Annual Meeting 2024 (Business Wire)
07:00AM	Sorry, but Blood Tests Wont Replace Stool Samples or Colonoscopies Yet (The Wall Street Journal)
06:00AM	Exact Sciences Schedules First Quarter 2024 Earnings Call (Business Wire)
Apr-05-24 10:16AM	Freenomes colorectal cancer blood test data underwhelm analysts (MedTech Dive)
Apr-04-24 10:15AM	1 Beaten-Down Cathie Wood Stock to Buy and Hold (Motley Fool)
06:05AM	Exact Sciences to Provide Mayo Clinic Patients with Individualized Cancer Tumor Information to Inform Treatment (Business Wire)
Apr-03-24 09:57AM	Exact Sciences' (EXAS) Oncoguard Esophagus Test Looks Promising (Zacks)
Apr-02-24 04:02PM	Exact Sciences, A Cathie Wood Stock, Surges As Rival Colon Cancer Test Pales (Investor's Business Daily)
Mar-29-24 08:09AM	Exact Sciences, Mayo Clinic share early data on esophageal cancer test (MedTech Dive)

EXACT Sciences Corp. is a cancer screening and diagnostics company. The firm focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer and Oncotype DX. The company was founded on February 10, 1995, and is headquartered in Madison, WI.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Baranick Brian	EVP, GM, Precision Oncology	Aug 05 '24	Option Exercise	0.00	2,712	0	15,991	Aug 06 05:30 PM
COWARD D SCOTT	Director	May 01 '24	Sale	60.15	67	4,030	44,644	May 02 07:00 PM
Cunningham Everett	Chief Commercial Officer	May 01 '24	Sale	60.15	136	8,180	47,042	May 02 07:00 PM
Herriott James	SVP, General Counsel & Sec	May 01 '24	Sale	60.15	30	1,804	9,866	May 02 07:00 PM
Elliott Jeffrey Thomas	Chief Financial Officer	May 01 '24	Sale	60.15	136	8,180	11,795	May 02 07:00 PM
Baranick Brian	EVP, GM., Precision Oncology	May 01 '24	Sale	60.15	110	6,616	13,279	May 02 07:00 PM
Condella Sarah	EVP, Human Resources	May 01 '24	Sale	60.15	102	6,135	72,611	May 02 07:00 PM
ORVILLE JACOB A	General Manager, Screening	May 01 '24	Sale	60.15	102	6,135	14,440	May 02 07:00 PM
Conroy Kevin T	President and CEO	May 01 '24	Sale	60.15	1,155	69,473	1,156,191	May 02 07:00 PM
Condella Sarah	EVP, Human Resources	Apr 01 '24	Sale	70.00	2,000	140,000	71,787	Apr 03 07:30 PM
Baranick Brian	EVP, GM., Precision Oncology	Apr 02 '24	Sale	79.43	924	73,393	13,171	Apr 03 07:30 PM
Condella Sarah	EVP, Human Resources	Mar 28 '24	Sale	70.00	2,000	140,000	73,787	Apr 01 04:30 PM
ORVILLE JACOB A	General Manager, Screening	Feb 29 '24	Option Exercise	0.00	4,724	0	16,478	Mar 04 08:42 PM
ORVILLE JACOB A	General Manager, Screening	Mar 01 '24	Sale	59.32	2,154	127,775	14,324	Mar 04 08:42 PM
LEVANGIE DANIEL J	Director	Mar 01 '24	Sale	57.50	5,000	287,500	22,975	Mar 04 08:42 PM
Herriott James	General Counsel	Feb 29 '24	Option Exercise	0.00	1,890	0	9,987	Mar 04 08:41 PM
Herriott James	General Counsel	Mar 01 '24	Sale	59.32	862	51,134	9,125	Mar 04 08:41 PM
Elliott Jeffrey Thomas	Chief Financial Officer	Feb 29 '24	Option Exercise	0.00	5,291	0	13,345	Mar 04 08:40 PM
Elliott Jeffrey Thomas	Chief Financial Officer	Mar 01 '24	Sale	59.32	2,412	143,080	10,933	Mar 04 08:40 PM
Doyle James Edward	Director	Mar 01 '24	Sale	57.50	2,000	115,000	50,110	Mar 04 08:39 PM
Cunningham Everett	Chief Commercial Officer	Feb 29 '24	Option Exercise	0.00	5,291	0	48,591	Mar 04 08:38 PM
Cunningham Everett	Chief Commercial Officer	Mar 01 '24	Sale	59.32	2,412	143,080	46,179	Mar 04 08:38 PM
Conroy Kevin T	President and CEO	Feb 29 '24	Option Exercise	0.00	18,143	0	1,307,767	Mar 04 08:38 PM
Conroy Kevin T	President and CEO	Mar 01 '24	Sale	59.32	8,271	490,636	1,299,496	Mar 04 08:38 PM
Condella Sarah	EVP, Human Resources	Feb 29 '24	Option Exercise	0.00	3,779	0	77,511	Mar 04 08:37 PM
Condella Sarah	EVP, Human Resources	Mar 01 '24	Sale	59.32	1,724	102,268	75,787	Mar 04 08:37 PM
Baranick Brian	Gen. Mgr., Precision Oncology	Feb 29 '24	Option Exercise	0.00	4,724	0	16,418	Mar 04 08:36 PM
Baranick Brian	Gen. Mgr., Precision Oncology	Mar 01 '24	Sale	59.32	2,323	137,800	14,095	Mar 04 08:36 PM
ORVILLE JACOB A	General Manager, Screening	Feb 26 '24	Option Exercise	0.00	3,954	0	13,633	Feb 28 07:38 PM
ORVILLE JACOB A	General Manager, Screening	Feb 27 '24	Sale	56.89	1,879	106,896	11,754	Feb 28 07:38 PM
Herriott James	General Counsel	Feb 26 '24	Option Exercise	0.00	1,648	0	8,881	Feb 28 07:38 PM
Herriott James	General Counsel	Feb 27 '24	Sale	56.89	784	44,602	8,097	Feb 28 07:38 PM
Cunningham Everett	Chief Commercial Officer	Feb 26 '24	Option Exercise	0.00	7,678	0	46,948	Feb 28 07:37 PM
Cunningham Everett	Chief Commercial Officer	Feb 27 '24	Sale	56.89	3,648	207,535	43,300	Feb 28 07:37 PM
Elliott Jeffrey Thomas	Chief Financial Officer	Feb 26 '24	Option Exercise	0.00	5,701	0	10,764	Feb 28 07:36 PM
Elliott Jeffrey Thomas	Chief Financial Officer	Feb 27 '24	Sale	56.89	2,710	154,172	8,054	Feb 28 07:36 PM
Conroy Kevin T	President and CEO	Feb 26 '24	Option Exercise	0.00	13,181	0	1,295,887	Feb 28 07:35 PM
Conroy Kevin T	President and CEO	Feb 27 '24	Sale	56.89	6,263	356,302	1,289,624	Feb 28 07:35 PM
Condella Sarah	EVP, Human Resources	Feb 26 '24	Option Exercise	0.00	3,954	0	75,612	Feb 28 07:35 PM
Condella Sarah	EVP, Human Resources	Feb 27 '24	Sale	56.89	1,880	106,953	73,732	Feb 28 07:35 PM
Baranick Brian	Gen. Mgr., Precision Oncology	Feb 26 '24	Option Exercise	0.00	3,954	0	13,721	Feb 28 07:34 PM
Baranick Brian	Gen. Mgr., Precision Oncology	Feb 27 '24	Sale	56.89	2,027	115,316	11,694	Feb 28 07:34 PM
Conroy Kevin T	President and CEO	Feb 23 '24	Option Exercise	13.96	102,837	1,435,605	1,344,266	Feb 26 05:00 PM
Condella Sarah	EVP, Human Resources	Feb 23 '24	Sale	59.72	1,021	60,974	71,658	Feb 26 05:00 PM
ORVILLE JACOB A	General Manager, Screening	Feb 22 '24	Sale	59.78	1,013	60,557	9,679	Feb 23 08:03 PM
Herriott James	General Counsel	Feb 22 '24	Sale	59.78	291	17,396	7,233	Feb 23 08:02 PM
Elliott Jeffrey Thomas	Chief Financial Officer	Feb 22 '24	Sale	59.78	1,351	80,763	5,063	Feb 23 08:01 PM
Cunningham Everett	Chief Commercial Officer	Feb 22 '24	Sale	59.78	1,350	80,703	39,270	Feb 23 08:00 PM
COWARD D SCOTT	Director	Feb 22 '24	Sale	59.78	663	39,634	44,493	Feb 23 07:59 PM
Conroy Kevin T	President and CEO	Feb 22 '24	Sale	59.78	11,565	691,356	1,241,429	Feb 23 07:59 PM
Condella Sarah	EVP, Human Resources	Feb 22 '24	Sale	59.78	1,013	60,557	72,679	Feb 23 07:57 PM
Baranick Brian	Gen. Mgr., Precision Oncology	Feb 22 '24	Sale	59.78	1,093	65,340	9,767	Feb 23 07:57 PM
ORVILLE JACOB A	General Manager, Screening	Feb 20 '24	Option Exercise	0.00	2,248	0	9,736	Feb 22 07:40 PM
ORVILLE JACOB A	General Manager, Screening	Feb 21 '24	Sale	61.50	1,078	66,297	8,658	Feb 22 07:40 PM
Herriott James	General Counsel	Feb 20 '24	Option Exercise	0.00	864	0	7,358	Feb 22 07:39 PM
Herriott James	General Counsel	Feb 21 '24	Sale	61.50	415	25,522	6,943	Feb 22 07:39 PM
Elliott Jeffrey Thomas	Chief Financial Officer	Feb 20 '24	Option Exercise	0.00	3,112	0	5,196	Feb 22 07:38 PM
Elliott Jeffrey Thomas	Chief Financial Officer	Feb 21 '24	Sale	61.50	1,493	91,820	3,703	Feb 22 07:38 PM
COWARD D SCOTT	Director	Feb 20 '24	Option Exercise	0.00	2,248	0	43,828	Feb 22 07:38 PM
COWARD D SCOTT	Director	Feb 21 '24	Sale	61.50	706	43,419	43,122	Feb 22 07:38 PM
Conroy Kevin T	President and CEO	Feb 20 '24	Option Exercise	0.00	10,374	0	1,234,731	Feb 22 07:37 PM
Conroy Kevin T	President and CEO	Feb 21 '24	Sale	61.50	4,975	305,962	1,229,756	Feb 22 07:37 PM
Condella Sarah	EVP, Human Resources	Feb 20 '24	Option Exercise	0.00	2,248	0	72,737	Feb 22 07:36 PM
Condella Sarah	EVP, Human Resources	Feb 21 '24	Sale	61.50	1,079	66,358	71,658	Feb 22 07:36 PM
Baranick Brian	Gen. Mgr., Precision Oncology	Feb 20 '24	Option Exercise	0.00	1,729	0	9,721	Feb 22 07:36 PM
Baranick Brian	Gen. Mgr., Precision Oncology	Feb 21 '24	Sale	61.50	895	55,042	8,826	Feb 22 07:36 PM
ORVILLE JACOB A	General Manager, Screening	Feb 14 '24	Option Exercise	0.00	2,031	0	8,454	Feb 16 06:26 PM
ORVILLE JACOB A	General Manager, Screening	Feb 15 '24	Sale	61.43	966	59,341	7,488	Feb 16 06:26 PM
Herriott James	General Counsel	Feb 14 '24	Option Exercise	0.00	883	0	6,915	Feb 16 06:25 PM
Herriott James	General Counsel	Feb 15 '24	Sale	61.43	421	25,862	6,494	Feb 16 06:25 PM
Elliott Jeffrey Thomas	Chief Financial Officer	Feb 14 '24	Option Exercise	0.00	3,972	0	3,972	Feb 16 06:24 PM
Elliott Jeffrey Thomas	Chief Financial Officer	Feb 15 '24	Sale	61.43	1,888	115,980	2,084	Feb 16 06:24 PM
COWARD D SCOTT	Director	Feb 14 '24	Option Exercise	0.00	3,972	0	42,956	Feb 16 06:23 PM
COWARD D SCOTT	Director	Feb 15 '24	Sale	61.43	1,376	84,528	41,580	Feb 16 06:23 PM
Conroy Kevin T	President and CEO	Feb 14 '24	Option Exercise	0.00	31,133	0	1,239,148	Feb 16 06:22 PM
Conroy Kevin T	President and CEO	Feb 15 '24	Sale	61.43	14,791	908,611	1,224,357	Feb 16 06:22 PM
Condella Sarah	EVP, Human Resources	Feb 14 '24	Option Exercise	0.00	2,031	0	71,454	Feb 16 06:21 PM
Condella Sarah	EVP, Human Resources	Feb 15 '24	Sale	61.43	965	59,280	70,489	Feb 16 06:21 PM
Condella Sarah	EVP, Human Resources	Jan 02 '24	Sale	73.50	2,000	147,000	69,423	Jan 04 05:19 PM
Baranick Brian	Gen. Mgr., Precision Oncology	Jan 02 '24	Sale	73.50	879	64,606	7,992	Jan 04 05:17 PM
Condella Sarah	EVP, Human Resources	Dec 14 '23	Sale	70.00	2,000	140,000	71,423	Dec 18 07:49 PM
Cunningham Everett	Chief Commercial Officer	Oct 11 '23	Option Exercise	0.00	27,504	0	50,916	Oct 13 07:59 PM
Cunningham Everett	Chief Commercial Officer	Oct 12 '23	Sale	66.49	13,007	864,835	37,909	Oct 13 07:59 PM

DGX

NTRA

VCYT

CSTL

CELC

RDNT

PSNL

FTRE

SERA

GH

XGN

LH

BDSX

EXAS

Upgrade your FINVIZ experience